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Abstract  
Activation of the G-protein coupled receptor (GPCR) chemokine receptor 5 (CCR5) has been 
shown to result in activation of the Gαi family of heterotrimeric G-proteins. However, little 
is currently known about the temporal characteristics of G-protein heterotrimer activation 
by CCR5. Furthermore, this simplistic model does not account for the range of changes 
CCR5 activation brings about. Recent evidence suggests that GPCRs may be able to signal 
through numerous permutations of heterotrimer. 
 
In order to assess G-protein activation and interaction with CCR5 functional stably 
transfected cell lines were created expressing Gαi2 fused to ECFP and Gβ1 fused to EYFP. 
The interaction of these constructs was confirmed by measuring fluorescent resonance 
energy transfer (FRET). Stably transfected cells exhibited a FRET ratio of 2.63% (±0.345%, 
n=3) over that of control cells. Following CCR5 stimulation with CCL3, Gαi2β1γ activation 
could be monitored in real time, in whole cell populations, on a fluorescent plate reader by 
monitoring FRET emissions. This assay system represents a novel approach to measuring G-
protein activation which can be used as a foundation to build more powerful FRET based 
assays. Measurement of G-protein interactions was further invested by BRET based studies.  
 
Transfection of dominant negative and constitutively active G-proteins alongside siRNA 
knockdown of G-proteins revealed that CCR5 is capable of signalling through other 
members of the Gαi family, with strikingly similar efficacy and potency to CCL3 stimulation. 
Dual knockdown of Gαi subunits and Gαq resulted in much attenuated calcium release 
following CCL3 stimulation, providing evidence that CCR5 may functionally couple to 
several types of G-proteins. Findings also support the theory that GPCRs can participate in 
domain swapping in order to rescue function.   
 
Treatment with gallein resulted in higher resting cytosolic cAMP but did not prevent CCR5 
mediated inhibition of cAMP production. Gallein treatment also resulted in significant 
increases in calcium release following CCR5 activation, highlighting Gβγ as a potential 
target for modulating CCR5 signalling events. Data herein emphasize the complexity of 
GPCR signalling, and also provide a foundation for exploring GPCR signalling using 
fluorescence resonance energy transfer methods in the future.    
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Chapter One 
Introduction 
1.1 G-Protein Coupled Receptors 
G-protein coupled receptors (GPCR) are a diverse family of transmembrane receptor 
proteins that work in concert with guanine nucleotide regulated proteins (G-proteins) 
(Oldham et al., 2007). GPCRs play important roles in cellular signalling networks involving 
processes such as neurotransmission, cellular metabolism, secretion, cellular 
differentiation and growth, inflammatory and immune responses, smell, taste and vision 
(McCudden et al., 2005). This superfamily of proteins is of importance in understanding 
many human diseases, and has been proved to be one of the most attractive targets for 
drug development and targeting (Henry, 2004). The breadth of physiological activities 
controlled by GPCRs is, in part, due to the wide range of ligands that interact with receptors 
of this class, as well as the number of different G-proteins to which they can be coupled. 
GPCRs status as a major class of receptor linked to signalling proteins that modulate a 
variety of biological functions, make them an attractive target for drugs. All members of the 
GPCR superfamily possess seven transmembrane (TM) spanning α helices with an extra 
cellular N-terminus and an intracellular C-terminus. The seven TM region of the receptor 
are bundled together in a circular fashion to help facilitate ligand recognition and binding 
(Kristiansen, 2004). Each receptor has alternating intra and extra cellular loops which can 
vary in length depending on the receptor type. The three extracellular loops and the N-
terminus are important for ligand specificity and binding, the intracellular loops and C-
terminus are thought to be responsible for G-protein specificity (Moller et al., 2001), β-
arrestin binding (Tohgo et al., 2003) and G-protein activation (Oppermann, 2004). These 
16 
 
obvious structural differences allow for variation in the outcome of intracellular signalling 
and allow ligand specificity to be carried through to G-protein binding.  
 
Recent crystallographic studies of the β2-adrenergic receptor (β2-AR) have helped shed light 
upon the receptor architecture and the conformational changes associated with activation 
of G-proteins following ligand binding. The exceptional work carried out in the crystallation 
of the human β2-adrenergic receptor (PDB 2RH1) (Cherezov et al., 2007) has given insight 
into the function of type A GPCRs other than rhodopsin. To facilitate crystallization and 
produce a high resolution structure, T4 lysozyme was fused in place of the 3rd intracellular 
loop (fig 1.1). The β2-AR has a fold composed of seven TM helices forming a helical bundle. 
Helices II,V, VI, and VII each have a proline induced kink along the span of the TM, which 
are thought to facilitate structural rearrangements required for G-protein 
activation(Yohannan et al., 2004). In addition to the 7TM domain β2AR has an short 
extracellular α-helix and an intracellular helix termed helix VIII; believed to be common in 
all type A GPCR (Katragadda et al., 2004). 
 
Comparison of β2-AR with rhodopsin reveals several minor differences in architecture of 
the helical bundle. Namely, the extracellular portions of helices I and III are angled away 
from the receptor, helix IV is translated away from the centre of the receptor, helix V is 
translated closer to the centre of the receptor, and helix VI angles away from the receptor 
on the cytoplasmic face. These structural differences may arise due to a difference in ligand 
binding properties (Cherezov et al., 2007). 
 
17 
 
Structural studies of rhodopsin β2-AR and form the basis for understanding the mechanisms 
of G-protien activation by GPCR. It is believed that ligand binding to a type A GPCR results 
in an outward movement of helix VI, thereby opening an intracellular crevice (Farrens et 
al., 1996) and breaking the ionic lock, believed to prevent G-protein activation, located 
between helix III and VI (Bhattacharya et al., 2008). 
 
The amount of ligands capable of activating GPCR is staggeringly large, natural ligands 
include photons, hormones, neurotransmitters, and molecules ranging from small peptides 
to large proteins. Binding of a GPCR to other GPCRs or small molecules has also been 
shown to modulate/potentiate the binding and activation characteristics of GPCR (Milligan, 
2003). Once GPCR has bound ligand its effects are mediated by the modulation of a series 
of second messengers. The increase or decrease in these second messengers leads to 
intracellular responses which underlie the physiological responses of the particular tissue 
or organ.  
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Figure 1.1 Model of β2AR-T4L. T4 lysozyme was inserted in the third intracellular loop to facilitate 
crystallization, shown here as the predominantly yellow structure, the seven TM helical bundle is coloured 
blue to red, with helix I and helix VIII being blue and red, respectively. PDB accession ID 2RH1 (Accessed 
12/03/10). Adapted from Cherezov et al.using Jmol viewer. (Cherezov et al., 2007)    
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1.1.2 CCR5 Structure and Function 
The GPCR superfamily has been categorised into 6 different classes (A-F), as defined by the 
GPCRDB classification scheme (Bettler et al., 2003). Class A GPCR, the largest of the GPCR 
superfamily classes, share significant homology to rhodopsin and are further sub-classified 
into subfamilies on the basis of their phylogenetic relationship (Joost et al., 2002). Based on 
this classification CCR5 is classed as an A1 receptor, alongside other chemokine receptors. 
All chemokine receptors share a similar structural design with all receptors being between 
340 to 370 amino acids in length, CCR5 has 352 residues, with similar C- and N-terminus 
structural motifs that confer ligand, signalling, and trafficking specificity to a particular 
receptor (Figure 1.2) (Oppermann, 2004).  
 
CCR5 is predominantly expressed on lymphocytes, monocytes, macrophages and dendritic 
cells in the immune system (Martin et al., 1999). It is also expressed on primary and 
secondary lymphoid organs and in the central nervous system (Bajetto et al., 2002). CCR5 
binds several chemokines with high affinity including CCL3, CCL4, CCL5 and CCL8 (Onuffer 
et al., 2002), all of which bring about cytoskeletal changes in lymphocytes and 
macrophages. Recent studies in CCR5 deficient mice show very limited defects in cell 
mediated immune processes, however absence of CCR5 has been implicated in allograft 
rejection (Dehmel et al., 2009). CCR5 constitutes the main functional co-receptor for M-
tropic HIV-1 strains and humans deficient in functional CCR5, a subpopulation that 
expresses a mutant form CCR5 containing a 32 residue deletion, termed CCR5-Δ32, have a 
reduced rate of HIV progression (Huang et al., 1996) with no other ill effects. CCR5 has also 
been implicated in the activation of TH1 helper cells (Galli et al., 2001) West Nile virus 
susceptibility (Lim et al., 2006) and arthritis (Pokorny et al., 2005). The redundancy CCR5 
exhibits, coupled with its high homology to many other physiologically important GPCR 
make it a good candidate to study GPCR signalling interactions.   
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Figure 1.2 Schematic representation of CCR5 showing the 2-dimentional conformation of CCR5. The plasma 
membrane is represented by the grey shaded area, conserved residues and those important amino for 
receptor function are highlighted. Of special importance to CCR5 are the two extracellular disulphide bridges, 
signified by the dashed and solid line, which are believed to hold the receptor in a conformation capable of 
binding specific chemokine ligands and the DRYLAVVHA motif, located intracellularly, which is conserved 
between all members of the chemokine receptor family. Residues critical for receptor function are shown as 
filled circles. (Oppermann, 2004) 
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1.1.2.1 Extracellular Domains   
The four extracellular loops of CCR5 each contain a cysteine residue that forms disulphide 
linkages between extracellular domains two and three, and one and four. These disulphide 
bonds hold the receptor in a conformation capable of allowing ligand access to the binding 
pocket and consequently binding chemokine (Blanpain et al., 1999). Comparatively, a 
typical class A GPCR contain only two cysteine residues in the extracellular domains which 
form a disulfide bond that links the first and second extracellular loops (Savarese et al., 
1992). Mutation to these conserved cysteine residues results in a decrease in receptor 
function due to impaired ligand binding (Wess et al., 2008). In addition to this conserved 
disulphide bridge, all chemokine receptors have two additional cysteines located in the N-
terminal domain and the third extracellular loop. These extra cysteines are thought to form 
a second disulfide bond, which confers an additional structural restriction on the GPCRs 
conformation that contributes to its stability (Baggiolini et al., 1997).  
 
Ligand specificity in CCR5 is conferred by the second extracellular loop. Studies comparing 
the binding properties of CCR5 and CCR2b, the chemokine receptor with the highest 
similarity to CCR5, showed that the region with the lowest homology was responsible for 
ligand specificity in CCR5 (Habasque et al., 2002). However, ligand specificity for chemokine 
receptors is not only defined by the second extracellular domain, CCR1 binding to ligand, 
for example, is reported to be mediated by the third extracellular loop (Monteclaro et al., 
1996) 
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1.1.2.2 Intracellular Domains 
The intracellular structure of CCR5 contains four loops, allowing binding of downstream 
signalling elements and β arrestin. It appears the first intracellular loop is completely 
dispensable for the correct function of the receptor, as the creation of five TM CCR5, 
having had the first and second TM domains removed, resulted in a fully functional 
chemokine receptor (Ling et al., 1999). The second intracellular loop contains a –DRY 
residue motif that is highly conserved between all class A GPCR (Rovati et al., 2007). The –
DRY motif is responsible for keeping the receptor in its inactive ground state; upon 
activation the arginine residue undergoes a conformational shift resulting in the formation 
of an active receptor (Cotecchia et al., 2002). Within the chemokine receptor family this 
highly conserved –DRY motif is extended to include further residues resulting in a 
conserved –DRYLAVHA motif across the chemokine receptor family (Oppermann, 2004). 
This second loop motif has been implicated in G-protein association with the receptor 
(Shibata et al., 1996) as well as playing a role β-arrestin binding to the receptor (Bennett et 
al., 2000). Although the third intracellular loop has been implicated in β-arrestin binding in 
other class A GPCR, this is not the case for CCR5 which contains an unusually short and 
positively charged third intracellular domain (Huttenrauch et al., 2002). No apparent 
functional use has been published for the third intracellular loop in CCR5. However, 
mounting evidence suggests that the sequence in a GPCRs third intracellular loop may be 
important for G protein specificity (Beqollari et al., 2009). The fourth intracellular loop is 
formed by post translational palmitoylation of three cysteine residues and their association 
with the inner leaflet of the plasma membrane; it has been shown to be essential to 
receptor trafficking (Blanpain et al., 2001) and acts as a docking site for G-Protein Receptor 
Kinases (GRK) and Protein Kinase C (PKC) to bind to and phosphorylate serine, threonine 
and tyrosine residues on the intracellular domains.  
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1.1.2.3 CCR5 Chemokine Ligands 
Chemokines are leukocyte activating peptides that facilitate migration to affected areas by 
stimulating actin cytoskeleton rearrangements and the degranulation of cells expressing 
chemokine receptors (Mackay, 2001). Synthesis of chemokines occurs in monocytes and 
macrophages, they are released in response to physical damage or pathogen challenge to 
the body, and approximately 50 chemokines are known to exist to date. The principle 
target for chemokines is bone marrow derived immune system cells (Mackay, 2001) 
 
There are four families of classification that chemokines can fall in to; each family is 
dependent on amino acid sequence, specifically, based on the configuration of cysteine 
residues at the N terminus. The families are; CC – two adjacent cysteines, CxC two cysteines 
separated by a single amino acid, C – a single cysteine residue and Cx3C – two cysteines 
separated by three amino acids (Thelen, 2001). 
 
Ligand binding to CCR5 is thought to occur as a two-step process. Firstly, the chemokine 
core binds to the exposed N-terminal via post-translationally sulphonated tyrosines (Zlotnik 
et al., 2000). These tyrosines are situated in a positively charged milieu; sulphonation 
increases the negative charge, thus increasing the affinity for chemokine binding. The 
chemokine also binds to adjacent regions on the second extra-cellular loop, it is this 
interaction that confers ligand specificity (Samson et al., 1997). The free amino terminal 
end of the chemokine can then bind to the third membrane helix, causing conformational 
change to CCR5, thus, activating the receptor (Blanpain et al., 1999). This process is the 
method used by chemoattractant leukocyte receptor systems (Farzan et al., 1999). 
However, different chemokines require different structural determinants to bind. This 
ensures that there is not a one size fits all binding method. The configuration of CCR5 lends 
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itself to predominantly binding to CCL3, CCL4 and CCL5 as well several other chemokines 
(Table 1.1), whereas CCR4, for example, binds predominately to CCL17 and CCL22 (Navenot 
et al., 2001). There are four described isoforms of CCL3 (CCL3, CCL3L1, CCL3(5–70), CCL3(2–
70)), which differ in their ability to bind and activate CCR5 (Mueller et al., 2006). CCL3L1, 
also known as LD78β, is a naturally occurring non allelic variant of CCL3. This isoform has 
been shown to be more potent than CCL3, a proline residue at position 2 is believed to 
confer this enhanced potency (Nibbs et al., 1999). Although not as potent as CCL3L1 some 
studies have shown CCL3(2–70) to be as efficacious as CCL3L1. These studies have led to 
the conclusion that binding and activation of chemokine receptors by chemokines is 
dependent upon the N-terminus of the chemokine (Mueller et al., 2006). 
Receptor Ligand 
CCR1  CCL3, CCL5, CCL7, CCL8, CCL13-16, CCL23 
CCR2  CCL2, CCL7, CCL8, CCL13 
CCR3  CCL11, CCL5, CCL7, CCL8, CCL13, CCL15, CCL24, CCL26 
CCR4  CCL17, CCL22 
CCR5  CCL3, CCL4, CCL5, CCL8, CCL14 
CCR6  CCL20 
CCR7  CCL19, CCL21 
CCR8  CCL1, CCL4, CCL17 
CCR9  CCL25 
CCR10  CCL26-28 
CXCR1  CXCL8 
CXCR2  CXCL1-3, CXCL5-8  
CXCR3  CXCL9-11 
CXCL13 CXCL12 
CXCR5  CXCR4  
CX3CL1 CXCL16 
CX3CR1 CXCR6  
XCR1  XCL1, XCL2 
Table 1.1 Chemokine Receptors and their Ligands. Many chemokine receptors have overlapping specificity for 
chemokines. Table adapted from IUPHAR-DB (Harmar et al., 2009) 
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1.1.3 Heterotrimeric G-Protein Structure 
G-proteins are made up of three different subunits α, β, and γ. The heterotrimeric G-
protein are typically classified into four families, based on sequence homology of the Gα 
subunit, they are: Gαi, Gαs, Gαq, and Gα12/13 (Simon et al., 1991). Crystal structures have 
been solved for at least one member of each family and have allowed structural 
characterisation of the Gα subunit (Figure 1.3). The Gα subunit consists of two domains; a 
GTPase domain, and α helical domain. The GTPase domain is conserved in all members of 
the G-protein superfamily, and is responsible for GTP hydrolysis and contains residues 
involved in Gβγ and effector binding. This domain also contains three flexible loops, termed 
switch regions 1-3, which undergo conformational changes upon GTP binding and 
hydrolysis (Mixon et al., 1995). The helical domain is composed of six α helices that form a 
lid over the GTP binding site, burying the core of the protein (Coleman et al., 1994).  
 
Upon GDP displacement and GTP binding the GTPase domain undergoes a number of 
conformational changes in switch regions I-III, resulting in decreased affinity for the Gβγ 
subunit and an increase for cellular effectors (Lambright et al., 1996). The classical view is 
that then the Gα subunit dissociates from the Gβγ subunit and activates its effectors, 
however this has recently been questioned, by demonstrating that some G-protein 
heterotrimers signal without dissociating (Bunemann et al., 2003). The helical domain also 
contains a fourth switch region that undergoes a nucleotide dependent conformational 
change (Mixon et al., 1995). Switch IV has been shown to form a binding region for GoLoco 
motifs found in regulator of G-protein signalling proteins (RGS) (Kimple et al., 2002).  
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Figure 1.3 Protein Explorer model of Gαi demonstrating the deep binding cleft into which GTP (ball and stick 
model) binds. Switch regions are located around the β-sheet formation. PDB Accession ID 1TAD. Adapted 
from McCudden et al. using protein explorer. (McCudden et al., 2005) 
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Interaction between Gα and Gβγ is believed to be modulated by an α helix formed by the 
extended N terminal of Gα. The N terminal of Gα units has 26-36 residues, of which the 
first 23 in Gα have been shown, in a heterotrimeric conformation, to form an α helix. The 
helix interacts with the Gβγ subunit, thus connecting them through ionic interactions. The 
helix is believed to form as a consequence of the N terminal myristate imposing 
conformational rigidity on the amino terminus (Preininger et al., 2008).  
 
The Gβ subunit forms a structurally stable functional heterodimer with the Gγ subunit that 
does not dissociate unless denatured (Schmidt et al., 1992). There are five Gβ known units 
and 12 known Gγ units (Fletcher et al., 1998) this suggests a large number of possible 
permutations for the Gβγ subunit. Most combinations do form and become functional 
dimers. However, there are some exceptions; for example Gβ2 cannot pair with Gγ1 (Spring 
et al., 1994). It has also been noted that some combinations have greater affinity for 
specific receptors for example Gβ1γ1 binds with higher affinity to rhodopsin then other 
potential combinations (McCudden et al., 2005).  
 
All Gβγ subunits contain seven tryptophan-aspartic acid sequences that repeat 
approximately every 40 residues, which form small anti parallel β strands (Neer et al., 
1994). This feature causes the Gβ subunit to adopt a propeller shape formation, known also 
as a torus-like structure (Figure 1.3). The dimerous structure of the Gβγ unit is stabilised by 
the Gγ subunit forming two α-helices. The C terminus helix interacts with the torus-like 
structure, binding to blades five and six, while the N terminus helix forms a coiled coil with 
the Gβ N-terminus (Sondek et al., 1996). 
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Figure 1.4 The Gβ1γ1 subunit, the torus structure of the β unit is clearly visible, the γ subunit is coloured in 
blue, its two α-helixes bind to the β unit to stabilise the dimer. PDB Accession ID 1TBG. Adapted from 
McCudden et al. using protein explorer.(McCudden et al., 2005) 
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The Gβγ interacts primarily at a hydrophobic pocket formed by switches I and II on Gα and 
five of the seven blades of the Gβ subunit. On formation of the heterotrimer the Gβγ 
subunit significantly alters the conformation of Gα (Wall et al., 1995). Unlike the Gα subunit 
the Gβγ subunit does not undergo a conformational change in order to activate it. Instead 
the active sites of the Gβγ unit are partially shared with the binding site for Gα. Therefore, 
classical G-protein theory suggests Gβγ is unable to signal whilst bound to Gα (Sondek et 
al., 1996). However this notion has recently been brought into question with the discovery 
of AGS proteins capable of activating signalling through the Gβγ subunit without causing 
dissociation of the heterotrimer (Yuan et al., 2007). 
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1.2 Downstream effectors of G-proteins 
The different classes of Gα subunit, once active, target different effectors dependent on 
their structural determinants. Structural differences between G-proteins result in targeting 
to, and the activation of, different downstream effectors (Skiba et al., 1996; Sprang, 1997). 
Activation or inhibition of other downstream effectors can also be achieved by interactions 
with the Gβγ subunit. Activation of CCR5 results in the targeting of several effectors (Figure 
1.4) 
 
1.2.1 Gα subunit signalling 
The activation of Gαq leads to the activation of the enzyme phospholipase C (PLC). To date 
there have been 12 mammalian PLC isoforms that can be divided into five isotypes based 
upon functional and structural characteristics; PLC-β, PLC-δ, PLC-γ, PLC-ε, and PLC-ζ. More 
recently a new phospholipase has been identified (PLC-η) which is calcium dependent and 
mainly expressed in nerve cells (Hwang et al., 2005a; Hwang et al., 2005b). All mammalian 
PLC contain X and Y catalytic domains as well as regulatory domains and require calcium for 
their activation. PLC-β is the only isotype that is activated by the action of Gαq binding. The 
activation of PLC-β results in the breakdown of the phospholipid phosphoinositol 
bisphosphate (PIP2) to the lipophilic compounds diacylglycerol (DAG) and inositol 
triphosphate (IP3). 
 
The activation of Gαs leads to the stimulation of adenylyl cyclase (AC) whereas, in classical 
models of G-protein signalling, activation of the Gαi subunit leads to inhibition of AC 
activity. AC activation results in an increase of the of the second messenger cyclic 
adenosine monophosphate (cAMP), which is responsible for the regulation of a plethora of 
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further proteins. Structurally, the AC complex consists of an N-terminal domain, two 
transmembrane clusters, each consisting of six α-helices, and two cytoplasmic loops, 
termed C1 and C2. It is here, within these cytoplasmic loops, that the active site is located 
and catalysis of ATP to cAMP occurs (Tesmer et al., 1997b). There are ten known isoforms 
of AC discovered in humans, each isoform has a slightly different expression profile and 
different protein association profile. Most tissues and cell types can express more than one 
isoform of AC, but expression is tightly regulated. Different isoforms are inhibited and 
activated in different ways, providing cells with a method to respond diversely to similar 
stimuli (Patel et al., 2001). For example AC V is directly inhibited by Gαi whereas AC II is not 
(Patel et al., 2001). AC I can be inhibited by Gβγ subunits whereas AC II and AC VII are 
stimulated by Gβγ (Taussig et al., 1994b). It is important to note, that while it is widely 
accepted that activation of the Gαi subunit results in inhibitory effects upon AC, the 
associated Gβγ subunit can actually activate several isoforms (see Table 1.2) including AC 
VII (Watts et al., 1997). The specific expression pattern of AC isoforms is not completely 
characterised, however, there is strong evidence that in human neutrophils isoforms III, VI, 
VII, and IX are predominantly expressed (Mahadeo et al., 2007).   
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AC Isoform Activators Inhibitors 
I Gαs, Ca
2+/CaM Gαi, Gβγ, CaM Kinase IV 
II Gαs, Gβγ, PKC P-Site analogues 
III Gαs, Ca
2+/CaM CaM Kinase III, P-Site analogues 
IV Gαs, Gβγ P-Site analogues 
V Gαs, PKC Gαi, Gβγ 
VI Gαs, Gαi, PKA, PKC 
VII Gαs, Gβγ, PKC P-Site analogues 
VIII Gαs, Ca
2+/CaM P-Site analogues 
IX Gαs P-Site analogues 
Soluble HCO3
- ? 
Table 1.2 Comparison of activators and inhibitors of adenylyl cyclase. Table adapted from T.B. Patel et al 
(2001).  
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1.2.2 Gβγ Subunit Signalling 
In recent years, knowledge of the roles heterotrimeric G proteins in cellular signalling has 
dramatically increased. Originally, the Gβγ dimer was thought to be necessary mainly for 
the inactivation of Gα subunits, allowing them to reassociate with the receptor for 
subsequent rounds of signalling. Thus, Gβγ was viewed as a negative regulator of Gα 
signalling. The first evidence for a direct role of Gβγ dimers in signalling came in 1987 when 
purified Gβγ subunits from bovine brain were shown to activate a cardiac potassium 
channel normally activated by muscarinic cholinergic receptor following acetylcholine 
release (Logothetis et al., 1987). We now know that Gβγ subunits can modulate many 
effectors via direct interaction that are also regulated by Gα subunits, including Kir3 
potassium channels, as well as PLCβ (Guo et al., 2003), phosphatylinsotitol 3-kinase 
(PI3K)(Neves et al., 2002), and isoforms of adenylyl cyclase (Taussig et al., 1994a). These 
Gβγ functions have been investigated heavily in recent years and many interactions have 
been shown to result in an increase in cytosolic calcium levels (Robishaw et al., 2004). 
 
Investigations into Gβγ targets have revealed that the interaction between Gβγ and Ca2+ 
channels is direct. To prove this observation, Gβγ was overexpressed in various cell lines 
and shown to inhibit calcium channel activity (Herlitze et al., 1996), whereas the 
overexpression of proteins that bind Gβγ, acting as scavengers of free Gβγ, were shown to 
suppresses this effect (Kammermeier et al., 2000). Currently, the mechanism by which Gβγ 
interacts with its downstream effectors is not entirely clear. Many of Gβγ effectors contain 
pleckstrin homology domains (PH); however, not all PH domain-containing proteins interact 
with Gβγ, making prediction of interactions difficult. Currently there are few studies into 
the critical residues involved in Gβγ interactions. However, the Gβ1γ2 interaction with the 
PH domain of GRK2 has been elucidated(Tesmer et al., 1997a), and residues important for 
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GIRK channels have also been by identified (He et al., 2002). This information may help 
deduce further Gβγ-effector interactions in the future. Recent studies have also implicated 
the Gβγ subunit as a mediator of cross talk between pathways (Kumar et al., 2007; Zagar et 
al., 2004) 
 
1.2.3 G-protein Mediated Calcium Release 
Following chemokine binding and stimulation of a chemokine receptor, the cytosolic 
concentration of free calcium can increase by 10 fold that of normal basal levels (Berridge 
et al., 2000). The most well studied pathways regarding G-protein mediated calcium 
release is the Gαq pathway. When Gαq associated receptors are activated, the PLC-β 
pathway is triggered resulting in PLCβ catalysed increases in IP3 from membrane anchored 
Phosphatidylinositol 4, 5-bisphosphate (PIP2). Free IP3 then diffuses into the cytoplasm 
from the inner plasma membrane leaflet resulting in the activation of with IP3 receptors 
(IP3R) located on the ER. The IP3R are a family of calcium release channels located on the 
endoplasmic reticulum, stimulation of these receptors results in the release of pooled 
calcium from the ER to the cytosol (Foskett et al., 2007). The overall mechanisms 
controlling the IP3R are complex and diverse, but the underlying principles of activation are 
the same; once IP3 binds the receptor a conformational change occurs causing the receptor 
‘gate’ to open, allowing the passage of calcium through a newly formed pore in the 
membrane. The release of calcium from the ER results in further downstream signalling 
events, one of which causes the modification of IP3 to either inositol 1,4-bisphosphate or 
inositol 1,3,4,5-tetrakisphosphate. These changes to IP3 and calcium levels act as a 
negative feedback loop, resulting in a loss IP3 binding and phosphorylation of the receptor 
and consequently its subsequent deactivation (Bugrim, 1999). 
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The classical calcium signalling pathway involves activation of Gαq linked receptors leading 
to the activation of PLC-β and subsequent production of IP3 is not the only mechanism by 
which GPCR can stimulate calcium release. The Gβγ subunit plays an equally central role in 
mediating intracellular calcium flux. When the Gαq subunit is activated the Gα and Gβγ can 
target different downstream effectors. The conformation of free Gβγ does not differ to Gβγ 
when bound to the Gα subunit (Sondek et al., 1996) suggesting that the Gα subunit acts as 
a negative regulator of Gβγ interactions. Gβγ subunits have been shown to directly interact 
with calcium signalling machinery within a cell and it has been proposed that IP3 receptors 
can be activated directly by Gβγ subunits (Zeng et al., 2003). Studies on the alpha 2A 
adrenergic receptor proved that the Gβγ subunits from activated Gαi heterotrimers are 
directly responsible for the stimulation of PLC-β and the release of calcium (Dorn et al., 
1997). There are also reports that free Gβγ subunits may also activate or enhance the 
activity of Gαq (Quitterer et al., 1999). It is suggested that Gαq activation by Gβγ is 
facilitated by Gβγ promoting Gαq activation by accelerating the receptor stimulated GTP-
binding (Quitterer et al., 1999). Studies have also shown that the activity of calcium ion 
channels can be potentiated or modulated by Gβγ binding (Dascal, 2001; Herlitze et al., 
1996). 
  
Following the initial rapid increase in cytosolic calcium by IP3 receptors there is a second 
slower phase involving extracellular calcium entry, believed to be necessary for 
maintenance of ER calcium stores (Parekh et al., 2005). The entry of extracellular calcium is 
known as capacitative calcium entry (Berridge, 1995). The emptying of ER calcium serves as 
a trigger for a message that travels to the PM, resulting in activation of store-operated 
channels (SOCs) allowing the movement of calcium from high concentration to low; 
Extracellular calcium is approximately at a 10,000 fold concentration across the PM (Parekh 
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et al., 2005). Activation of SOCs leads to the long-term increase in cytosolic calcium 
concentration, which in turn replenishes intracellular stores. The mechanism for this 
second phase that couples ER calcium store depletion with calcium entry into the cell is not 
yet fully understood.  
 
1.2.4 G-protein mediated cAMP Regulation 
The cytosolic concentration of cAMP in a cell is kept at a relatively low concentration; 
extracellular signals can cause cAMP levels to increase by more than 20 fold within seconds 
of GPCR activation. The basal level of cAMP in a cell is kept low by cAMP 
phosphodiesterase activity which hydrolyses cAMP to adenosine 5’-monophosphate (AMP) 
(Conti et al., 2003). Binding of PTX sensitive Gαi subunits to AC is specified by a post 
translational N-terminal acylation, and results in a lowering of the intracellular cAMP 
concentration (Taussig et al., 1994b). Binding of Gαs subunits occurs at a different site to 
Gαi and results in an increase of cAMP - thus, AC is under dual control and turnover of 
substrate can be fine tuned by levels G-protein binding (Simonds, 1999). 
  
Increases in cAMP concentration results in further downstream effects mediated by cAMP-
dependent Protein Kinase A. Phosphorylation of specific residues on a target protein allows 
regulation of their function and PKA is also responsible for phosphorylation, and the 
consequent deactivation, of GPCRs. PKA is a holoenzyme made up of four subunits; two 
catalytic and two regulatory. The regulatory subunits undergo a conformational change 
following the binding of cAMP, allowing them to dissociate from the catalytic subunits 
resulting in active PKA. The relationship between cAMP and adhesion of leukocytes is not 
well understood. However, recent studies suggest that lowering of cAMP may be 
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physiologically relevant and facilitate the migration of dendritic cells towards lymph nodes, 
and inhibit firm adhesion of other leukocytes (Burzyn et al., 2002).  
 
1.2.5 CCR5 Mediated Cytoskeleton Reorganisation 
Ultimately, the activation of CCR5 leads to chemotaxis of a cell along a chemotactic 
gradient towards areas that have a high concentration of chemokine. Movement of the cell 
is brought about by the reorganisation of its cytoskeleton. The main effectors involved in 
initiating chemotaxis of the cell are predominantly under the control of Gβγ subunit 
targeting (Neptune et al., 1997). 
 
Upon G-protein heterotrimer activation Gβγ binds to and activates PLCβ, ultimately, 
resulting in intracellular calcium mobilisation. The subsequent calcium influx activates PKC, 
which goes on to phosphorylate the fourth intracellular loop of CCR5, setting in motion 
desensitisation mechanisms. PLCβ activation also results in the MAPK pathway becoming 
activated which up regulates gene transcription for cytokine production (Lee et al., 2003). 
However, studies in mice have shown this pathway to be dispensable for chemotaxis (Li et 
al., 2000). In contrast, mice deficient in PI3K showed severe defects in leukocyte 
chemotaxis (Hirsch et al., 2000). 
 
Upon activation, CCR5 has been shown to activate PI3K-κ as well as RhoA resulting in the 
formation of lamellipodia. RhoA is a member of the Rho family of small GTPases, a family 
which also includes Rac and Cdc42. Their activation results in the co-ordinated 
rearrangement of the actin cytoskeleton, which determines cell polarity, adhesion and 
motility (Oppermann, 2004). The focal adhesion proteins (FAK), FAK and Pyk2, are also 
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activated following CCR5 stimulation, these two proteins play an important role in cell 
motility and spreading (Ganju et al., 1998). Activation of FAK and Pyk2 also results in the 
activation of integrins by binding to their cytoplasmic face, promoting cell adhesion and 
migration (Hecht et al., 2003). 
 
Evidence has recently emerged demonstrating that GPCR do not only rely on classical G-
protein signalling pathways to signal. Work by Mueller et al. demonstrated the ability of 
Janus Kinase2/ Signal Transducers and Activator of Transcription (JAK/STAT) pathways to be 
activated upon CCR5 stimulation in the presence of PTX, an inhibitor of Gαi signalling 
(Mueller et al., 2004a). This suggests CCR5 can activate JAK2 in a G-protein independent 
manner. G protein independent activation of the JAK2/STAT pathway though a GCPR has 
also been demonstrated by Marrero et al. who showed that angiotensin via the AT1 
receptor activates the JAK2/STAT pathway (Marrero et al., 1995). 
 
1.2.6 G-protein Interactions with Other Signalling Pathways 
For some time now the notion of discrete signalling pathways working independently 
towards bringing about physiological changes has been questioned. There is accumulating 
evidence that GPCR signalling pathways work as highly regulated cell specific networks, 
with proteins working in concert to bring about changes (Gurevich et al., 2008). Although 
research into this area is plentiful, describing interactions in a mechanistic fashion is 
proving to be difficult in living systems. Recently crosstalk between CCR5 and the 
neurokinin-1 receptor has been described, which results in enhanced chemotaxis of 
macrophages (Chernova et al., 2009). However, finding a definite model of cross-talk 
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between GPCRs and G-proteins is difficult. Compounds that inhibit one part of a pathway 
may also affect other signalling pathways thus complicating mechanistic studies.  
 
Figure 1.5 Activation of CCR5 by binding of chemokine results in the activation and inhibition of several 
signalling pathways. Gαi subunits inhibit adenylyl cyclase resulting in the reduction of cAMP production. Gβγ 
targets several pathways, ultimately resulting in the release of cytosolic stores of calcium, cytoskeleton 
rearrangement and the formation of lamellipodia, and desensitisation of the active receptor.  
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1.3 Methods to Infer and Monitor Protein-Protein Interactions 
The protein-protein interactions that underpin the correct function of the cell were for so 
long invisible by ordinary scientific methods; interactions were inferred on the basis of 
indirect assay systems and putative interactions. However, the fundamental importance of 
understanding the mammalian interactome has led to the development of a plethora of 
direct assay methods capable of identifying protein-protein interactions. Each method has 
its own strengths and weaknesses, especially with regard to the sensitivity and specificity of 
each method. These strengths and weaknesses need to be taken into account when 
creating a suitable assay to measure interactions. In the interest of brevity it is not possible 
to discuss all methods at our disposal, however, the key methodologies for investigating G-
protein heterotrimer interactions will be discussed here. 
 
1.3.1 Indirect Methods 
Indirect methods rely on measuring the physiological changes brought about from the 
activation of a protein of interest. In the case of CCR5 stimulation, the activation of the Gαi 
family of heterotrimers results in a reduction of cAMP, an increase in IP3 production and 
cytosolic calcium release. Measurement of calcium release is one of the most common in-
cell measurements used to assess GPCR activity. The release of calcium following GPCR 
stimulation can be attributed typically to Gαq or the Gβγ subunits of an active heterotrimer 
acting on downstream effectors. Changes in intracellular calcium can be measured with 
ion-sensitive dyes, whose excitation and emission properties change dependent on 
whether or not they have bound calcium – One such widely used dye is Fura-2 AM.  
 
Accurate measurement of cAMP and IP3 in a cellular system has, until recently, relied upon 
the radioactive labelling of such molecules. Traditionally the measurement of cAMP relied 
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upon the use of 125I-cAMP. Cells of interest are lysed and the cytosol used to determine the 
AMP concentration by using cAMP antibodies and 125I-labeled cAMP in a competition 
binding assay. Free cAMP from the sample competes with the radiolabeled cAMP and thus 
reduced antibody-coupled radioactivity, the amount of radioactivity left in the assay 
mixture following thorough washing is inversely proportional to the concentration of cAMP 
in the sample. Similar methods are employed to measure levels of IP3, where the 
incorporation of 32P ions into IP3 and a competitive capture assay is undertaken to 
determine IP3 concentrations. The biggest drawback to these methods is the associated 
safety concerns when handling radioactivity and the need for specialist equipment. 
Recently it has become possible to perform cAMP assays using a bioluminescence assay 
based on the principle that cAMP stimulates PKA activity, decreasing the available ATP in 
assay solutions, leading to decreased light production in a coupled luciferase reaction.  
 
The addition of compounds that have been proven to prevent certain interactions, such as 
PTX catalysed ribosylation acting on Gαi subunits to prevent the active conformation, 
combined with the use of these assays can yield information about the protein-protein 
interactions involved in certain cellular responses. However, as the results are inferred 
from the measurement of second messengers downstream of initial interactions, there is 
an undefined margin for error.  
 
1.3.1.1 Small Interfering Ribonucleic Acids 
The use of small interfering ribonucleic acids (siRNA), coupled with the measurement of 
second messengers is another way that protein-protein interactions can be inferred. siRNA 
is a short sequence of double stranded RNA that complements a section of the genetic 
sequence involved in coding for a protein of interest. Predesigned synthesised siRNA is 
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freely available to purchase, and can be easily introduced into cells. Once inside the cell, 
the siRNA undergoes strand separation and are integrated into the RNA induced silencing 
complex (RISC). The antisense strand of the siRNA then binds its complementary mRNA 
sequence, which results in the targeted destruction of the mRNA and thus active protein 
(Matranga et al., 2005). By effectively removing the protein of interest from the cell, its 
effects can be measured, allowing its protein-protein interactions to be inferred. In 
combination with direct methods of measuring interactions, such as immunoprecipatation, 
siRNA can help categorically confirm interactions.  
 
1.3.2 Direct methods  
Direct methods of measuring protein-protein interactions have flourished in the post 
genomic era, due to newly discovered genes without characterised functions. Identifying 
and understanding the interactions of these proteins plays an important part in helping 
decipher their function. Many of these developed methods can also help identify the 
kinetics of interactions and the cellular location. 
 
The major breakthrough in screening for protein-protein interactions was made by the 
creation of the yeast 2 hybrid (Y2H) system (Fields et al., 1989). Briefly, the Y2H system 
works by relying on the modular structure of transcription factors in yeast. By splitting a 
particular transcription factor into two halves and fusing them to two proteins of interest, 
termed the bait and prey, its function would only be restored if the proteins of interest 
interacted. This technique was limited to protein interactions in the nucleus. But the 
principle of fusing complementary portions of proteins to bait and prey was transferable 
and extended to allow measurements of interactions in other locations (Piehler, 2005).  
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Built on the back of the Y2H system, protein complementation assays (PCA), using proteins 
other than transcription factors revolutionised interactome studies. By tagging prey and 
bait proteins with complementary portions of enzymes, fluorophores or ubiquitin, the 
interactions of many more proteins could be measured. The ubiquitin system has been 
applied successfully to identify interactions that occur between membrane proteins using 
reporter proteins (Thaminy et al., 2004), methods using split enzymes such as lactamase 
have also been employed for this purpose (Galarneau et al., 2002). However, both systems 
rely on reporters that are time shifted from the actual event of interaction and may require 
incubation with a substrate. These issues can be overcome by tagging bait and prey 
proteins with two halves of a GFP. Bimolecular fluorescence complementation (BiFC) has 
been successfully used in many applications, and recently has been exquisitely used to 
identify the interactions between the Gβ and γ subunits in vivo (Hynes et al., 2008).  
 
Although Y2H and PCA methods are adequate for identifying interactions, more 
instantaneous methods are required to assess the kinetics and localisation of these 
interactions in living cells. Two similar methods currently exist that fulfil these criteria, they 
are fluorescence resonance energy transfer (FRET) and bioluminescence resonance energy 
transfer (BRET). These techniques, unlike the Y2H system, are currently fairly cumbersome 
and require expensive equipment, such as powerful confocal microscopes. However, with 
the recent development of plate readers capable of measuring FRET and BRET signals, the 
experimental processes could potentially be simplified and streamlined into a high 
throughput screening (HTS) system.  
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1.4 Fluorescence and Bioluminescent Resonance Transfer  
Fluorescence resonance energy transfer (FRET) is the transfer of electron excitation energy 
from a donor fluorophore to an acceptor fluorophore. When a donor fluorophore is excited 
with suitable mono-chromatic light, its excitation energy can be transferred non-
radiatively, that is to say without the appearance of a photon, to an acceptor fluorophore 
by means of intermolecular long range dipole-dipole interactions (Forster, 1949).  
 
FRET can be thought of as a molecular yardstick, allowing the interactions between 
molecules and proteins to be measured, provided they are labelled with suitable 
fluorophores. It is important to note that the efficiency of FRET energy transfer is inversely 
proportional to the sixth power of the distance between donor and acceptor fluorophores 
(Maki et al., 1976). This means the ability to transfer energy between fluorophores rapidly 
decreases over distance. The effective range for FRET to occur over is 1-10 nm dependent 
on experimental conditions (dos Remedios et al., 1995). Interestingly, this distance is within 
the extent of conventional protein dimensions and similar to those of multimeric protein 
complexes observed in biological systems (New et al., 2003). 
  
Technological advances in light microscopy imaging, combined with the availability of 
genetically encoded fluorescent proteins have provided the tools necessary to assess the 
temporal protein associations inside living cells (Heim et al., 1996). Interactions between 
adequately labelled proteins can be monitored by observing the emission of the acceptor 
fluorophore in a system; the detection of acceptor fluorophore emission indicates a level of 
donor-acceptor interaction. Ideally, emission of the acceptor fluorophore does not overlap 
with the emission of the donor allowing for easy quantification of the interaction. 
Workable FRET pairs need to include sufficient separation in excitation spectra for selective 
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stimulation of the donor, an overlap greater than 30% between the emission spectrum of 
the donor and the excitation spectrum of the acceptor to obtain efficient energy transfer, 
and reasonable separation in emission spectra between donor and acceptor fluorophores 
to facilitate independent measurement of the fluorescence of each fluorophore (Pollok et 
al., 1999). In biological systems the most commonly used donor-acceptor pair is enhanced 
cyan fluorescence protein and enhanced yellow fluorescence protein, both derivatives of 
green fluorescence protein (GFP). 
 
1.4.1 Fluorescence proteins for FRET 
GFP was first described in the jellyfish Aequorea Victoria in 1955 and was subsequently 
extracted, purified and identified as a protein in 1962 (Shimomura et al., 1962). However, 
its use in molecular biology did not begin outright until 1994 when it was successfully 
cloned and expressed (Chalfie et al., 1994). Adjustments to GFP’s excitation and emission 
spectra were made shortly after this breakthrough providing more robust fluorophores for 
use in molecular biology. Fluorescence is dependent upon a region of the protein that 
forms an imidazolidinone ring; the residues serine 65, tyrosine 66, and glycine 67. Mutating 
residues in close proximity to this imidazolidinone ring skews the absorbed and emitted 
wavelengths of GFP resulting in variations of GFP (Kretsinger, 2005). Various mutations 
have resulted in the development of Cyan FP, Yellow FP, Red FP, Saffron FP, Blue FP as well 
as many more minor variations. Many factors affect the ability of protein pairs to behave as 
FRET pairs, special consideration must be given to the amount of spectral overlap between 
the fluorophores, the distance between them, and the quantum yield of the donor protein. 
Many pairings have been tried since the inception of the FRET technique, one pair which 
satisfies all these requirements is ECFP and EYFP. Consequently, ECFP and EYFP has become 
one of the most widely utilised donor acceptor pairs for protein-protein interaction studies. 
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The excitation wavelength of EYFP overlaps with the emission wavelength of ECFP (Figure 
1.5) allowing FRET to occur without too much overlap with its emission spectra with the 
emission spectra of EYFP (Gryczynski, 2005). 
 
1.4.2 Living System FRET measurements 
Measurements of many protein-protein interactions by FRET have been conducted in intact 
cells. Some examples of interactions that have been studied by FRET are GPCR dimerisation 
studies, β-arrestin binding to GPCRs, and protein folding interaction with chaperones (Rye, 
2001). The introduction of FRET for the study of G-protein activation in intact cells begun in 
Dictyostelium (Janetopoulos et al., 2001) and was later utilised in other systems including 
yeast (Yi et al., 2003) and mammalian systems (Azpiazu et al., 2004; Bunemann et al., 
2003). Currently, the majority of this work has been performed with the use of confocal 
microscopy equipment, and until recently there was not an adequate plate reader system 
capable of measuring the fast kinetics seen in G-protein activation in a FRET based assay 
(Talbot et al., 2008) 
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Figure 1.6 Normalised absorbance and emission spectra for ECFP and EYFP. The emission spectra of ECFP 
has substantial overlap with the absorbance spectra of EYFP absorbance, resulting in the non radiative 
transfer of energy to EYFP, resulting in EYFP fluorescence following ECFP excitation, when ECFP is within  
10 nm.  
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1.4.3 Bioluminescence Resonance Energy Transfer 
Bioluminescence is a naturally occurring form of chemiluminescence where energy is 
released by a chemical reaction in the form of light emission. This natural phenomenon can 
be used to investigate protein-protein interactions in living systems in the same way as 
FRET. By replacing the donor fluorophore used in FRET with a protein capable of producing 
light in a chemiluminescent way a more sensitive system can be created.  
 
In nature, the sea pansy Renilla reinformas, along with other aquatic organisms respond to 
mechanical stimulation with the release of calcium from intracellular stores, which results 
in an indirect stimulatory effect upon its species specific luciferase – renillia luciferase 
(rLuc). Light is produced from rLuc by the catalysis of colentrazine with ATP and oxygen to 
colenteramide, on its own this results in emission at approximately 480 nm. However, GFP 
is located closely and energy is transferred by resonance energy transfer resulting in a 
spectral shift to 520 nm.  
 
Several modifications to this system have made it more suitable for the measurement of 
protein-protein interactions in mammalian cells; such as the development of more stable 
substrates, codon optimised rLuc cDNA and decreasing spectral overlap for donor and 
acceptor emissions. The major advantage of using BRET over FRET is the reduction of 
autofluorescence and incidental fluorescence. However, BRET does suffer from low 
emission from the donor and acceptor fluorophore and therefore has the need for high 
quality microscopes and powerful photomultiplier detection units, which can be 
prohibitively expensive. In practice BRET has been used successfully to measure GPCR 
dimerisation in mammalian cells (Angers et al., 2000) and has undergone vast 
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improvements which allow it to measure many more, previously invisible protein-protein 
interactions (Xu et al., 2007).  
 
1.5 Aims and Hypothesis 
The studies outlined in this thesis represent a planned body of research directed at 
developing a robust assay to elucidate the protein-protein interactions involved in CCR5 
mediated heterotrimeric G-protein activation. Prior to commencing this research, existing 
knowledge supported the notion that CCR5 may interact with more than one family or 
permutation of heterotrimeric G-proteins. It was hypothesised that it may activate 
different heterotrimers dependent upon the ligand and cell specific environment the 
receptor is located in. Typical assay methods employed to investigate these interactions in 
living cells, in real time, rely on inferring interactions from indirect assays that measured 
downstream effectors. Resonance energy transfer approaches allow a novel approach to 
identifying protein-protein interactions 
 
To investigate this hypothesis this research was designed to approach the problem 
addressing three main aims; 
i. The creation and characterisation of suitable cell lines suitable for use in high 
throughput, real time FRET or BRET assays.  
ii. The development and implementation of a high throughput FRET or BRET assay 
system to measure protein-protein interactions. 
iii. To explore the molecular interactions of CCR5 activated G-proteins, using existing 
technologies.  
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Chapter Two  
Materials and Methods 
2.1 Cell Culture 
All cell lines were grown at 37°C, 5% CO2. Human Embryonic Kidney cells stably transfected 
with CCR5 (HEK.CCR5) were a kind gift from British Biotech (Oxford, UK) and were cultured 
in complete DMEM (Invitrogen) (DMEM, 2mM L-glutamine, 10% foetal calf serum 
(Invitrogen), 100 U/mL penicillin 100 µg/mL streptomycin (Invitrogen), 1mM sodium 
pyruvate (Invitrogen), 100µm nonessential amino acids (Invitrogen)) and supplemented 
with 100µg/ml hygromycin B in order to maintain selection pressure for CCR5. Chinese 
Hamster Ovary cells stably transfected with CCR5 (CHO.CCR5), as described (Mueller et al., 
2002b), were cultured with complete DMEM supplemented with 400µg/mL G418, to 
maintain selection pressure. HeLa RC-49 cells stably expressing CCR5 were obtained from 
D.Kabat (Platt et al., 1998) and cultured in complete DMEM. Materials for cell culture and 
buffer composition were bought from Fisher Scientific, unless otherwise stated. Gallein was 
bought from Tocris and dissolved in DMSO at a stock concentration of 75 mM.  
 
2.1.1 Routine Conditions 
Cells were grown in polystyrene 75 cm2 vented cap flasks (Nunc) in a humidified cell culture 
incubator (Thermo Scientific) with CO2 levels maintained at 5%, cell culture was performed 
in a HEPA filtered vertical laminar airflow cabinet (Heraeus). Upon reaching approximately 
80% confluency, cells were washed in PBS (Invitrogen) (1.5 mM potassium phosphate 
monobasic, 3mM potassium phosphate dibasic, 150 mM NaCl; pH 7.2) and resuspended by 
soaking in PBS supplemented with 1 mM EDTA for 10 minutes at 37°C. The majority of cells 
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lifted from the cell culture surface within 10 minutes, the remaining were resuspended by 
gentle agitation of the culture apparatus. Aliquots of cell suspension were centrifuged for 5 
minutes at 800 x g and the supernatant was removed. Cells were resuspended in complete 
DMEM supplemented with selection antibiotics and plated at the appropriate density into 
cell culture flasks. Cells for cryopreservation underwent the same resuspension procedure, 
but were resuspended in FCS supplemented with 10% DMSO (Sigma-Aldrich) (v/v) and 
gently pipetted into vials suitable for cryogenic preservation of mammalian cells. Vials were 
wrapped in tissue and placed in a cell freezing container at -80°C overnight. This allowed 
for the critical cooling rate (1°C/min) required for successful cryopreservation of cells. Long 
term storage of samples was achieved by transferring vials to liquid nitrogen. Batches of 
stable transfectants were typically preserved between passage 3 and 6.  
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2.2 Calcium Flux Measurements 
2.2.1 Fura-2 loading 
Detachment of cells was achieved by removal of the media and incubation with EDTA/PBS 
(1mM EDTA). Cells were pelleted by centrifugation at 1000 x g for 3 minutes and washed 
twice in calcium flux buffer (CAF) (137 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1.5 mM CaCl2, 
10mM HEPES pH 7.4, 25mM D-Glucose) to remove residual EDTA and lysed cells. Cells were 
resuspended to concentration of 2x10-6/ml in CAF and loaded with the membrane 
permeable acetoxymethylester (AM) form of fura-2 (Sigma-Aldrich) at a concentration of  
2 µM. The AM moiety facilitates membrane permeability of fura-2 by masking negative 
charges of it carboxyl groups, creating an uncharged and hydrophobic compound capable 
of diffusing across the cell membrane. Once inside the cell, the AM group is cleaved by 
cellular esterases, resulting in trapping fura-2 in the cytosol. A stock solution of fura-2 AM 
was made in DMSO to a final concentration of 1 mM and stored at -20°C in the dark. All 
cells were loaded with Fura-2 for 40 minutes at 37°C in the dark.  
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2.2.2 Ratiometric Measurement of Calcium Release 
Following the loading of cells with Fura-2, cells were pelleted by centrifugation at 1000 x g 
for 3 minutes and washed twice in CAF before being resuspended to a concentration of 
2x106/ml in CAF. Cells were gently pipetted into black, solid bottomed, 96 well plates 
(Fisher Scientific, UK) and placed in a plate reader. Ratiometric measurements were 
achieved using a BMG fluorostar spectrofluorometer (BMG Labtech, Germany) set to excite 
cells sequentially at 340 nm and 380 nm and measure the resulting emission intensities 
alternately at 510 nm. In order to ensure a standard light path, 100 µl of loaded cells were 
pipetted into each well. Data were recorded by Fluorostar control software (BMG Labtech, 
Germany). 
 
2.3 Spectrophotomic and Statistical Data Analysis 
All spectrophotomic data pertaining to calcium flux measurements, FRET, BRET and 
qualitative cAMP measurements was measured using a BMG fluorostar optima fitted with 
relevant excitation/emission filters (Table 2.1). Relative emissions were recorded by BMG 
Optima Evaluation software in conjunction with Microsoft Windows. Data was further 
transferred to Microsoft Excel 2007 for statistical analysis. Significance between recorded 
means was calculated in Excel by performing unpaired, two-tailed t-test on samples. Real 
time traces, area under curves and sigmoidal curve fitting was performed in GraphPad 
Prism 4. Likewise, logEC50 and efficacy values were calculated in GraphPad Prism 4.  
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2.3.1 Calcium Flux Analysis  
Wells containing Fura2 loaded cells were alternately excited at 340 nm and 380 nm and 
resulting emission intensities were measured at 510 nm. Fluorostar control software was 
programmed to excite samples at 340 and 380 nm with an interval of 1.1 seconds between 
light pulses, allowing real-time ratiometric measurement of calcium mobilisation following 
stimulation. Respective fluorescent emissions were recorded and a ratiometric trace 
produced by calculating the ratio of 340 nm emission over 380 nm emission in Microsoft 
Excel 2007. The pre-stimulation baseline was averaged and subtracted from the maximal 
ratiometric measurement recorded following stimulation. This value was then divided by 
the average pre-stimulation value to provide the standard calcium flux value. This method 
of analysis allows for comparison between experiments where cell number differs. 
  
2.3.2 FRET and BRET Analysis 
FRET measurements were performed in solid bottom, black, 96 well plates (Costar) using a 
BMG Fluorostar plate reader. Filters were set to excite ECFP at 435 nm and EYFP at 510 nm 
and resulting emissions recorded at 485 nm and 530 nm, respectively. Filters were 
programmed to alternately switch between excitation and emission filters with an interval 
of 1.1 seconds between light pulses. The amount of flashes per measurement was set to 
ten per well in order to avoid photobleaching. Subsequent emissions were recorded, 
allowing the real time ratiometric measurement of the FRET signal. As no external light 
source is used for BRET experiments, filters were set to record emission at 530 nm and 
overall luminescence. Ratiometric FRET data was produced by dividing fluorescent emission 
485 nm by fluorescent emission 530 nm. Traces for real time FRET measurements were 
created in GraphPad Prism 4 by plotting points on a xy scatter graph. A curve was fitted to 
data points by plotting the weighted average of each point’s nine neighbours. To easily 
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compare changes in the FRET ratio, the area under the post-stimulation curve (AUC) was 
calculated. This was performed in GraphPad Prism 4. To ensure comparative readings were 
accurate, the baseline for measuring the AUC was set to 1 and the area under all peaks 
above the baseline was calculate and graph dimensions were equalised.  
BRET experiments were performed in solid bottomed, white, 96 well (Costar) plates using a 
BMG Fluorostar platereader. Fluorescent emission was recorded at 530 nm and 
luminescence by selecting emissions to be recorded at 485 nm. Traces and graphs were 
created using the same process as for FRET. 
Assay Excitation (nm) Emission (nm) 
Ca Flux 340-10 510-12 
Ca Flux 380-10 510-12 
ECFP 435-p 485-p 
FRET 435-p 530-12 
EYFP 510-12 530-12 
BRET None 485-p 
BRET None 530-12 
cAMP None Lens 
Table 2.1. Combinations of filters used for different experimental procedures. 
2.3.3 Concentration Response Curve Fitting and Analysis. 
Concentration response graphs were plotted and analysed with GraphPad Prism 4. Cells 
were stimulated with varying concentrations of CCL3 and calcium mobilisation was 
monitored. Calcium flux values were recorded and plotted on a xy scatter graph against the 
corresponding CCL3 concentration. Collated data points were fitted to a nonlinear 
regression curve using a sigmoidal dose-response equation which assumes a hill co-efficient 
of 1. In-built data analysis software calculated logEC50 values and bottom and top values.   
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2.4 Fluorescence Microscopy 
2.4.1 Slide Preparation for CCR5 and Fusion Protein Visualisation  
Cells were resuspended by incubation with 1 mM EDTA/PBS, washed in PBS three times 
and resuspended in complete growth media containing appropriate selection antibiotic to a 
density of 2x106/ml. Glass coverslips were meanwhile rinsed in 70% ethanol and allowed to 
dry in sterile conditions. Coverslips were placed in 35 mm cell culture dishes with 2 ml of 
complete DMEM containing appropriate selection antibiotics. A final concentration of 
2x105 cells were added to each dish and left to incubate at 37°C overnight. The following 
day, glass coverslips were removed from cell culture dishes and gently washed three times 
in PBS. Cells were fixed in 4% paraformaldehyde solution for 10 minutes at 4°C and washed 
following incubation. Cells to be stained for CCR5 expression were incubated for 35 
minutes at 4°C with anti-CCR5 antibody HEK/1/85a/7a, an antibody raised against intact 
CHO.CCR5 cells and the CCR5 N-terminal peptide (Mueller et al., 2002a), washed three 
times with PBS, and incubated for 35 minutes at 4°C with TRITC or FITC labelled anti-rat IgG 
(see Table 2.2 for a full list of antibodies). Cells were washed three times with PBS and 
mounted with glycerol onto a glass slide. CCR5 localisation and expression of G-protein 
fusion proteins linked to ECFP or EYFP was visualised using a Zeiss fluorescent microscope 
in combination with Axiovision imaging software (Zeiss, Germany). 
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Table 2.2 Antibodies used for CCR5 immunofluorescent staining of CCR5 
 
2.4.2 siRNA Transfection Visualisation  
AllStars™ negative control siRNA (Qiagen) modified to contain a rhodamine moiety was 
used to determine transfection rates of siRNA. Cells were transfected in clear bottomed, 
black, 96 well plates and, after 72 hours, washed with PBS and viewed on a Leica DM IL 
fluorescence microscope fitted with a CY3 filter cube (excitation λ546 nm) (Leica, 
Germany). Cells were counter stained with DAPI (Sigma-Aldrich) in order to visualise the 
nucleus. DAPI was dissolved in PBS to a final concentration of 100 ng/ml and incubated 
with cells grown in a clear bottomed, black, 96 well plate at 37°C, 5% CO2. Following 
incubation cells were washed three times in PBS and viewed under the microscope.  
 
Antibody Manufacturer Dilution 
Anti CCR5 HEK/1/85a/7a 
Gift from J. A. Mackeating, 
Reading (Mueller et al., 
2002b) 
Undiluted 
Anti Rat TRITc conjugated 
IgG 
Sigma- Aldrich 1:200 
Anti Rat FITC Conjugated IgG Sigma-Aldrich 1:1000 
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2.5. Cloning and Molecular Biology Techniques  
2.5.1 Plasmids 
The pcDNA3.1 vector was used for amplification of all inserts in E.coli. pcDNA3.1 with insert 
were either used for transfection or inserts were excised and ligated into pcDNA6 v5-His or 
pZEO SV2 ready for transfection. The specific cloning practice utilised for different 
experimental procedures is outlined where relevant. 
 
2.5.2 Primers 
All primers were purchased from Invitrogen and resuspended in PCR quality water to a final 
concentration of 250 µM. 
Gαi2-ECFP 
5’ Primer 5’ TCG GAT CCA TGG GCT GCA CCG TG 3’ BAM HI introduced 
3’ Primer 5’ TTG GAT CCA AGA GGC CGC AGT CCTT CAG 3’ BAM HI introduced 
EYFP-Gβ1 
5’ Primer 5’ TTA AGC TTC TTC CAG ATC TTG AGG AAG C 3’ HIND III introduced 
3’ Primer 5’ CGA AGC TTA TGG TGA GCA AGG GCG AGG 3’ HIND III introduced 
hrLuc-Gαi2 
5’ Primer 5’ TTA AGC TTC TTC CAG ATC TTG AGG AAG C 3’ HIND III introduced 
3’ Primer 5’ CGA AGC TTA TGG TGA GCA AGG GCG AGG 3’ KPN I introduced 
Table 2.3 A list of primers used and the cut sites introduced to inserts used. 
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2.5.3 Transformation of DH5α 
E.coli DH5α (Invitrogen) was transformed with various plasmid constructs for amplification 
of plasmids. 35 µl of E.coli DH5α were thawed on wet ice and gently mixed by stirring with 
a pipette tip. 1-5 µg of plasmid construct was added to E.coli that had been left to thaw on 
ice and incubated on ice for a further 30 minutes. Cells were heat shocked at 42°C for 90 
seconds and placed on ice for 2 minutes. 965 µl of pre-warmed LB broth was added to heat 
shocked cells and incubated in a rotary shaker at 37°C, 225 rpm for 2 hours. 200µl of 
bacterial broth was spread on LB agar plates containing ampicillin (20 µg/ ml) and grown 
overnight at 37°C. Colonies were picked the following day and incubated overnight in 2 ml 
cultures containing ampicillin (20 µg/ ml). 
 
2.5.4 Plasmid Isolation (analytical) 
Transformed bacterial cultures were centrifuged at 3900g for 5 minutes. The supernatant 
was discarded and the pellet resuspended in 200μl STET-L buffer (Sucrose 8% (v/v), Tris/HCl 
pH8 50 mM, EDTA 50mM, Triton X-100 0.1% (v/v), and lyzozyme 10 mg/mL). The mixture 
was then placed in a heat block for 60 seconds at 100°C. After heating, the mixture was 
immediately transferred to ice and then centrifuged at 9000 RCF for 15 mins. The pellet 
(cell lysate) was removed from the supernatant and 200 μl of isopropanol was added. 
Samples were then centrifuged at 9000 RCF for 40 mins. The supernatant was removed and 
200 μl of 70% ethanol was added to the pellet, which was then centrifuged at 9000 RCF for 
five minutes. The supernatant was carefully pipetted out and the pellet was air dried. 
Plasmids were then resuspended in 20μl of P1 + RNAse buffer (Invitrogen).  
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2.5.4.1 Plasmid isolation (amplification) 
Transformed E.coli DH5α was picked from an ampicillin resistant agar plate with a sterile 
pipette tip and grown in 2 ml of LB media supplemented with ampicillin (25µg/mL) at 37°C, 
225 RPM. The culture was then transferred into 100ml of LB/Ampicillin media and grown 
over night at 37°C, 225 RPM in a conical flask. The following morning the bacterial culture 
was decanted into a 50 ml plastic centrifuge tube and centrifuged at 15000 x g at 4°C for 15 
minutes. Reagents for plasmid isolation were purchased as part of a commercially available 
midiprep kit and used in accordance to the manufacturer’s instructions. Briefly, the 
supernatant was discarded and cells resuspended in 5 ml of resuspension buffer P1 (50mM 
Tris-Cl, pH 8.0, 10mM EDTA, 100ug/mL RNase A) by careful agitation. 5ml of lysis buffer P2 
(200mM NaOH, 1% SDS) was immediately added following resuspension and the sample 
mixed by carefully inverting the tube 10 times followed by incubation for 5 minutes at 
ambient temperature. Following incubation, 5 ml of neutralisation buffer P3 (3 M 
potassium acetate, pH 5.5) was added and mixed by careful inversion of the tube. The 
sample was centrifuged at 15000 x g for 10 minutes at 4°C to remove cellular debris. 
Meanwhile a DNA affinity column was equilibrated in equilibration buffer (750mM NaCl, 
50mM MOPS, pH7, 15% isopropanol, 0.15% Triton X-100). The supernatant was added to 
the column and allowed to flow through by gravity. The loaded column was washed twice 
with wash buffer (1M NaCl, 50mM MOPS, pH 7.0, 15% isopropanol), the flow-though 
discarded and 5 ml of elution buffer (1.25M NaCl, 50mM Tris-Cl, pH 8.5, 15% isopropanol) 
added to the column. The flow-through was collected and 3.5 ml of isopropanol added, 
before centrifuging the sample for 60 minutes at 15000 x g, 4°C. The supernatant was 
carefully removed and gently rinsed with 3 ml of 70 % ethanol. The sample was centrifuged 
for 5 minutes at 15000 rcf, 4°C and the supernatant removed. The pellet was allowed to air 
dry for 5 minutes and resuspended in 200 µl of TE buffer (10mM Tris-Cl, pH 8.0, 1mM 
EDTA). Plasmid concentration was determined by U.V. spectrophotometry.  
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2.5.5 Plasmid Digestion 
Analytical digests were performed to confirm the correct insertion of inserts into plasmids. 
Plasmid digestions were also performed to isolate inserts for further processing. For 
analytical digests, 1 µl of isolated plasmid was mixed with x10 buffer (NEB) and 20U of the 
relevant restriction enzyme in a total reaction volume of 10 µl, made to volume by the 
addition of nuclease free ddH2O (Promega). The mixtures were incubated at 37°C for 2 hrs 
and analysed by agarose electrophoresis. For digests involved in further processing, 16 µl 
plasmid, 2 µl x10 buffer and 200U of relevant restriction enzyme were used in a total 
reaction volume of 20 µl, made up to volume by the addition of nuclease free ddH2O. 
 
2.5.6 Agarose Gel Electrophoresis DNA Separation and Purification 
Digested plasmids were separated on 1% agarose gel (w/v), made by mixing agarose 
powder in TAE buffer (500 mM TRIS, 50 mM Acetate, 7 mM EDTA, pH 7.1) and boiling the 
mixture in the microwave until the agarose dissolved. The mixture was left to cool to 
approximately 60°C then 10 µl ethidium bromide (10mg/mL) was added. The mixture was 
swirled and poured into a cast to set for one hour, with a well casting comb in order to 
create wells for samples. The set gel slab was placed in an electrophoresis tank (Bio-Rad), 
covered with TAE buffer. Digested plasmids were mixed in a 1:4 ratio with X4 sample 
loading buffer (50 mM TRIS, 5 mM EDTA, 25% Sucrose, 2 mg/mL bromophenol blue). 20 µl 
of the resulting mixture was loaded to each well. Electrophoresis was performed for 45 
minutes at 110 volts. Ethidium bromide intercalates double stranded DNA, allowing for 
fluorescence visualisation of fragments by excitation with UV light. During brief 
visualisation, in order to prevent denaturation of DNA, excised fragments were cut from 
the gel and placed in plastic tubes. Agarose was solubilised and DNA isolated using a 
commercially available purification kit (Qiagen). 
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2.5.7 Polymerase Chain Reaction 
For PCR, 10µL of X10 Taq reaction buffer (Bio-Rad), 1 µL of forward primer, 1µL of reverse 
primer, 5 µL of 2 mM dNTP (NEB), 8 µL of 25 mM MgCl2, 500 ng of template DNA were 
added to a PCR compatible microfuge tube and the volume made to 100 µl by the addition 
of PCR quality water (Bio-Rad). 0.5 µL of Taq polymerase was added to the reaction mixture 
and the microfuge tube placed in a thermal cycler. The reaction mixture was heated to 
94°C for 40 seconds, followed by cooling to 55°C for 90 seconds and heating to72°C for 60 
seconds. This cycle was repeated 30 times, with the 30th cycle holding the 72°C extension 
for five minutes before cooling the reaction mixture to 4°C. A control containing no DNA 
template was run to ensure no contamination. Amplification of the desired sequence was 
confirmed by running samples on an agarose electrophoresis gel loaded. Amplified 
sequences were purified with a commercially available purification kit.  
 
2.5.8 Phophatase Treatment of Sequences 
Cut vectors were treated with calf intestinal phosphatase (CIP) (NEB) to prevent re-
annealing of cut ends. Samples were resuspended in TEbuffer (NEB) to a concentration of 
0.5 µg/10 µL, CIP was added to a final concentration of 0.5 U/µg DNA. The reaction was 
incubated at 37°C for 60 minutes and resulting DNA purified using a commercially available 
plasmid purification kit (Qiagen).  
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2.5.9 Purification of DNA after Enzymatic reactions 
Enzymes and other impurities were removed from DNA containing solutions by passing the 
reaction mixture through a Qiaquick DNA clean up kit (Qiagen). Buffer PN was added to the 
DNA mixture and pipetted to spin column containing a silica membrane and centrifuged for 
1 minute at 8000 x g. Nucleic acids in the mixture adsorb to the silica membrane in the 
high-salt conditions provided by buffer PN, while other impurities are collected in a 
disposable tube and discarded. 30µL of PCR quality water (p.H. 7-8.5) was added directly to 
the silica membrane and left to stand for 1 minute before centrifuging for 1 minute at 
17,000 x g. DNA concentration was determined by absorbance at 260 nm.  
 
2.5.10 Ligation 
For ligation 100-250 µg of DNA was added to ligation buffer (660 mM TRIS-HCl, 50 mM 
MgCl, 10 mM ATP, pH 7.6) and 1 µL (1U) of T4 DNA Ligase (NEB) was added to the mixture 
and incubated at room temperature for 3 hours. Ligated constructs were confirmed by 
digestion and analytical agarose electrophoresis.  
2.6 Transfection 
2.6.1 Transfection of DNA 
Transfection of plasmid constructs into HEK.CCR5, CHO.CCR5 and HeLa RC-49 were 
performed using GeneJuice (Novagen), Lipofectamine (Invitrogen), or FuGene(Roche), 
following the manufacturers procedure for transfection of adherent cells in a 35 mm cell 
culture dish. Cells were seeded one day prior to transfection and were always between 50-
80% confluent when transfected. Exact amounts of GeneJuice and plasmid were optimised 
for each cell type and plasmid (Table 2.4).   
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2.6.2 Transfection of siRNA 
siRNA sequences were resuspended in siRNA resuspension buffer (Qiagen) to a final 
concentration of 20 µM. HeLa RC-49 were resuspended by incubation with EDTA/PBS for 10 
minutes at 37°C, washed and resuspended to a final concentration 5 x 104 /ml in complete 
DMEM. Cells were seeded immediately before transfection into a 24 well plate, 500µl of 
cell suspension was added to each well and the plate incubated at 37°C 5%CO2. For each 
well to be transfected 100 µl of plain DMEM and between 7.5 ng – 15 ng of siRNA was 
added to the media in an RNAse free plastic vial and immediately vortexed for 10 seconds. 
1.5 µl of INTERFERin (Polyplus, France) was then added to the mixture, mixed by agitation 
with the pipette and incubated in sterile conditions at room temperature for 15 minutes. 
Following incubation, which allows transfection reagent – siRNA complexes to form, 100 µl 
of mixture was added to each well. The cell culture dish was mixed by swirling the plate 
gently then subsequently incubated for 72hrs at 37°C, 5% CO2 before harvesting for 
experiments. Final siRNA amounts used during transfection were optimised for each 
sequence (Table 2.5). 
 
2.6.3 Transfection Reagents and Volumes 
Reagent Manufacturer Ratio to Plasmid DNA (µL:µg) 
GeneJuice Novagen 10:5 
FuGene Roche 10:5 
Lipofectamine Invitrogen 10:4 
Table 2.4 Reagents and Ratios for Plasmid DNA transfections in 35mm dishes 
Reagent Manufacturer Ratio to siRNA (µL:ng) 
INTERFERin Polyplus 1.5:7.5-15 
Table 2.5 Reagent and Ratios for siRNA transfections in 24-well plates per well 
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2.7 Western Blotting 
Western blot analysis enables the qualitative detection of a specific protein from a mixture 
of proteins by utilising antibodies directed against the protein of interest. Not only does it 
provide information about the level of protein expression but also the size of the protein. 
 
2.7.1 Protein Extraction and Preparation  
Protein was extracted from cells cultured in a 35 mm cell culture dish using a combination 
of cell lysis buffer (Tris-HCl 0.1 M, 20% glycerol, 10% SDS, pH 7.6) and sonication of cellular 
material. Cultured cells were resuspended with EDTA/PBS and centrifuged at 4000g for five 
minutes. The pellet was resuspended by vigorous pipetting in lysis buffer followed by 
approximately 10 pulses with a sonicating probe for 2 s at 80% amplitude and 0.8 pulse. 
Samples were spun for 5 minutes at 14000 g, the pellet discarded and x4 sample buffer (4% 
SDS, 0.02% bromophenol blue, 20% glycerol, 10% mercaptopropandiol, 80 mM Tris pH 6.8) 
added to the supernatant to ensure all proteins are denatured and to facilitate loading to 
the gel. Samples were then heated to 95°C for 5 minutes and placed on ice to cool during 
the assembly of apparatus.  
 
2.7.2 SDS-PAGE Gel Electrophoresis and Protein Transfer 
Samples were run on a 13% acrylamide resolving gel (0.67155g Tris/SDS 2% pH 8.8, 13% 
acrylamide v/v, 0.1% ammonium persulphate w/v, 0.01% TEMED v/v) and loaded onto a 
4.5% acrylamide stacking gel (0.1089g Tris/SDS 2% pH 8.8, 4.5% acrylamide v/v, 0.1% 
ammonium persulphate w/v, 0.01% TEMED v/v). Protein samples were loaded to the gel 
together with broad range protein marker (NEB). Samples were run at room temperature 
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at a constant voltage of 200V, until the dye front reached the bottom of the gel, which 
typically took 45 minutes.  
Protein transfer was achieved using a Bio-Rad semi-dry electroblotter. Sponges, filter paper 
(Whatman) and nitrocellulose membranes (Whatman) were soaked in transfer buffer 
(pH8.3, 25 mM Tris, 192 mM glycine, 10% methanol) at room temperature for 15 minutes 
prior to assembly. The SDS-Page gel was placed together with the nitrocellulose membrane 
in a sandwich of thick filter papers and sponges, and a voltage of 15V was passed through 
the stack for 45 minutes to ensure complete transfer.  
 
2.7.3 Immunoblotting and Development 
To avoid unspecific binding of antibodies to transferred proteins, membranes were 
incubated in a blocking solution of 0.5% Tween-20 in PBS (PBS-T) with 5% fat-reduced milk 
powder (Marvel) for one hour at room temperature with gentle shaking. Membranes were 
then washed for 10 minutes in PBS-T three times before being incubated with primary 
antibody diluted in 5% PBS-T overnight at 4°C in a rotary wheel. Dilution factors for primary 
antibodies were 1:100 for HEK/1/85a/7a and 1:500 for all probed Gα subunits (Table 2.6). 
Membranes were then washed for 10 minutes in PBS-T three times before being incubated 
with secondary antibody for one hour at room temperature on a shaking plate. Secondary 
antibodies were diluted in blocking buffer by a dilution factor of 1:10000 (Table 2.7). 
Membranes were then washed for 10 minutes, three times in PBS-T. Proteins were 
detected using Novax Chemiluminescence reagents (Pierce) according to the 
manufacturer’s instructions. The light reaction produced was detected with an X-ray film 
(GE-Healthcare Life Sciences)) and developed using an automatic X-ograph developing 
machine (Kodak) according to the manufacturer’s guidelines. Developed films were then 
photographed using a digital camera (Samsung) and transferred to computer file.
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2.7.4 Antibodies for Immunoblotting 
Antibody Manufacturer Dilution 
Anti CCR5 HEK/1/85a/7a 
(Rat) 
A kind gift from J. A. 
Mckeating, Reading 
1:100 
Anti-Gαi2 
(Rabbit) 
Santa-Cruz 1:500 
Anti-Gαq 
(Rabbit) 
Santa-Cruz 1:500 
Anti-Gαi1/3 
(Rabbit) 
Santa-Cruz 1:500 
Table 2.6 Primary Antibody Details 
Antibody Manufacturer Dilution 
Anti-Rat IgG Horseradish 
Peroxidase 
Sigma-Aldrich 1:10000 
Anti-Rabbit IgG Horseradish 
Peroxidase 
Sigma-Aldrich 1:10000 
Table 2.7 Secondary Antibody Details 
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2.8 cAMP Measurement  
cAMP levels were determined using the bioluminescent cAMP-GloTM assay developed by 
Promega. The assay allows for the measurement of cAMP without the use of radioactive 
compounds or the need for prohibitively expensive antibody ELISA assays. The assay is 
based on the activation of protein kinase A by cAMP, resulting in decreased ATP levels in 
homogenised cell lysate. In this assay, bioluminescence produced is proportional to levels 
of ATP, and therefore reversely proportional to cAMP levels.  
 
HeLa RC-49 cells were grown to approximately 80% confluency in 35 mm cell culture 
dishes. Cells were resuspended in EDTA/PBS, centrifuged at 1000 g for five minutes and 
resuspended in induction buffer (PBS containing 1 mM Isobutylmethylxanthine (IBMX)), to 
prevent phosphodiesterase activity, to a density of 1.5 x 105 /ml and incubated for 30 
minutes at 37°C 5% CO2. Cells were then incubated in induction buffer containing 10 µM 
forskolin (Tocris), an activator of adenylyl cyclase, and treated with Gallein or a DMSO 
control and incubated for a further 20 minutes. Following treatment, cells were centrifuged 
and resuspended to 1.5 x 105 /ml in induction buffer. For dose response curves, cells were 
treated with varying concentrations of CCL3 for 3 minutes, before the addition of lysis 
buffer (Promega, proprietary formula). The qualitative amounts of cAMP under different 
conditions were determined using the cAMP-Glo assay according to the manufacturer’s 
instructions (Promega). 
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Chapter Three 
Creation and Characterisation of 
Cells Stably Expressing Tagged G-
Proteins 
3.1 Introduction 
The task of measuring protein-protein interactions in living cells is fraught with difficulty, 
with no single method able to simply and adequately detect the vast variety of interactions 
within living cells. FRET has, in recent years, become a relatively popular method to 
disseminate the interactions of a protein couple in model single cell systems. Transient 
transfection of DNA coding for the protein(s) of interest linked to a fluorescent protein is a 
well defined method of monitoring interactions. Although there are advantages to this 
methodology, there are several drawbacks and limitations associated with single cell work. 
Over-expression of tagged protein is often required in order to create a system capable of 
being monitored by FRET, this can result in the loss of normal physiological function of the 
cell. Transient transfection required to create this system can result in inconsistent 
expression between cells. Measurement of FRET in single cell systems often relies upon a 
laboratory being equipped with a high quality live cell imaging confocal microscope. 
Development of a stable expression system would circumnavigate these issues and allow 
for rapid high throughput screening of ligand specific protein-protein interactions. 
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At present there are no cell lines that possess all the characteristics required for the 
measurement of protein-protein interaction by FRET. However, several cell lines are 
suitable to use for creating stable cell lines due to their ease of transfection and simplicity 
of cell culture. Human Embryonic Kidney 293 (HEK) cells and Chinese Hamster Ovary (CHO) 
cells are well established and well characterised cell lines to carry out transfections in, and 
have previously been described to stably over express CCR5 with no physiological 
perturbation (Mueller et al., 2002b; Mueller et al., 2004a). The ease of transfection and 
culture will aid the clonal selection of cells exhibiting qualities required for the creation of a 
cell line capable of being used to measure G-protein activation by FRET. 
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3.2 Results 
A prerequisite to the creation of stable cell lines is the creation of plasmids containing the 
coding sequence for the protein of interest. Plasmids containing full length, sequence 
verified, and expression verified cDNA sequences for human Gαi2 and human Gβ1 were 
bought from Missouri S&T cDNA Resource Center. These sequences were free of 
exotraneous 3’ and 5’ untranslated regions and were propagated in pcDNA3.1+. 
 
During the course of this project several plasmids containing G-protein fusion constructs 
were created. pcDNA3.1:Gαi2-ECFP and pcDNA6/V5-His:EYFP-Gβ1 were initially created 
alongside pcDNA3.1:EYFP-Gβ1 and pcDNA6/V5-His:Gαi2-ECFP for transfection into 
HEK.CCR5, which stably expresses CCR5 concomitantly with a hygromycin resistance gene. 
pcDNA3.1 contains a geneticin resistance gene and pcDNA6v5-His contains a blasticidin 
resistance gene, therefore allowing selection of multiple transfectants. The stable 
expression of CCR5 in CHO.CCR5 cells was selected by the concomitant expression of a 
geneticin resistance gene, consequently additional vectors for transfection of constructs 
were created to allow multiple selection in CHO.CCR5. pZeo SV2:EYFP-Gβ1 containing a 
zeocin resistance gene was created to circumnavigate the problem of identical resistance 
genes in plasmids and facilitate selection of stable cell lines in CHO.CCR5. pcDNA6/V5-
His:Gαi2-ECFP was used in CHO.CCR5 as well as HEK.CCR5. For a full list of plasmids used in 
the creation of stable cell lines see Table 3.1. 
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Cell line 1st plasmid Expression 2nd plasmid Expression 3rd plasmid Expression 
HEK.CCR5 
Parental 
pIRES:CCR5 
(Hygromycin B) 
CCR5     
HEK.CCR5 
EYFP 
pIRES:CCR5 
(Hygromycin B) 
CCR5 
PcDNA6 V5-HIS 
(Blasticidin) 
EYFP-Gβ1   
HEK.CCR5 
ECFP 
pIRES:CCR5 
(Hygromycin B) 
CCR5 
PcDNA6 V5-HIS 
(Blasticidin) 
Gαi2-ECFP   
HEK.CCR5 
EYFP-ECFP 
pIRES:CCR5 
(Hygromycin B) 
CCR5 
PcDNA6 V5-HIS 
(Blasticidin) 
EYFP-Gβ1 
PcDNA3.1 
(G418) 
Gαi2-ECFP 
       
CHO.CCR5 
Parental 
PcDNA3:CCR5 
(G418) 
CCR5     
CHO.CCR5 
EYFP 
PcDNA3:CCR5 
(G418) 
CCR5 
pZeo SV2 
(Zeocin) 
EYFP-Gβ1   
CHO.CCR5 
ECFP 
PcDNA3:CCR5 
(G418) 
CCR5 
PcDNA6 V5-HIS 
(Blasticidin) 
Gαi2-ECFP   
CHO.CCR5 
ECFP-EYFP 
PcDNA3:CCR5 
(G418) 
CCR5 
PcDNA6 V5-HIS 
(Blasticidin) 
Gαi2-ECFP 
pZeo SV2 
(Zeocin) 
EYFP-Gβ1 
Table 3.1. A complete list of stable cell lines produced during this project. Plasmid and cDNA inserts used for stable cell line production are listed; the antibiotic resistance gene used for 
selection of the stable cell line is in brackets.  
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3.2.1 Creation of Plasmids for HEK.CCR5 Stable Expression 
Gαi2 cDNA was amplified by PCR introducing Xma1 cut sites at the 5’ and 3’ regions, and 
ligated into pAC409. Guided by previous studies showing fusion of ECFP does not perturb 
the normal activity of the G alpha subunit (Janetopoulos et al., 2001). ECFP was obtained 
by PCR amplification of the ECFP cDNA sequence located in pECFP-C1, purchased from 
Clonetech, with primers coding for N and C terminus Pst1 cut sites. The amplified cDNA was 
purified by agarose gel electrophoresis solubilisation and inserted into pAC409:Gαi2 at the 
naturally occurring Pst1 cut site (5’ CTGCAG 3’) 304 bases into the Gαi2 cDNA sequence. 
Correctly expressed Gαi2-ECFP has ECFP inserted between a leucine and glycine residue 
which form the turn between the 1st and 2nd alpha helix of the G-protein. The pAC409:Gαi2-
ECFP construct was amplified by PCR with primers that introduced BamH1 sites at the 5’ 
and 3’ regions. (Gα BamHI 5’, 5’ TCG GAT CCA TGG GCT GCA CCG TG 3’, GαBamH1 3’, 5’ TTG 
GAT CCA AGA GGC CGC AGT CCTT CAG 3’). The Gαi2-ECFP construct ligated into pGEM, 
amplified, excised, and was purified by agarose gel electrophoresis solubilisation then 
ligated into pcDNA3.1(+) creating a plasmid construct that allows for selection in 
transfected mammalian cells with G418 (Figure 3.1A). 
 
The cDNA sequence for Gβ1 was amplified by PCR introducing a 5’ EcoR1 cut site and a 3’ 
BamH1 cut site, purified by agarose gel electrophoresis solubilisation and ligated into 
pVL1392. EYFP was obtained by PCR amplification of the EYFP cDNA located in pEYFP-N1, 
purchased from Clonetech, with primers coding for 5’ and 3’ EcoR1 cut sites. Isolated EYFP 
was then ligated into pGEM, transformed into E.coli and amplified, the plasmid was 
purified by midiprep and EYFP was excised with EcoR1 and purified by agarose gel 
electrophoresis solubilisation. The resulting fragment was then ligated to the N-terminus of 
pVL1392:Gβ1. The EYFP-Gβ1 construct was amplified by PCR with primers containing HindIII 
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cut sites to the 5’ and 3’ regions (Gβ1 HindIII 5’, 5’TTA AGC TTC TTC CAG ATC TTG AGG AAG 
C3’, Gβ1 HindIII 3’, 5’CGA AGC TTA TGG TGA GCA AGG GCG AGG3’) and then ligated into 
pcDNA6/V5-His allowing selection in mammalian cells with blasticidin (Figure 3.1B). The 
EYFP-Gβ1 construct was removed from the pcDNA6/V5-His vector by restriction nuclease 
digest with Hind III and ligated into pcDNA3.1(+)to form an additional vector for 
transfection.  
 
 
Figure 3.1 Schematic representations of the plasmids produced and transfected to create stable 
HEK.CCR5 expressing G-proteins tagged with fluorescent proteins. Both plasmids contain ampicillin 
resitance genes for selection in bacteria. (A) ECFP is approximately 700 bp in length and Gαi2 is 
approximately 1100 bp in length. However, Insertion of ECFP at the Pst1 site in the Gαi2 cDNA gives rise 
to two coding regions of approximately 300 bp and 800 bp. pcDNA3.1 contains a neomycin resistance 
gene allowing selection using G418 in mammalian cells. (B) EYFP is approximately 700 bp in length and 
Gβ1 is approximately 1000 bp in length. The blasticidin resistance gene in pcDNA6/V5-His allows 
selection in mammalian cells using blasticidin. 
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3.2.2 Selection of Stable Single Expression HEK.CCR5  
Following transfection, with either pcDNA6/V5-His:EYFP-Gβ1 or pcDNA3.1:Gαi2-ECFP, cells 
were left to grow for 72 hours and then harvested and seeded out at low density in a 96 
well plate in appropriate selection media. Proliferation and morphology of transfected cells 
was monitored by periodic viewing with a light microscope, proliferation in both 
transfectants was noted to be slightly slower than in the parental cell line. There was no 
noticeable effect upon cell morphology following transfection. 
Several cell lines that had a similar proliferation rate to the parental cell line were scaled 
up. Cell morphology was observed not to be different to parental cells and expression of 
fluorescent construct appeared to be relatively high and uniform in the selected cell lines. 
The cell lines chosen for further studies displayed excellent expression of tagged G-protein 
(Figure 3.2). 
 
 
Figure 3.2 (A) HEK.CCR5 Gαi2-ECFP showing population wide expression of Gαi2 ECFP. (B) HEK.CCR5 EYFP-Gβ1 
stable cell line, showing population wide expression of EYFP-Gβ1. These pictures are representative of the 
stable cell lines cultured in further experiments. 
A B 
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3.2.3 Characterisation of Stable HEK.CCR5 Single Transfectants 
Stable single expression cell lines were characterised by measuring response to CCL3 
stimulation compared to the parental cell line. Expression of constructs had no significant 
effect on potency of CCL3 activating CCR5 mediated calcium release. Log Ec50 values of 
stable HEK.CCR5 Gαi2-ECFP and HEK.CCR5 EYFP-Gβ1 closely matched parental value of -
7.451M (±0.1107 M, n=6) being -7.472 M (±0.1376 M, n=6) and -7.554 M (± 0.1482 M, n=3), 
respectively (Figure 3.3). This clearly indicates that the stable expression of either construct 
does not perturb the normal signalling mechanisms of CCR5. 
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Figure 3.3 Dose response curves of single stable transfected cell lines. (A) HEK.CCR5 EYFP-Gβ1 shows no 
decrease in efficacy or potency for CCL3 following transfection and selection. Log EC50 HEK.CCR5 -7.451 M, 
HEK.CCR5 EYFP-Gβ1 -7.554. (B) HEK.CCR5 Gαi2-ECFP shows no decrease in efficacy of potency for CCL3 
following transfection and selection. Log EC50 HEK.CCR5 -7.451 M, HEK.CCR5 Gαi2-ECFP -7.472 M.  Plotted 
points were normalised to the maximal HEK.CCR5 calcium flux. Each point represents three or more 
individual experiments. 
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3.2.4 Creation of HEK.CCR5 EYFP-Gβ1 Gαi2-ECFP 
HEK.CCR5 EYFP-Gβ1 was favoured for transfection with pcDNA3.1:Gαi2-ECFP to create a 
stable cell line capable of FRET, due to its quicker proliferation rates. Following 
transfection, stable cell lines were selected using a dual selection media containing 
blasticidin, G418, and hygromycin. Cells that survived were harvested and seeded into a 96 
well plate at low density. Cell proliferation and morphology was monitored by observation 
with light microscope. Proliferation was markedly impaired in the stable HEK.CCR5 EYFP-
Gβ1/Gαi2-ECFP and cells noticeably clumped together. A result of which was the inability to 
form a consistent adherent monolayer. When cells reached approximately 80% confluence 
they were scaled up into a 24 well dish. Wells with slow proliferating and non adherent cell 
lines were discarded. Once cells reached approximately 80% confluence they were seeded 
onto coverslips and expression was observed by fluorescent microscopy. Several cell lines 
expressed very low amounts of recombinant protein and were discarded. Eight dual 
expression cell lines expressed both constructs with relative constancy across the cell 
population and were scaled up for further characterisation. 
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3.2.5 Characterisation of Dual Fluorescence HEK.CCR5 
Scaled up stable HEK.CCR5 EYFP-Gβ1/Gαi2-ECFP were assigned identification initials. 
Measurement of Log EC50 values by dose response calcium flux measurements indicated 
that signalling had been perturbed in some cell lines, these cell lines were discarded. Cell 
lines 3, 5, B1, B2, and C1 were not significantly perturbed by stable expression of Gαi2-ECFP 
and EYFP-Gβ1 (Table 3.2). However, cell line 3 was discarded due to observed unusual 
morphology. Cell lines 5 and C1 were discarded due to a significant decrease in CCL3 
efficacy. Cell lines B1 and B2 displayed signalling responses and proliferation rates closest 
to that of the parental cell line and therefore were selected for FRET experiments. 
However, there was a substantial loss in the adherence of these cells to cell culture 
surfaces, consequently making the culture of these stable cell lines difficult. 
The Fate of HEK.CCR5 EYFP-Gβ1 Gαi2-ECFP Sub-Clones  
Cell line Log EC50 [M] n Notes 
Parental -7.746 3  
2 -5.979 2 Discarded 
3 -8.034 2 Unusual Morphology 
4 N/A 0 Discarded, slow proliferation  
5 -7.876 2 Low efficacy 
A5 -6.810 3 Discarded 
B1 -7.140 3 Further studies 
B2 -7.863 3 Further studies 
C1 -7.489 2 Low efficacy 
Table 3.2 Log Ec50 values for HEK.CCR5.Y/C selected stable cell lines. Log Ec50 values were determined by 
plotting dose response curves using CCL3 as the ligand. It was not possible to get an n=3 result for all created 
stable cell lines due to difficulties with cell culture.  
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Stable cell line B2, here on in referred to as HEK.CC5.Y/C, was selected for further studies 
over cell line B1 as it was found to adhere with greater resolve to microscopy coverslips 
during washing, albeit with greatly reduced adherence compared to parental cell lines. Log 
EC50 values for HEK.CC5 Y/C closely resembled those of the parental cell lines, however 
there was a difference in maximal response when stimulated with CCL3 (Figure 3.4A). 
HEK.CCR5.Y/C on average signalled at 77.68% (±10.26%, n3) of the parental maximal 
response following treatment with 1 µM CCL3, suggesting expression of both constructs 
together interferes with CCR5 regulated calcium release. Analysis by Student’s t-test 
showed there to be no significant difference for any of the plotted points. 
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Figure 3.4. Characterisation of HEK.CCR5.Y/C. (A). Dose response curve of HEK.CCR5.Y/C and HEK.CCR5 
(control). Log Ec50 values; Control-7.746 M, HEK.CCR5.Y/C -7.863 M. Curves are the result of three 
independent experiments. No significant difference was observed between points. (B). Relative fluorescence 
levels of HEK.CCR5.Y/C. EYFP fluorescence is measured at 530 nm after excitation at 510 nm. ECFP 
fluorescence is measured at 485 nm following excitation at 410 nm. FRET is the emission at 530 nm following 
excitation at 410 nm.    
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Fluorescence was measured for three channels to confirm and quantify expression of 
fluorescent protein in transfected cell lines. In HEK Y/C cells there is a trend towards 
increased FRET coupling as well as enhanced ECFP and EYFP fluorescence (Figure 3.4B). 
HEK.Y/C exhibited a 4.7% (±2.63%, n=3) increase in FRET emission. Cells also fluoresced at a 
0.91% (±1.33%, n=3) and 1.59% (±1.81%, n=3) greater intensity for ECFP and EYFP. 
However, variance in expression levels over time lead to inconsistent results and difficulty 
with reproducibility. Data show a trend that constructs are being expressed in HEK cells and 
forming donor-acceptor complexes in conjunction with typical G-protein heterotrimers. 
Fluorescence images of HEK Y/C further confirmed the likelihood of formation of donor 
acceptor complexes, showing co-localisation of Gαi2-ECFP and EYFP-Gβ1 at the plasma 
membrane (Figure 3.5).  
 
Microscopy of HEK.CCR5.Y/C was difficult due to issues with adherence. Cells grown on 
coverslips would come loose, even with gentle washing in PBS. Fluorescent images show 
expression of fluorescent constructs and an altered morphology to that of cells grown in a 
cell culture flask  
 
Due to difficulties in imaging and culture of HEK.CCR5.Y/C studies with this cell line were 
not pursued beyond preliminary measurements of resting FRET levels. Instead a new series 
of stable double fluorescent cell lines were created in CHO cells stably expressing CCR5. 
CHO.CCR5 had been previously created for other studies (Mueller et al., 2002a). 
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Figure3.5 Fluorescent microscopy images of HEK.CCR5.Y/C. (A) Immunofluorescence of CCR5 expression in 
HEK.CCR5.Y/C. Cells were labelled with the anti CCR5 IgG HEK/1/85a/7a and stained with TRITC conjugated 
anti rat IgG. Images show functional CCR5 is adequately expressed and co-localised at the plasma membrane. 
(B) Stable expression of Gαi2-ECFP. Arrows indicate tagged G-protein is expressed and co-localised at the 
plasma membrane. (C) Stable expression of EYFP-Gβ1. Good examples of plasma membrane localisation are 
indicated with arrows. (D) Overlay, image clearly shows CCR5 and tagged G-proteins co-localise at the plasma 
membrane. 
A B 
D C 
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3.3.1 Creation of Plasmids for Stable Expression in CHO.CCR5 
CHO cells, like HEK cells, are well characterised cell lines used commonly in the expression 
of recombinant proteins and the pharmacological study of G-protein signalling. Similarly, 
they also have the advantage of being cells that transfect readily, express relatively high 
yields of the transfected protein and have simple cell culture requirements (Geisse et al., 
1996). In addition, they are renowned for their resilience in in vitro cell culture (Puck et al., 
1958). Although origin of the cells is not human, sufficient studies have shown expression 
of recombinant human protein in CHO does not affect protein folding or post translational 
modifications. As such, CHO.CCR5 provides a perfect model for proof of concept and can be 
considered analogous to a human derived cell line. 
 
CCR5 expression is maintained in CHO.CCR5 by the expression of a G418 resistance gene, 
therefore ruling out the use of the already created, G418 resistance gene containing, 
pcDNA3.1:Gαi2-ECFP construct used previously. Additional plasmid constructs were created 
for expression of fluorescently tagged G-proteins in CHO.CCR5 cells and to allow the 
selection of stable cell lines. Fusion protein constructs made for expression in HEK.CCR5 
were removed from their vectors by restriction endonuclease digestion. EYFP-Gβ1 was 
excised with HindIII, HEK.CCR5.Y/C, purified by agarose gel electrophoresis and ligated into 
pZeo SV2, Gαi2-ECFP was excised with BamHI and ligated into pcDNA6/V5-His (Figure 3.6). 
Restriction digests were carried out to ensure the correct orientation of constructs into 
new vectors (Figure 3.7). 
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Both constructs are approximately 1.7 kb in length. Correct orientation of EYFP-Gβ1was 
determined with HindIII and EcoRI digestion, yielding a 700 base pair EYFP fragment and a  
1 kb Gβ1 fragment (Figure 3.7). Correct orientation of Gαi2 was determined PstI digestion, 
which yields two fragments of approximately 700 bp and 800 bp corresponding to ECFP and 
part of Gαi2, respectively (Figure 3.8 B). Incorrect insertion of Gαi2 is characterised by the 
appearance of a 300 base pair fragment (Figure 3.8 A)  
 
Figure3.6 Schematic representations of the plasmids produced and transfected to create stable CHO.CCR5 
expressing G-proteins tagged with fluorescent proteins. (A) ECFP is approximately 700 bp in length and Gαi2 is 
approximately 1100 bp in length. However, Insertion of ECFP at the Pst1 site in the Gαi2 cDNA gives rise to 
two coding regions of approximately 300 bp and 700 bp. pcDNA6/V5-His allows selection in mammalian cells 
using blasticidin and selection in bacteria using ampicillin. (B) EYFP is approximately 700 bp in length and Gβ1 
is approximately 1000 bp in length. The zeocin resistance gene in pZeo SV2 allows selection in bacterial and 
mammalian cells using zeocin. 
 
  
A B 
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Figure3.7. Analytical digests of pZeo SV2:EYFP-Gβ1. (M) 1 kb Marker. (1) HindIII digest, showing excised 
construct of approximately 1.7 kb running below the 2 kb marker. (2) EcoRI digest, showing excised Gβ1. (3) 
Hind III and Eco RI digest, showing excised Gβ1 and EYFP. 
 
Figure 3.8. Analytical digests of pcDNA6/V5-His:Gαi2-ECFP (A) Incorrect construct insertion. (M) 1 kb Marker.  
(1) PstI digest, giving rise to 800 bp and 300 bp fragments. (B) Correct construct insertion (M) 1 kb marker. (1) 
BamHI, showing excised construct just below the 2 kb marker. (2) PstI digest showing excised ECFP at 
approximately 700 bp and an excised fragment of Gαi2 at approximately 800 bp  
M                 1                  2                 3
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1 kb
0.75 kb
A B 
1 kb
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M         - 1
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3.3.2. Selection of Stable Single Expression Cell Lines 
Following transfection with either pcDNA6/V5-His:Gαi2-ECFP or pZeo SV2:EYFP-Gβ1 cells 
were cultured to approximately 80% confluency. Cells were harvested and seeded into a 96 
well plate at very low density and cultured in relevant selection media. Once stable cell 
lines reached 80% confluency relative expression of fluorescent construct was quantified 
using a plate reader. Cells with higher fluorescence readouts were harvested and seeded 
into 24 well plates, non-proliferating or slow proliferating cell lines were discarded. In total 
23 ECFP clones were initially scaled up. Stable cell lines were examined for expression by 
fluorescent microscopy. Only one CHO.CCR5 Gαi2-ECFP clone was found to have uniform 
expression, this cell line underwent subcloning to produce a stable cell line with good 
expression and proliferation rates (Figure 3.9A). This cell line was used for all further 
studies. For creation of CHO.CCR5 EYFP-Gβ1 the same process was followed. In total, 17 
EYFP clones were scaled up, all of which displayed normal morphology and proliferation 
rates. Several of these clones were found to have relatively high expression rates and 
uniform expression, one clone was selected for further study (Figure 3.9B). 
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Figure 3.9 Fluorescent microscope images of single stable transfectants (A) CHO.CCR5 stably expressing 
pcDNA6/V5-His:Gαi2-ECFP, there is clear localisation to the plasma membrane of Gαi2-ECFP. High levels of 
Gαi2-ECFP can also be seen located in discrete punctations within the cell. (B) CHO.CCR5 stably expressing 
pZeoSV2:EYFP-Gβ1. EYFP Gβ1 is found at the plasma membrane as well as in punctations within the cell. 
These images are representative of typical cell population expression of pcDNA6/V5-His:Gαi2-ECFP or pZeo 
SV2:EYFP-Gβ1  used throughout the project. 
A B 
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3.3.3 Characterisation of CHO.CCR5 Stable Single Transfectants  
Characterisation of single expression stable cell lines was performed by comparing the 
intracellular release of calcium following CCR5 activation with CCL3 to that of the parental 
cell line. Both stable cells lines responded normally to CCL3 activation. Log EC50 values of 
CHO.CCR5 Gαi2-ECFP and CHO.CCR5 EYFP-Gβ1 closely matched the Log EC50 value of 
CHO.CCR5 of -7.146 M (±0.1577 M, n=3), being -6.950 M (±0.139 M, n=3) and -7.247 M 
(±0.1557 M, n=3), respectively. Efficacy of CCL3 was not affected by expression of either 
construct (Figure 3.10). 
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Figure 3.10 Dose response curves for CHO.CCR5 single transfectants (A) CHO.CCR5 EYFP-Gβ1 shows no 
decrease in efficacy or potency for CCL3 following transfection and selection. Log EC50 CHO.CCR5 -7.146 M, 
CHO.CCR5 EYFP-Gβ1 -7.247 M. (B) CHO.CCR5 Gαi2-ECFP shows no decrease in efficacy or potency for CCL3 
following transfection and selection. Log EC50 CHO.CCR5 -7.146 M, CHO.CCR5 EYFP-Gβ1 -6.950 M. Plotted 
points were normalised to CHO.CCR5 calcium flux following 1 µM stimulation with CCL3. Each plotted point 
represents three individual experiments. 
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3.3.4 Creation and Characterisation of CHO.CCR5 Stably expressing 
pcDNA6/V5-His:Gαi2-ECFP/pZeo SV2:EYFP-Gβ1 
CHO.CCR5 Gαi2-ECFP was selected for transfection with pZeo SV2:EYFP-Gβ1 following 
characterisation. Creation of the single expression ECFP cell line had required the creation 
of several subclones in order to ensure uniform and high expression of Gαi2-ECFP without 
influencing cell morphology, it was therefore reasoned that similar problems could be 
encountered if transfection of pcDNA6/V5-His:Gαi2-ECFP into a stable CHO.CCR5 EYFP-Gβ1 
cell line was attempted. Following transfection, cells were cultured in selection media 
containing blasticidin and zeocin (Invitrogen) and upon reaching 80% confluence were 
harvested and seeded into a 96 well plate at very low density. Cells with favourable 
proliferation characteristics were sub cloned by harvesting and seeding into a new 96 well 
plate. On reaching 80% confluency cells were scanned for fluorescence of both ECFP and 
EYFP in a plate reader, one subclone was selected for further studies.  
 
The concomitant stable expression of pcDNA6/V5-His:Gαi2-ECFP and pZeo SV2:EYFP-Gβ1  
had no significant effect CCL3 potency at CCR5. Log EC50 values for CHO.CCR5 and 
CHO.CCR5.Y/C were closely matched at -6.948 M (±0.123 M, n=3) and -6.871 M (±0.1853 
M, n=3), respectively. However, CCL3 efficacy was affected by concomitant expression. 
Maximal CHO.CCR5.Y/C response to CCL3 being only 70.03 % (± 7.12%, n=3) that of the 
parental (Figure 3.11A). This suggests that expression is interfering with signalling via the 
CCR5 receptor. Analysis by student’s t test shows this difference is not significant at any 
concentration, although nears significance at 1 uM CCL3 (p=0.07963). Interestingly these 
data are very similar to those gained from HEK.CCR5.Y/C. 
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Fluorescence was measured for three channels to confirm and quantify expression of 
fluorescent protein in transfected cell lines. In CHO.CCR5.Y/C cells there is significant FRET 
coupling (p=0.01674) as well as enhanced EYFP and ECFP fluorescence (Figure 3.11B). 
CHO.CCR5.Y/C exhibited a 2.63% (±0.345%, n=3) increase in FRET emission. EYFP and ECFP 
emission increased by 5.79% (±3.42%, n=3) and 3.86 % (±2.634%, n=3), respectively. Data 
show a trend that constructs are being expressed in CHO.CCR5.Y/C and forming donor-
acceptor complexes akin to typical G-protein heterotrimers. Fluorescence images of 
CHO.CCR5.Y/C further confirmed the likelihood of formation of donor acceptor complexes, 
showing co-localisation of Gαi2-ECFP and EYFP-Gβ1 to the plasma membrane (Figure 
3.12).CHO.CCR5 Y/C, like HEK.CCR5, had a reduced propensity to adhere to cell culture 
surfaces, however, comparatively, they adhered with greater resilience. Proliferation rates 
for CHO.CCR5 Y/C were also slower to that of the parental cell line, but displayed 
comparable morphology to CHO.CCR5. Expression of both constructs was uniform and of a 
reasonable level (Figure 3.12). 
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Figure 3.11 Characterisation of CHO.CCR5 Y/C (A) Dose response curve of CHO.CCR5 Y/C and CHO.CCR5, 
values were normalised to CHO.CCR5 Δ340/ Δ380 at 1 µM CCL3 stimulation. Log Ec50 values; Control-6.948 M, 
CHO.CCR5 Y/C -6.871 M. Curves are the result of three independent experiments. No significant difference 
was observed between any CHO.CCR5 and CHO.CCR5 Y/C points. (B) Relative fluorescence levels of CHO.CCR5 
Y/C. EYFP fluorescence is measured at 530 nm after excitation at 510 nm. ECFP fluorescence is measured at 
485 nm following excitation at 410 nm. FRET is the emission at 530 nm following excitation at 410 nm. FRET 
measurements were significantly higher in CHO.CCR5 Y/C than in CHO.CCR5 (p=0.01674, n3), EYFP and ECFP 
readings were higher but did not reach significance.   
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Figure 3.12 Fluorescent microscopy images of CHO.CCR5 Y/C. (A) Immunofluorescence of CCR5 expression in 
CHO.CCR5 Y/C. Cells were labelled with the anti CCR5 IgG CHO/1/85a/7a and stained with TRITC conjugated 
anti rat IgG. Functional CCR5 is adequately expressed and targeted to the plasma membrane. (B) Stable 
expression of Gαi2-ECFP. Arrows indicate tagged G-protein is expressed and targeted to the plasma 
membrane. (C) Stable expression of EYFP-Gβ1. (D) Overlay, CCR5 and tagged G-proteins co-localise at the 
plasma membrane, arrows indicate regions where there is substantial co-localisation.   
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3.4 Discussion  
The aims of this chapter were threefold; to create a stable cell line expressing both Gαi2 and 
Gβ1 fused to either EYFP or ECFP forming a FRET donor acceptor pair, to characterise 
effects the expression of these fusion G-proteins may have on signalling through isolated 
CCR5, and to measure interaction of fusion G-proteins by FRET in a population of live 
mammalian cells. The development of a robust stable expression cell line may have 
applications in high throughput screening of compounds, allowing the measurement of 
heterotrimer activation and kinetics following stimulation with different agonists. Other 
potential advantages of developing a stable cell line to measure G-protein interactions are 
decreased throughput time; cells would not have to be cultured through two transient 
transfections, a stable cell line could be continually cultured instead. By removing the need 
for repeated transient transfections, reproducibility in experimental outcome will be 
improved. Stable cell lines have a defined expression of constructs, whereas expression in 
transient transfected cells can vary. 
 
The measurement of G-protein interactions and their receptor mediated activation with 
FRET has been demonstrated in living cells previous to this study. Measurements of G-
protein interaction and activation were first shown in Dictyostelium discoideum 
(Janetopoulos et al., 2001). Although proving the concept that the measurement of G-
protein activation with FRET was possible in this simple eukaryotic system, limitations to 
the use of this model include the potential absence or reduced number of isoforms of some 
G-proteins as well as potential differences in the cellular role or binding partners of 
Dictyostelium and mammalian G-proteins (Williams et al., 2006). More recently, G-protein 
interactions and activation kinetics were measured in HEK cells expressing the α2A-
adrenergic receptor. The study used transiently transfected cells and took FRET 
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measurements from single cells using live confocal microscopy and complex image 
processing software (Bunemann et al., 2003). The creation of a stable cell line and an assay 
procedure that can be performed in a plate reader could simplify and streamline the 
measurement of protein-protein interactions, allowing FRET to become a routine method 
for the discovery of protein-protein interactions.  
 
Native CCR5 expressing cells, predominantly T cells, macrophages, and dendritic cells, also 
express other members of the chemokine receptor family and which exhibit overlapping 
ligand specificity. It was therefore necessary to use transfected cells that do not exhibit 
overlapping ligand specificity. HEK and CHO cells stably transfected with CCR5 were used to 
create an analogous system in this study for several reasons. Native HEK and CHO cells do 
not express chemokine family receptors, so the stable introduction of CCR5 into the cells 
allows for isolation of the receptor and it signalling pathways. The isolation of a single 
receptor of interest ensures no unintended activation of downstream signalling through 
other chemokine receptors. The transfection, cell culture and creation of stable cell lines in 
HEK or CHO is also comparatively easier than in native CCR5 expressing cells.  
 
Although transient transfection has the advantage of allowing quick expression and analysis 
of products, one of its major drawbacks is ensuring reproducibility of results. Selection of a 
stable transfectant ensures defined gene expression, thus promoting greater 
reproducibility of results. Current methods of measuring protein interactions by FRET 
employ timely and expensive procedures which typically focus on isolating a single cell 
from a transiently transfected population, and measuring FRET with a confocal microscope 
equipped with complex and expensive imaging soft- and hardware (Hein et al., 2005). 
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While this has yielded some interesting results regarding the dynamics and interaction of 
G-protein heterotrimers, results may be misleading due to the variable levels of expression 
of fusion protein. High expression levels have been shown to increase the likelihood of 
forced spurious interactions occurring (Massotte, 2003). Measurements from a single cell 
opposed to a cell population may also give rise to misleading results, a single cell may be 
undergoing unique stresses when it is measured that don’t represent those of the entire 
cell population.  A stable cell line may circumnavigate these problems. However, one 
drawback of creating stable cell lines is the extensive time required culturing, isolating, and 
characterising clones before any experimental methods can be carried out. 
 
Adequate expression of recombinant protein in stable cell lines relies on several factors. 
For expression to occur cDNA sequences must reach the nucleus following transfection, for 
creation of stable cell lines the cDNA sequence must be integrated into the hosts 
chromosomal DNA. To ensure the constitutive expression of constructs, constructs were 
located downstream of either a CMV immediate early promoter/enhancer or SV40 early 
enhancer promoter regions. The mechanisms of plasmid integration into a mammalian 
host’s chromosome are still not well understood and are believed integrate randomly into 
the hosts DNA following a typical plasmid DNA transfection (Hayata, 2002). The position at 
which transfected cDNA integrates into the genome can have an effect on transcription 
levels. Integration into inactive heterochromatin results in little or no construct expression, 
whereas integration into active euchromatin will result in transcription (Wurm, 2004). The 
creation of single fusion protein stable cell lines was relatively straightforward. However, 
proliferation rates for the selected stable cell lines decreased in both CHO.CCR5 and 
HEK.CCR5 transfectants for all combinations of transfections. For all created cell lines, 
except CHO.CCR5 Gαi2-ECFP, expression of the constructs was evident in a majority of sub 
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clones. It is a possibility that integration of this Gαi2-ECFP was predominantly located in 
heterochromatins, resulting in lower transcription of the construct. Another factor that 
may have altered the expression of the fusion construct is methylation of the integrated 
cDNA. Methylation of chromosomal DNA prevents its transcription (Yoder et al., 1997). 
Chromosomal and transfected DNA methylation has been widely reported and 
acknowledged to play a role in regulation of gene expression (Bird et al., 1999), but the 
mechanisms by which methylation is targeted is not clearly understood. It is also a 
possibility that the Gαi2-ECFP transgene introduced into CHO.CCR5 was methylated 
following integration, leading to lower transcription levels.  
 
Stable transfection and expression of either EYFP-Gβ1 or Gαi2-ECFP had no noticeable effect 
upon cell morphology, demonstrating that the introduction of single heterotrimeric G-
protein subunits fused to a fluorescent protein is not toxic to the cells.  Fluorescent images 
show that fusion proteins are located in the cytoplasm and at the plasma membrane, which 
suggest that the introduction of EYFP or ECFP does not induce protein mis-folding and 
aggregation. However, the doubling time of single transfecant stable cell lines was 
markedly increased. The observed decrease in proliferation may be explained by the extra 
stresses the cells are under following transfection. The forced expression or over 
expression of transfected constructs artificially  removes energy from the cell ecosystem 
that would have otherwise been used for cell growth (ATCC, 2007). The result of this is the 
stable cell line has a slower than normal growth rate.  
 
The addition of a large fluorophore such as ECFP or EYFP, which are approximately 30 kDa, 
to a heterotrimeric G-protein could prevent normal interactions of the G-Protein 
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heterotrimer unit with the CCR5 cytosolic tail and/or between the sub units of the 
heterotrimer by steric hindrance. CCR5 activation is well characterised and has been shown 
to result in lowering of cAMP levels and the release of intracellular calcium (Mueller et al., 
2002b). Measurement of calcium release following stimulation with CCL3 did not show any 
evidence of canonical Gαi pathways being perturbed by the stable expression of one 
fluorescently labelled G-protein. Maximal response values were almost identical to stable 
cell lines as in the parental cell lines. In HEK.CCR5 single stable cell lines Log EC50 values 
were close to that of the parental value of -7.451 M, being -7.452 M in Gαi2-ECFP 
containing clones and -7.554 M in EYFP-Gβ1 clones. In CHO.CCR5 single stable cell lines’ 
signalling through CCR5 was also unaffected, maximal responses were similar and Log Ec50 
values were not significantly different from the parental value of -7.146 M, being -6.950 M 
in CHO.CCR5 Gαi2-ECFP and -7.247 M in CHO.CCR5 EYFP-Gβ1. This demonstrates that the 
introduction of a single G-protein fusion protein does not interfere with signalling through 
CCR5. 
 
The creation of stable HEK.CCR5.Y/C encountered various setbacks, following selection of 
stable cell lines proliferation rates had reduced substantially. Typical parental HEK.CCR5 
would reach 80% confluence in approximately 3 days, whereas in HEK.CCR5.Y/C cells it 
would take approximately 14-18 days. Selection stresses were not very well tolerated in 
HEK.CCR5 cells, this manifested in morphological changes and cells becoming detached 
from cell culture surfaces with very gentle agitation. Regardless of these difficulties, the 
expression of constructs was measured by fluorescence, CCR5 signalling characterised, and 
FRET interactions were detected in stable cell lines. HEK.CCR5.Y/C expressed higher 
fluorescence in all measured channels than HEK.CCR5 and FRET was measured to be 4.72% 
(p=0.2139, n3) higher than wild type, confirming interaction of EYFP-Gβ1 and Gαi2-ECFP 
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with one another. The introduction of a second fluorescently labelled G-protein interfered 
with CCL3 stimulated signalling through CCR5. There was an overall trend for reduced 
calcium release following CCL3 stimulation in HEK.CCR5.Y/C. This was most evident at 
higher CCL3 concentrations with HEK.CCR5.Y/C only responding at 77% (p=0.1902, n3) of 
parental values following treatment with 1µM CCL3 and 70% (p=0.2230 , n3) following 
treatment with 300 nM CCL3. However, these differences were not significant when 
assessed by students two tailed t-test. The Log Ec50 value was not significantly altered in 
HEK.CCR Y/C compared to parental being recorded as -7.863 M and -7.746 M, respectively. 
These results indicate CCR5 signalling is moderately but not significantly ablated in stable 
cell lines and that the constructs orientate to permit FRET. However, the introduction and 
expression of two new antibiotic resistance genes as well as two fusion proteins put 
extreme stress upon the cells. The difficulties associated with culturing and performing 
experiments with these cells made them unsuitable for further experimentation.  
 
Different plasmids were selected for the creation of a stable CHO.CCR5.Y/C cell line, due to 
CHO.CCR5 using a blasticidin resistance gene to select for CCR5 expression. CHO.CCR5.Y/C 
also proliferated at a slower rate than the parental cell line taking approximately 12-14 
days to reach 80% confluence, slightly quicker than HEK.CCR5.Y/C. The CHO.CCR5.Y/C cell 
line was more resilient to the stresses encountered during selection, and although 
proliferation was slow, adherence to the cell culture surfaces was not significantly 
diminished, nor was typical morphology noticeably disrupted. EYFP-β1 and Gαi2-ECFP 
localised in the cytosol and at the plasma membrane and gave rise to a small but significant 
FRET reading in resting cells 2.63% above parental (p=0.0167, n3) which demonstrates the 
stable interaction of tagged subunits in the cell. CHO.CCR5.Y/C also had higher fluorescence 
emission readings for EYFP, 5.79% above parental (p=0.1968, n3), and ECFP, 3.86% above 
101 
 
parental (p=0.06217, n3). Although these values seem small they correspond well to values 
published for the FRET interactions between GPCR and G-proteins (Hein et al., 2005; Lohse 
et al., 2008). There was, as with HEK.CCR5.Y/C, an overall trend for reduced calcium release 
in stable CHO.CCR5.Y/C following CCL3 stimulation. This was most evident at higher CCL3 
concentrations with HEK.CCR5.Y/C only responding at 70% (p=0.1515, n3) of parental 
values following treatment with 1 µM CCL3. The Log Ec50 value was not significantly altered 
in CHO.CCR5.Y/C compared to parental being recorded as -6.948 M and -6.871 M, 
respectively.  
 
These results provide evidence that although fluorescent proteins are bulky, fusion to G-
proteins still allows for formation of the G-protein heterotrimer and their close proximity to 
one each other and the GPCR. However, there was a noticeable trend for a decrease in 
functionality when measuring calcium release following CCL3 stimulation. Bunemann and 
colleagues hypothesise that the Gαi heterotrimer family undergo subunit rearrangement 
rather than dissociation (Bunemann et al., 2003). I speculate that the addition of ECFP and 
EYFP may affect the heterotrimers ability to bind to downstream effectors. The β subunit is 
known to bind and activate its’ targets by binding to them using the same face that binds to 
the α subunit (Davis et al., 2005), increasing steric hindrance at on a heterotrimer that 
potentially doesn’t dissociate may prevent activation following association of the β subunit 
with its downstream targets, thus resulting in a decrease in calcium released following 
stimulation. It should be stressed that the measurement of calcium release acts as an 
indirect method of measuring G-protein activation, only providing information about 
downstream effects.  
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The creation and characterisation of CHO.CCR5.Y/C in this study demonstrates a system 
capable of measuring G-protein heterotrimer interactions in resting cell populations and 
represents a system with the potential to measure G-protein dynamics in live cell 
populations. High homology exists between members of the Gαi/o family making it a 
possibility that the measurement of interactions between different constellations of 
heterotrimer is a reality.  
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Chapter Four 
Monitoring Heterotrimer Activation 
by CCR5 with FRET 
4.1 Introduction 
Fluorescent resonance energy transfer (FRET) is a phenomenon where energy is passed 
from a donor chromophore that is in close proximity to an acceptor chromophore in a 
nonradiative manner. The donor/acceptor pair must exhibit overlapping spectral 
properties, that is to say the emission wavelength of the donor must overlap with the 
absorbance properties of the acceptor for energy transfer to occur. The most commonly 
used donor-acceptor pair used in biological systems is ECFP and EYFP. Both ECFP and EYFP 
are mutant variants of GFP. Mutations were made in a region of the protein that forms an 
imidazolidinone ring, resulting in skewed absorption and emission wavelengths of GFP 
(Kretsinger, 2005). The absorption wavelength of EYFP overlaps with the emission 
wavelength of ECFP allowing FRET to occur (Gryczynski, 2005). 
  
It is important to note that the efficiency of FRET energy transfer is inversely proportional 
to the sixth power of the distance between donor and acceptor fluorophores (Stryer et al., 
1967). This means the ability to transfer energy rapidly decreases over distance. The 
effective range for FRET to occur over is 1-10nm dependent on experimental conditions 
(dos Remedios et al., 1995). Interestingly, this distance is within the extent of conventional 
protein dimensions and similar to those of multimeric protein complexes observed in 
biological systems (Sheng et al., 2007). Therefore donor acceptor fluorophores will undergo 
FRET if tagged to proteins that closely interact.  
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G-protein heterotrimers have been shown to precouple to relevant receptors in a targeted 
manner, and are known to closely interact with each other in their inactive state (Nobles et 
al., 2005). In this inactive state the heterotrimer is formed of Gα subunit bound to GDP, 
associated to the Gβγ dimer. The close association of the heterotrimer prevents the active 
faces of the Gα and Gβγ subunits from interacting with downstream effectors. The binding 
of a ligand to CCR5 results in a conformational change in the receptor resulting in the 
movement of the membrane spanning helices and intracellular loops that are connected to 
the precoupled heterotrimeric G-proteins. This shift in the receptors shape allows 
previously masked regions of the Gα subunit to be exposed and catalyzes the release of 
GDP for exchange with GTP (Farrens et al., 1996). The binding of GTP to the Gα subunit 
results in the destabilisation of the heterotrimer allowing their interaction with 
downstream effectors. There is some uncertainty as to whether the heterotrimer 
undergoes full dissociation or a large structural rearrangement that allows the active faces 
of the subunits to become exposed. Currently both ideas are being courted by different 
groups. The Gαi2 subunit has been shown to fully dissociate (Digby et al., 2006) and remain 
bound to the Gβγ subunit (Bunemann et al., 2003) using FRET to measure interactions.  
 
This chapter does not aim to address the contentious issue of heterotrimer dissociation 
versus structural rearrangement, but rather develop a high throughput FRET assay as a 
method to scan the ligand G-protein specificity conferred on a GPCR by the ligand it 
interacts with. Successful development of such an assay may expedite the understanding of 
GPCR - G-protein signalling specificity. As such, a heterotrimeric G-protein complex that has 
been shown to interact with CCR5 and can be activated by CCL3 was chosen to provide 
proof of concept for this assay system.  
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4.2 Results 
Following the creation and characterisation of CHO.CCR5.Y/C, an assay was developed with 
the aim of measuring the CCL3 stimulated activation and kinetics of Gαi2 and Gβ1 through 
CCR5. A problem common to plate reader based FRET assay is interference with readings 
from high cellular autofluorescence. Early in assay development CHO.CCR5 were identified 
as highly autofluorescent cells. High autofluorescence masks signals from transfected 
fusion proteins, thus increasing the noise to signal ratio. Cellular autofluorescence was 
particularly noticed through ECFP (ex 435 nm, em 485nm) and FRET (ex 435 nm, em 530) 
channels when measured in the plate reader. Therefore cells were diluted in several 
different buffers, CAF, PBS, Hanks balanced salt solution (HBSS), and HEPES, and 
autofluorescence was measured through ECFP and FRET channels for CHO.CCR5 in order to 
assess the effect of buffers had on autofluorescence. Cells were diluted to 2 x 106/mL and 
results were normalised to readings from CHO.CCR5 diluted in CAF for each experiment. 
There was little difference in readings and PBS was found to perform satisfactorily. As such 
cells were resuspended in PBS for all experiments (Table 4.1). 
Buffer ECFP% EYFP% N 
CAF pH7.4 100 (±0) 100 (±0) 4 
PBS pH7.4 98.62 (±1.34) 99.95 (±0.84) 4 
HBSS pH7.4 101.79 (±2.71) 101.68 (±2.23) 4 
HEPES pH7.4 101.23 (±1.79) 101.78 (±3.78) 4 
Table 4.1. The effect of varied buffer composition on measured autofluorescence for CHO.CCR5. All readings 
were normalised to readings for CHO.CCR5 diluted in CAF at a concentration of 2 x 10
6
/ml   
106 
 
4.2.1 Sodium Butyrate Treatment of CHO.CCR5.Y/C 
The relatively high autofluorescence resulted in substantial noise in FRET traces. Initially 
there was concern that the levels of donor and acceptor expression in CHO.CCR5.Y/C would 
be too low for the measurement of subtle changes in cell fluorescence in an entire cell 
population. In an attempt to increase signal to noise ratios, CHO.CCR5.Y/C were treated 
with 5 mM sodium butyrate (NaBu), a histone deacetylase inhibitor (Candido et al., 1978), 
for 24 hours to increase levels of transcription in CHO.CCR5.Y/C, therefore increasing 
expression of G-protein fusion proteins.  
 
Three excitation channels were measured, ECFP (ex 430 nm, em 485 nm), EYFP (ex 510 nm, 
em 530 nm), and FRET (ex 430 nm, em 530 nm), and normalised to fluorescence readings 
from untreated CHO.CCR5. Incubation of CHO.CCR5 with 5 mM NaBu for 24 hours resulted 
in no significant change in ECFP (101.15%, ±4.82%, n=8) or EYFP (100.13%, ±5.81%, n=8) 
emissions, however FRET emission was significantly decreased (93.39%, ±7.37%, n=8, 
p=0.0389) (Figure 4.1, Table 4.2).  
 
Untreated CHO.CCR5.Y/C consistently exhibited significantly higher levels of fluorescence 
for ECFP (103.73%, ±3.82%, n=8, p=0.0282), EYFP (105.09%, ±4.77%, n=8, p=0.0194) and 
higher levels of FRET emission (103.22%, ±3.89, n=8 p=0.0517) than untreated CHO.CCR5, 
corresponding well to previous results gathered during creation of CHO.CCR5.Y/C. NaBu 
treatment of CHO.CCR5.Y/C did not lead to any increase in average fluorescence, but did 
increase the variability of fluorescence readings (Figure 4.1, Table 4.2). 
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Figure 4.1. Fluorescence measurement for cell populations following 24 hr 5 mM sodium butyrate treatment 
CHO.CCR5 NaBu EYFP ECFP FRET 
Mean 100.1323 101.1549 93.39244 
SEM ±2.054 ±1.706 ±2.606 
P Value P>0.05 P>0.05 P=0.0389 
CHO.CCR5.Y/C EYFP ECFP FRET 
Mean 105.0952 103.7311 103.222 
SEM ±1.688 ±1.353 ±1.376 
P Value P=0.0194 P=0.0282 P>0.05 
CHO.CCR.Y/C NaBu EYFP ECFP FRET 
Mean 104.0036 104.1082 102.3467 
SEM ±4.762 ±4.207 ±3.353 
P Value P>0.05 P>0.05 P>0.05 
n 8 8 8 
Table 4.2. Fluorescence values for CHO.CCR5 and CHO.CCR5.Y/C with 5 mM NaBu treatment, all values were 
normalised to untreated CHO.CCR5 fluorescence measurements for each repeat.  
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4.2.2 Fluorescent Emission in Following CCL3 Stimulation 
The conformational change of the G-protein heterotrimer can be measured directly by 
measuring the ratio of emissions at 485 nm and 530 nm when excited at 430 nm. A larger 
gap between the Gα and Gβγ unit would result in a reduction in emission at 530 nm and an 
increase at 485 nm. Fluorescence levels were measured for a 30 second period prior to 
activation, by addition of 500 nM CCL3, in order to calculate a resting base line for samples. 
Following activation with CCL3 there was a rapid increase in the ECFP fluorescence in 
CHO.CCR5.Y/C and CHO.CCR5 of roughly 2.5% (Figure 4.2A). Increases in the control could 
partly be the result of cellular disturbance caused by the volume of CCL3 injected into the 
well, and changes in autofluorescence as a result of cellular activation. A concomitant 
decrease in emissions measured in the FRET channel was also recorded following CCL3 
stimulation (Figure 4.2B).  
 
Measurement of two emission wavelengths is achieved by rapid alternation between 
filters, a consequence of which is in an increase in the time between points measured. 
Emission at one wavelength can be measured every 1.1 seconds, for two discrete emissions 
measurements can be taken every 2 seconds. Although this system is not appropriate for 
measurement of extremely rapid kinetic interactions, it allows monitoring of dissociation 
and reassociation of the Gαi2 heterotrimer. 
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Figure 4.2. Emission traces for CHO.CCR5.Y/C. (A) ECFP emission, measured at 485 nm, increased following 
stimulation with 500nM CCL3 at 30 seconds. (B) FRET emission measured at 530 nm decreases following 
Stimulation with 500 nM CCL3 at 30 seconds. These traces are a representative trace from three independent 
experiments.  
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4.2.3 CHO.CCR5.Y/C Exhibit variation in their FRET Ratio  
FRET ratio measurement of the activation and dissociation of the G-protein heterotrimers 
was very variable between repeats during an assay (Figure 4.3), this led to extreme 
variation for measured points and therefore large standard deviation. For clarity, all data 
points were normalised to the average prestimulation FRET ratio and the curve was 
smoothed by plotting the weighted average for each data point and its five neighbouring 
values according to the Savitsky and Golay smoothing filter (Savitzky et al., 1964). Following 
CCL3 stimulation there was an overall trend for the normalised FRET ratio to be higher in 
CHO.CCR5.Y/C than CHO.CCR5. However, readings suffered from high noise to signal ratio, 
therefore differences between CHO.CCR5.Y/C and CHO.CCR5 seem comparatively small. 
Quantification of the change in FRET ratio can conveniently be compared by measuring the 
area under the curve (AUC) following stimulation that is above that of the baseline. For 
comparison the FRET ratio in Figure 4.3A peaks at 7% above baseline and has a total curve 
area of 1.944 units whereas Figure 4.3B peaks at 2.81% above baseline and has a total 
curve area to 0.4676 units, approximately a quarter of the value seen in Figure 4.3A. This 
highlights the considerable variation between assay runs and difficulties when measuring 
FRET in whole cell populations. 
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Figure 4.3. FRET ratio varies between repeats in the same sample. Addition of 500 nm CCL3 indicated by 
arrow (A) FRET ratio for CHO.CCR5.Y/C, showing rapid dissociation of the Gαi2 heterotrimer and reassociation 
approximately 60 seconds. (B) FRET ratio for repeat of A measured immediately after. High noise and 
variability of FRET ratio masks the dissociation kinetics of the heterotrimer. The Figure represents the 
maximum variation seen in duplicate runs from one experiment and is a single representative of fourteen 
independent experiments.  
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4.2.4 Kinetics of Gαi2 Activation by CCR5 
The activation of the Gαi2 Gβ1γ heterotrimer was successfully monitored by measuring the 
FRET ratio in stable cell lines. In total, six independent experiments measuring activation of 
the heterotrimer by FRET were performed. Activation and conformational change of Gαi2 
β1γ occurs rapidly after CCL3 addition to the well, unfortunately limitations with 
instrumentation didn’t allow for the measurement of the millisecond kinetics of this 
activation. However, results demonstrate that there is substantial dissociation of subunits 
within six seconds of CCL3 being added. Following activation, reassociation of the 
heterotrimer can be observed by monitoring the decrease in the FRET ratio. Following 
dissociation, reassociation of the heterotrimer occurs over the next 70-100 seconds, which 
is comparable with the slow GTPase activity of the alpha subunit (Figure 4.4). Following 
stimulation with 500 nM CCL3 the FRET ratio for CHO.CCR5.Y/C peaked at 3.66% over 
baseline (±3.51%, n=6) and the area under the curve, above baseline, was 2.270. The FRET 
ratio for CHO.CCR5 peaks immediately after injection 1.75% (±4.29%, n=6) over base line, 
which could be an artefact from disturbance caused by the injection of chemokine to the 
well. The FRET ratio undulates with an almost consistent frequency, peaking several times 
well after stimulation. For comparison the total peak area above baseline is 0.951.  
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Figure 4.4 Dissociation of the Gαi2 β1γ heterotrimer can be measured using the FRET ratio between the sub 
units. 500 nM CCL3 was added at 30 seconds, the FRET ratio rapidly increases in CHO.CCR5.Y/C, peaking at 
3.66% (±3.51%, n6) more than resting levels and at most 3.30% higher than post stimulation levels in 
CHO.CCR5. (Peak AUC, CHO.CCR5 0.951, CHO.CCR5.Y/C 2.270) The substantial increase in FRET ratio indicates 
that dissociation has taken place. Data are the results of six independent experiments. 
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To ensure observed changes in the FRET ratio were evoked by CCL3 stimulated dissociation 
of Gαi2 and β1γ subunits, CHO.CCR5.Y/C were incubated with 100 ng/ml pertussis toxin 
(PTX). Pertussis toxin catalyses the irreversible ADP-ribosylation of the Gαi family 
preventing its activation and dissociation (Neer et al., 1984), for 24hrs to prevent Gαi2 
activation. Upon stimulation with 500 nM CCL3 no overall change in the FRET ratio was 
observed in PTX treated CHO.CCR5.Y/C. PTX treated cells peaked 2.42% over base line 
(±3.06%, n4), but probably as an artefact of injection. CHO.CCR5.Y/C peaked 4.13% 
(±3.03%, n4) over baseline, although this peak was measured 30 seconds after stimulation 
(Figure 4.5). The most robust indication of PTX abrogation of FRET ratio is the difference 
between the peak area under curve over baseline. PTX treated cells had a peak AUC of 
0.801, which is comparable to that of CHO.CCR5, whereas CHO.CCR5.Y/C have an AUC of 
2.315.  
Figure 4.5 Inactivation of Gαi2 by treatment with 100 ng/ml pertussis toxin prevents an increase in FRET ratio 
following stimulation with 500 nM CCL3 at 30 seconds. CHO.CCR.Y/C PTX (peak AUC 0.801, peak 2.42% 
±3.06%, n=4) CHO.CCR5.Y/C (Peak AUC 2.315, peak 4.13%, ±3.03%, n=4) Traces represent data from four 
independent experiments.   
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The addition and incubation of NaBu decreased levels of autofluorescence in CHO.CCR5, 
particularly for measurements on the FRET channel. In an attempt to maximise the signal to 
noise ratio cells were treated with 5mM sodium butyrate for 24 hours prior to activation. 
FRET ratios were normalised to their pre-stimulatory base line. Lower FRET channel 
measurements led to higher pre-stimulation CHO.CCR5 FRET ratios. Normalising the 
CHO.CCR5 trace to the base line led to a proportional reduction in noise amplification, 
allowing differences in FRET ratios to be clearly inspected. It did not affect the 
CHO.CCR5.Y/C trace, which peaked at 4.37% (±3.99%, n4) higher than base line; 
comparatively CHO.CCR5 peaked at 1.75% (±1.66%, n4) above baseline in the first 120 
seconds following stimulation. Peak AUC was much lower for CHO.CCR5 following 
treatment with NaBu at 0.146, CHO.CCR5.Y/C peak AUC was slightly higher to previous 
observations at 2.677, due to the increase in the length of the signal. Incubation with NaBu 
prior to measurement lead to a decrease in the signal to noise ratio, but affected the 
duration of the increase in FRET ratio by approximately 75 seconds (Figure 4.6). 
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Figure 4.6 The effect of 5 mM NaBu treatment on FRET ratios in CHO.CCR5.Y/C and CHO.CCR5. There is a 
clearer difference between CHO.CCR5 (Peak AUC 0.146, Peak 1.75%, ± 1.66%, n=4) and CHO.CCR5.Y/C (Peak 
AUC 2.677, peak 4.37%, ± 3.66%, n=4) following NaBu treatment, duration of the FRET ratio signal is 
prolonged in CHO.CCR5.Y/C. Traces represent data from four independent experiments. 
 
As an alternative way to confirm changes in FRET ratio were due to the activation of the 
fluorescently tagged heterotrimer 10 µM mastoparan, an activator of PTX sensitive G-
proteins (Higashijima et al., 1988), was added to cells directly before the assay began. 
Activation of G-proteins by mastoparan could not be measured due to technical limitations, 
but the FRET ratio was measured in comparison to that of CHO.CCR5 before and after CCL3 
stimulation. Accordingly, there was no discernable increase in the normalised FRET ratio of 
mastoparan treated CHO.CCR5.Y/C, which peaked at 2.56% (± 2.66%, n=4) over basal and 
had a peak AUC of 1.240 compared to that of CHO.CCR5, which peaked at 1.56% (± 2.35%, 
n=4) and had a AUC of 1.362 cells following CCL3 addition (Figure 4.7).  
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Figure 4.7 Mastoparan activation of the heterotrimer prior to CCL3 addition, led to no change in FRET ratio 
following stimulation with CCL3. CHO.CCR5 (peak AUC 1.362, peak 1.56%, ±2.35%, n=4), CHO.CCR5.Y/C (Peak 
AUC 1.240, Peak 2.56%, ±2.35%, n=4). Traces represent data from four independent experiments. 
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The lack of increase in the FRET ratio suggests that all Gαi2 and β1γ heterotrimers had 
dissociated before reading took place. This hypothesis is backed up by measuring FRET 
ratios in prestimulated cell populations that have not been normalised (Figure 4.8). 
CHO.CCR5 cells treated with mastoparan displayed no variation to untreated control cells. 
CHO.CCR5.Y/C cells tended to display a marginally higher, although not significant, FRET 
ratio than control. This is most likely a consequence of donor acceptor pairs not associating 
in a 1:1 ratio, therefore leading to an increased emission at 485 nm. Pretreatment of cells 
with mastoparan resulted in an increase in prestimulation FRET ratios of 2.25% (±4.66% 
n=4), calculated by measuring 30 the FRET ratio for 30 seconds and taking the mean 
average. This suggests that 10µM mastoparan treatment activates all PTX sensitive G-
protein heterotrimers rapidly after treatment. This supports previous studies performed in 
vesicles showing rapid activation of Go following mastoparan treatment(Higashijima et al., 
1988).  
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Figure 4.8 Treatment of CHO.CCR.Y/C with 10 µM mastoparan before addition of 500 nM CCL3 resulted in 
higher prestimulation FRET ratios. (CHO.CCR5) 1.0000±0.0319, (+mastoparan) 0.9989±0.0209. 
(CHO.CCR5.Y/C) 1.0033±0.0255 (+mastoparan) 1.0225±0.0466. All data has been normalised to the average 
prestimulation ratio obtained for untreated CHO.CCR5 cells. Bar chart represents the mean and SEM of four 
independent experiments.  
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4.3 Discussion 
 
The aim of this chapter was to characterise the interaction and activation kinetics of the 
Gαi2 heterotrimer when activated by CCR5 following CCL3 stimulation. A further aim of this 
chapter was to develop an assay capable of measuring this interaction in whole cell 
populations in real time. Experimental data from this chapter provides proof of concept 
supporting the notion that FRET measurements can be performed in a live whole cell 
population to measure protein-protein interactions and their activation kinetics, in a high 
throughput system. However, during development of this assay numerous drawbacks to 
the experimental approach undertaken were discovered, which render this assay, in its 
current condition, unfeasible.  
 
As discussed in the previous chapter, creation of a stably transfected cell line was a 
prerequisite for the development of a whole cell population assay. Aside from already 
discussed cell culture issues relating to multiple stable transfections, there are other issues 
that limit the further development of this assay system. The majority of successful live cell 
FRET work has been performed on small regions of interest in transiently transfected cells, 
with the use of confocal microscopy (Nikolaev et al., 2007; Nobles et al., 2005). This 
approach to measuring the FRET ratio has technical advantages over the whole cell 
population approach trialled by me in this research. Isolation of a region of interest in an 
individual cell allows for selection of areas that are robustly expressing fluorescent 
constructs of interest, as well as minimising autofluorescence signals that naturally occur 
from incidental excitation of cytosolic compounds. Most autofluorescence originates from 
mitochondria and lysosomes (Monici, 2005); structures which are easily excluded from 
readings with a confocal microscope (Sangmi et al., 2009), but impossible to exclude from 
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whole cell readings on a plate reader. Several of the most commonly expressed cellular 
compounds, NADPH, FAD and lipofuscin, have overlapping excitation and emission spectra 
with both ECFP and EYFP. The abundance of these compounds is increased during times of 
cellular stress and protein misfolding (Herr et al., 2001). 
 
Each of these compounds interferes with fluorescence readings. Lipofuscin is a highly 
oxidised crosslinked protein aggregate, typically associated with the postmitotic aging. 
Lipofuscin structures absorb light between 364 nm and 633 nm (Marmorstein et al., 2002) 
with fluorescent emissions peaking at 450 nm and 530 nm following excitation at lower 
wavelengths (Benson et al., 1979). Although relatively little is known about the processes 
surrounding accumulation of lipofuscin, recent work has indicated that oxidative stress as a 
consequence of protein misfolding increases its accumulation (Bader et al., 2006). Although 
the levels of protein misfolding were not investigated in CHO.CCR5.Y/C, there is an 
increased likelihood of misfolding incidences in stably transfected cells that overexpress 
constructs (Friguet, 2006). The over expression of transfected constructs could potentially 
raise oxidative stress in cells, due to compensatory degradation of over expressed G-
protein subunits. 
 
During cellular oxidative stress events reactive oxygen species (ROS) is generated. A 
countermeasure employed by cells to minimise damage caused by ROS is an increase in the 
production of NADH/NADPH (Ying, 2008) and FAD for use in flavoproteins (Massey, 2002). 
NADH and NADPH absorb light at 340 nm and 260 nm with broad peaks and are 
responsible for fluorescence peaking at 450 nm (De Ruyck et al., 2007) in cells examined by 
fluorescent microscopy. The lenses used to excite cells in order to record FRET ratios from 
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CHO.CCR5.Y/C prevent wavelengths below 410 nm exciting cells, therefore 
autofluorescence from NADH/NADPH will be minimised when using the plate reader, 
however, this is not the case when analysing cells by fluorescent microscopy. FAD 
complexed proteins are also upregulated as a consequence of increased cellular stress from 
enhanced protein production (Pahl, 1999). FAD complexed enzymes have long been known 
to interfere with cellular fluorescent readings and have a broad excitation peak at 450 nm 
and a broad emission peak at 535 nm (Benson et al., 1979). This, coupled with lipofuscins 
emission, could account for the highly variable emission at 535 nm seen in CHO.CCR5.Y/C 
when measured with the EYFP channel. It is also likely that Lipofuscin emission at 450 nm 
interfered with ECFP readings, recorded from the FRET channel. Direct measurements of 
the FRET channel may have been enhanced by lipofuscin emission, although as the 
fluorescent signal from lipofuscin is relatively constant and is not photosensitive, emissions 
would just add to the noise in recordings. However FAD is extremely photosensitive and 
degrades quickly on exposure to light which could possibly have resulted in perturbation of 
the FRET ratio by decreasing EYFP emission seen over long periods of exposure to 
excitatory wavelengths (Scheideler et al., 1988).  
 
There are two straightforward methods that could potentially help minimise problems with 
the signal to noise ratio in a plate reader FRET system. The first method utilises differences 
in the properties of light emitted at the same wavelength but by different fluorophores. 
Fluorescence polarisation spectroscopy is a technique used to differentiate emission from 
large and small fluorophores. It exploits the anisotropy of a molecule, i.e. the ability of a 
molecule to produce a different result if measured from a different direction. Small 
molecules rotate quickly, whereas large molecules rotate slowly. Illumination of large 
fluorophore, such as ECFP, with plane polarised light will result in a large proportion of 
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emitted light remaining polarised with respect to the excitation source, due to its slow 
rotation. Whereas illumination of small fluorophores results in less light remaining 
polarised  (Knight et al., 2002).   
Another approach that can be considered in order to increase the signal to noise ratio is to 
use a brighter donor acceptor pair. Although, the ECFP-EYFP donor acceptor pair is well 
characterised and has been extensively utilised in many successful FRET studies, there are 
drawbacks to their use in a live cell system. Some problems with employing fluorescent 
proteins for FRET are that they exhibit relatively broad emission and small stokes shift, 
ECFP and EYFP emission is contaminated with cellular autofluorescence, reduced quantum 
yield compared to GFP, and ECFP photobleaches rapidly (Marc et al., 2006).  In response to 
the growing interest in FRET based method to investigate protein-protein interactions 
numerous improvements to the basic CFP/YFP acceptor donor pair have been made. 
Several mutations have been made to both proteins in order to create fluorescent proteins 
with higher quantum yields. The Cerulean CFP Mutant and MiCy protein, derived from 
stony coral, display less complex, and slower decay kinetics and enhanced quantum yield 
compared to ECFP (Karasawa et al., 2004; Rizzo et al., 2004). Mutations made to EYFP 
resulted in the development of Venus and Citrine EYFP, which both displayed higher 
quantum yield, quicker recovery times, lower photosensitivity and higher resistance to 
acidic conditions (Griesbeck et al., 2001; Nagai et al., 2002). Although there is not a great 
improvement in the spectral overlap or stokes shift of these variants; they are brighter and 
when used in tandem and result in an enhanced FRET signal, and therefore a higher signal 
to noise ratio. More recently the FRET optimised ECFP and EYFP derivatives, YPet and CyPet 
have been developed that exhibit a sevenfold increase in FRET signal compared to an ECFP-
VenusEYFP pair (Nguyen et al., 2005). However, these constructs suffer from an increase 
propensity to dimerise, resulting in perturbation of the FRET signal. Selective mutation to 
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the proteins can reduce the propensity for them to dimerise making the YPet CyPet FRET 
pair a superior alternative to the ECFP-EYFP pair used in this study (Ohashi et al., 2007).        
 
An interesting development in the development of donor acceptor pairs is the use of a 
‘dark’ acceptor, i.e. an acceptor that doesn’t fluoresce. Resonance Energy-Accepting 
Chromoprotein (REACh) is a mutant form of YFP that fluoresces at 2% that of YFP emission. 
The use of REACh as an acceptor in a FRET pair allows for the use of EGFP, which is 
photophysically superior to all other fluorescent proteins in terms of emission, and allows 
the removal of spectral filtering from assay apparatus (Ganesan et al., 2006).   
 
Obtaining and culturing a stable triple transfected cell line is often unsuccessful using 
traditional plasmid transfection technologies (Kingsbury et al., 2000). More recently, with 
the development  of lentiviral transfection techniques the generation and use of a triple 
transfected stable cell lines has been reported in HTS studies (Yamanaka et al., 2007).  The 
data gathered in this project indicate that a high through put method of measuring protein-
protein interactions by FRET could become a reality if the difficulties with cell culture can 
be overcome. A lentiviral approach to generating the stable cell lines, the use of a brighter 
FRET pair, and improved spectroscopic techniques may provide methods to overcome the 
pitfalls encountered during the development of this assay.  
 
Regardless of the circumstantial limitations placed on this research, these data represent 
the first cell based high throughout protein-protein interaction assay capable of measuring 
the kinetics of activation in G protein heterotrimers. The cornerstone of this assay was the 
development of a triple transfected stable cell line expressing consistent levels of donor 
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acceptor FRET pairs. To my knowledge the development of a stably transfected cell line 
expressing a fluorescent protein FRET pair to measure protein interactions, in a high 
throughput system, represents a completely unique approach to solving the problem of 
mapping protein-protein interactions. Results from this chapter may not provide a robust 
assay system for the systematic identification of G-protein heterotrimer interactions and 
kinetics, but they do recapitulate G-protein heterotrimer characteristics. Monitoring of the 
FRET ratio in CHO.CCR5.Y/C cells revealed that following stimulation with CCL3 Gαi2 and Gβ1 
undergo a conformational change brought about by the CCR5 receptor. This conclusion was 
confirmed by treatment of the cells with PTX, which prevented an increase in the FRET 
ratio following stimulation, or by mastoparan treatment which also prevented an increase 
in the FRET ratio, but resulted in an increased FRET ratio prior to stimulation.  Limitations 
with the temporal spacing of measurements meant very rapid interactions could not be 
monitored. However, data obtained show that G-protein heterotrimers are activated in less 
than 4 seconds following CCL3 addition and reassociation occurs over a period of 2 
minutes.  
 
Several studies have suggested that heterotrimers from the Gαi family do not undergo 
dissociation following activation (Lohse et al., 2008), but rather a conformational change, 
which allows the active face of the protein to interact with downstream effectors. 
Unfortunately this is not a question that can be addressed with this assay system. The FRET 
ratio in performed assays never returns to basal levels, which could suggest that following 
activation and dissociation of the heterotrimer Gα and Gβγ subunits reassociate with non 
tagged subunits, however without massive reduction in background noise it is impossible to 
ascertain whether long term changes in the FRET ratio are due to this or the relative 
photobleaching of autofluorescent compounds. However, with the continued development 
126 
 
of plate reader technology and brighter fluorescent proteins a FRET based whole cell 
population assay to measure protein-protein interactions in real time could become a 
reality in the near future. 
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Chapter Five 
Development of a BRET Assay to 
Measure Gαi2 Gβ1 Interaction 
5.1 Introduction 
Studies of G-protein association and activation using a FRET based system assay, although 
partially successful, were not as successful as anticipated. Low proliferation rates, the 
potential for photobleaching of fluorescent fusion constructs, and a high signal to noise 
ratio owing to autofluorescence contributed to inconclusive results. Consequently, a 
bioluminescence resonance energy transfer (BRET) based assay was developed in order to 
circumnavigate some of these problems. To expedite the development of this assay a 
transient transfection approach was used as an alternative to the creation of stable cell 
lines. In a BRET system, resonance energy transfer is accomplished by utilising light 
produced by the conversion of colenterazine into colenteramide by renilla luciferase. 
Photons are emitted at approximately 480 nm, comparable to ECFP’s emission of 485 nm 
and, as with FRET, will non-radiatively transfer energy to an acceptor protein if within 
adequate proximity. As there is no external light source involved in BRET, it results in very 
low cellular autofluorescence.  
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BRET incorporates the attractive advantages of FRET while avoiding the difficulties 
associated with fluorescence excitation. Additionally, BRET has been shown to be workable 
in transiently transfected cells examined in a plate reader (Angers et al., 2000) and has 
recently been utilised to investigate the functional selectivity of the GPCR EP4 (Leduc et al., 
2009). With this in mind, it was decided to run a preliminary investigation to see if BRET 
assays in transiently transfected cells could provide an alternative method for the 
measurement of G protein heterotrimer protein-protein interactions.  
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5.2 Results 
5.2.1 Creation of pcDNA3.1:hrLuc-Gαi2 
cDNA for humanised renilla luciferase, a kind gift from Dr. M. Bouvier, was amplified by PCR 
to introduce HINDIII and KPNI cut sites at the 5’ and 3’ prime ends respectively (hrLuc HIND 
5’, 5’GAA GCT TAT GAC CAG CAA GCT GTA CGA CC 3’) (hrLuc KPN I 3’, 5’ CGG TAC CGA GCC 
GAT CCC CCT GCT CGT TCT TCA 3’). PCR products were purified by gel electrophoresis 
purification, ligated in pGEM, and transformed into DH5α competent E.coli for 
amplification. The plasmid was purified by a commercially available plasmid purification kit, 
hrLuc was then excised from the plasmid by digestion with KPNI and HIND III and purified 
by gel electrophoresis solubilisation. The excised fragment was ligated to the C terminus of 
Gαi2 in pcDNA3.1:Gαi2 linearised with KPNI. The construct was then transformed into E.coli, 
scaled up and purified with a commercially available plasmid purification kit.  
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5.2.2 Optimisation of hrLuc Transient Transfection 
CHO.CCR5 were seeded into a 35mm dish at a density of 2 x 105 per dish. Cells were 
transiently transfected the following day at varying concentrations of pcDNA:hrLuc-Gαi2 
and transfection reagent (Genejuice, Novagen). 72 hours after transfection the relative 
levels of expression of hrLuc-Gαi2 was examined by measuring luminescence at 485 nm 
following addition of, and 30 minute incubation with, EnduRen (Promega). Expression of 
transfected rLuc-Gαi2 was plasmid concentration and transfection reagent concentration 
dependent. The optimal concentration of plasmid and transfection reagent was selected 
for its high luminescence and low variability and was determined to be 2 µg plasmid and 6 
µl transfection reagent (Figure 5.1). Transfection of pZeoSV2:EYFP-Gβ1 into CHO.CCR5, 
under these conditions, had previously been determined to be 2 µg plasmid and 4 µl 
transfection reagent. 
Figure 5.1 Varying expression of rLuc-Gαi2 in CHO.CCR5 under different transfection conditions. Total 
luminescence at 485 nm was normalised to background levels in CHO.CCR5 not expressing rLuc-Gαi2 but in 
the presence of rLuc substrate, EnduRen. Measurements were performed on a BMG Fluorostar optima FL 
platereader, the data represent the mean ± SEM of three independent experiments.   
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5.2.3 Dual Transient Transfection  
Transfection of either plasmid singularly resulted in robust expression of the construct. 
However, transfection of more than one plasmid construct resulted in a decrease in EYFP 
and rLuc expression, as examined by luminescence and fluorescence readings (Figure 5.2). 
Various transfection conditions were tried, including transfection of the second construct 
one day after the first. However, no significant increase in the expression of both 
constructs was seen through varying the protocol. Nevertheless, increases in fluorescence 
and luminescence were significantly above that of control cells for dual transfected cells. 
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Figure 5.2. Relative expression levels of transient transfection of rLuc and EYFP in CHO.CCR5 assay system 
determined spectroscopically. (A) rLuc expression is altered by concomitant transfection of EYFP-Gβ1. 
CHO.CCR5 transiently transfected with renillia luciferase in the absence of EnduRen, have a background 
luminescence of 5.23%, ±1.116 (p=0.000151) maximal luminescence in the presence of EnduRen. CHO.CCR5 
transfected concomitantly with rLuc and EYFP, in the presence of EnduRen, show luminescence of 
47.76%,±1.8055 (p=0.00129) maximal luminescence. (B) EYFP-Gβ1 expression is effected by concomitant 
transfection of rLuc. Single transfection resulted in EYFP fluorescence 133.04%, ±2.476 (p=0.00004) that of 
control, whereas concomitant transfection with rLuc resulted in EYFP fluorescence decreasing to 107.01%, 
±2.674 (p=0.0192) that of control. The data represent the mean and SEM of three independent experiments.  
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5.2.4 Substrate Kinetics and BRET 
The kinetics of EnduRen turnover by rLuc in transiently transfected cells was investigated 
following EnduRen addition at a final concentration of 60 µM. Luminescence increased 
rapidly after addition of EnduRen and peaked after approximately 2000 seconds. This peak 
in luminescence signal plateaued and remained relatively stable for approximately a 
further 4000 seconds. After 7000 seconds the signal slowly decreases. Emission at 520 nm 
was concomitantly measured (Figure 5.3).  
Figure 5.3 Luminescence and fluorescence levels following EnduRen addition in transiently transfected 
CHO.CCR5. Solid lines CHO.CCR5 rLuc emission; Blue 485 nm, yellow 520 nm. Dashed lines CHO.CCR5 rLuc 
EYFP; Blue 485 nm Yellow 520 nm. These are representative traces from a single experiment.   
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Surprisingly, there was not a great deal of difference between normalised emission at 520 
nm for cells transfected only with rLuc and those with both rLuc and EYFP. This observation 
was quantified by calculating the proportional emission (PE) at 520 nm compared to that at 
485 nm. For Figure 5.3 the proportional emission for CHO.CCR5 transfected with rLuc was 
94.77 and for CHO.CCR5 transfected with rLuc and EYFP was 98.52. When this method is 
applied to all kinetic traces undertaken there is a trend for rLuc and EYFP transfected cells 
to have a higher PE. (Table 1). Raw PE values are variable between runs due to the variance 
in the levels of luminescence and fluorescence and the photo detection electrode’s 
dependence upon those levels during calibration. Therefore, raw values have been 
normalised to the raw PE of rLuc transfectants. Normalised PE for rLuc and EYFP 
transfected CHO.CCR5 was on average 1.14% (±1.571, n6) higher than that of CHO.CCR5 
transfected only with rLuc, suggesting interaction of the Gαi2-rLuc and EYFP-Gβ1 constructs 
to form a functioning BRET pair.  
Run # rLuc PE rLuc+EYFP PE Normalised rLuc+EYFP PE 
1 87.58 88.41 1.0094 
2 87.61 88.43 1.0093 
3 97.5 96.61 0.9908 
4 86.76 87.74 1.0112 
5 94.77 98.52 1.0395 
6 94.19 94.94 1.0079 
Table 5.1. Proportional emission of transiently transfected CHO.CCR5. PE values are calculated from all data 
points from entire traces by representing emission at 520 nm as a percentage of 485 nm emission. 
Normalised values indicate there is a non significant trend for cells with rLuc and EYFP to have a higher PE. 
rLuc+EYFP PE, 1.0114, ±0.0157 (p=0.1351)  
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There are several published methods for calculating the BRET ratio. Data recorded 
throughout these investigations were analysed using equations published by Angers et al 
(Angers et al., 2000) and BMG Labtech. The real time BRET ratio traces determined using 
these equations revealed no usable data regarding protein-protein interactions, there was 
too little resolution between values recorded for control cells and dual transfectants. This 
was most likely due to the very high emission recorded from rLuc only transfected cells in 
the 520 nm channel. There was also large variation in emission values recorded on a point 
by point basis, which, when analysed using BRET ratio calculations, amplified these 
variations. Analysis of the proportional emission shows very low distinction between 
ratiometric measurements for rLuc only and rLuc and EYFP transfected cells (Figure 5.4) 
 
 
Figure 5.4 Proportional emission of CHO.CCR expressing Gαi2-rLuc and Gαi2-rLuc & EYFP-Gβ1. Proportional 
emission was very variable and showed little resolution between control and BRET capable CHO.CCR5, 
making it difficult to draw conclusions about protein-protein interactions in a real time trace. These are 
representative traces from a single experiment.   
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5.3 Discussion 
The aim of this chapter was to characterise the interaction and activation kinetics of the 
Gαi2 heterotrimer when activated by CCR5 following CCL3 stimulation. A BRET based assay 
was constructed as an alternative to earlier FRET based protein-protein interactions. 
Luminescence at 485 nm and fluorescence at 520 nm were measured concomitantly in 
order to calculate interactions of Gαi2 and Gβ1 fusion proteins capable of undergoing BRET. 
Transient transfection into CHO.CCR5 of single constructs resulted in robust expression. 
However, co-transfection of both constructs into CHO.CCR5 resulted in a reduced 
transfection efficiency and/or expression. 
  
Reduction in expression of transfected plasmids has previously been reported in several 
studies. Suppression of a plasmid containing a reporter gene when co-transfected with 
another plasmid was first reported for β-galactosidase (Farr et al., 1992). Expression of β-
galactosidase was shown to be modulated by the type of promoter on the other plasmid 
and the cell type that the co-transfection was taking place in. Interestingly, renillia 
luciferase expression has been shown to be suppressed by co-transfection with plasmids 
containing different promoter regions, in MCF-7 breast cancer cells. Suppression of renillia 
luciferase was reported to be between 3 fold to 252 fold, dependent upon the promoter 
region on the other plasmid (Vesuna et al., 2005). These findings were reiterated, and 
expression was shown to be transgene and cell line dependent, as well as influenced by 
GPCRs such as androgen receptors. (Mulholland et al., 2004). These reports combined with 
experimental data gathered during the development of this assay system suggest that co-
transfection of renillia luciferase is more complex than commonly anticipated. Low 
expression of renillia luciferase and consequentially low luminescence in co-transfected 
CHO.CCR5 cells ready for BRET analysis represents a huge hurdle to overcome in the 
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development of this assay. Potentially these issues could be circumnavigated by the use of 
bi-or poly-cistronic vectors, i.e. vectors capable of expressing two or more proteins of 
interest from one transcription sequence. The plasmid pIREs has been used in mammalian 
cells for this purpose, and recent investigations show that repeated insertions downstream 
of the IRES (internal ribosome entry sites) promoter region are equally transcribed, 
allowing equal transcription of recombinant proteins (Bouabe et al., 2008). The cloning of 
two genes into one plasmid requires extra planning, but ultimately could result in more 
consistent expression levels of tagged constructs.  
 
Nevertheless, there are numerous reports of successful BRET assays being utilised to 
monitor protein-protein interactions in live cells (Gales et al., 2005; Xu et al., 2007). Early 
assays utilised the same donor and acceptor couple as used in this investigation. However, 
potential problems with luminescence levels were reported and the need for extremely 
sensitive light measuring equipment was also stressed (Xu et al., 1999). The majority of 
published BRET assays have since been performed with modified donor and/or acceptor 
proteins as well as with specialised equipment. An example is the use EYFP topaz as the 
acceptor, EYFP topaz has a 17 fold greater emission over standard EYFP (Angers et al., 
2000). Further subsequent improvements to the initial BRET assay system have been made. 
One such improvement, is the creation of the proprietary BRET2 system (Perkin Elmer, 
wherever) which results in a substantially higher level of luminescence and a greater 
spectral resolution between rLuc and acceptor protein emission. BRET2 utilises a mutant 
form of rLuc, that in conjunction with deepblueC substrate, emits light at 395 nm, and a 
mutant form of GFP, called GFP2, which emits light at 510 nm. This assay system has been 
used widely and successfully by many groups (Bertrand et al., 2002; Kocan et al., 2008) and 
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has the advantage that emission for donor and acceptor are spectrally discrete from one 
another and mutations to rLuc result in enhanced luminescence signals. 
 
Data acquired using this system showed a small overall increase in emission at 520 nm in 
cells expressing the EYFP-Gβ1 construct over control cells. This trend suggests that there is a 
diminutive transfer of energy due to the close proximity of the Gαi2 and Gβ1 proteins. 
However, this result represents the summation of all temporal points measured. The assay 
system, as it stands, is not robust enough to allow real time monitoring of interactions.  
 
BRET as a technique to measure protein-protein interactions offers some attractive 
advantages over the use of FRET, namely the removal of an external light source, which 
removes the risk of photobleaching fluorescent proteins and eradicates cellular 
autofluorescence; both of which can have significant impacts on the ability of a consistent 
FRET ratio to be measured. In addition, the use of a luciferase as the primary light source 
guarantees that light emitted by the fluorophore is a result of resonance energy transfer.    
However, no technique is perfect and in its current form BRET suffers from some technical 
limitations. As with FRET, the addition of donor and acceptor proteins to native proteins 
potentially reduces the ability of proteins to interact through steric hindrance of the native 
proteins interaction sites. Alternatively the candidate proteins could be interacting without 
allowing the donor acceptor pair to be in adequate proximity for resonance energy 
transfer. The latter of these two situations means that means that a BRET assay displaying 
no BRET does not necessarily prove non-interaction. Therefore it may be prudent to 
experiment with different combinations of donor acceptor fusion constructs.  
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Another consideration for the development of a BRET assay to measure the interaction of 
G-protein interactions is the limitations of the equipment used. The plate reader used in 
these assays was a fluorostar optima (BMG labtech, Germany) which has only been 
validated for measurement of basic BRET2 assays by the manufacturer. One concern is that 
the photo multiplier detector is not sensitive enough to record the low emission signals 
that were measured in this assay configuration. Data garnered during the development of 
this assay also indicated that there is considerable overlap in rLuc emission with the EYFP 
filter used, resulting in false readings for EYFP fluorescence. This observation strongly 
supports the development of enhanced BRET methods, such as BRET2, that allow a larger 
spectral window between donor and acceptor emission.  
In summary, earlier FRET experiments have recapitulated that Gαi2 and Gβ1 interact and 
disassociate upon activation of the CCR5 receptor. The same conclusion cannot be made 
from data obtained from these BRET studies. However, analyses of data by long temporal 
integration of BRET signals suggest that the subunits do interact. For a BRET based assay to 
measure protein-protein interactions of G-protein heterotrimers in real time to become 
reality, associated instrumentation must continue its technological development, and the 
use of various donor acceptor proteins must continue to be optimised.  
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Chapter Six 
The Impact of Mutant Forms of Gα 
on CCR5 Signalling 
6.1 Introduction 
Mutations to different regions of the Gα subunit give rise to dominant negative (DNM) and 
constitutively active (CAM) mutant phenotypes of the subunit. Data gained from these 
mutant forms, when expressed in a cell, can provide information about signalling cascades 
through a particular receptor. DNM Gα, when expressed in cells, competes with wild type 
Gα for binding of other proteins involved in the G-protein cycle and can block or reduce the 
response caused by wild type Gα. CAM Gα either has a reduced GTPase activity or no GTP 
binding capability, but is locked in the active conformation. Therefore, CAMs constantly 
bind downstream effectors, which results in constitutive activation of those effectors, 
although currently the mechanisms by which they achieve this are not well understood. 
 
The Gα subunit has a conserved guanine nucleotide binding region formed of five 
conserved polypeptide regions or boxes, termed G1-G5 (Tesmer et al., 1997b). DNM Gαi2 
has a single point mutation in the G3 box, in which a glycine has been exchanged for a 
threonine at position 203 (G203T). This mutation results in abrogated ability to bind GTP 
and an increased rate of dissociation from GDP (Inoue et al., 1995). CAM Gαi2 has a single 
point mutation in the G3 box, in which a glutamine is exchanged for a leucine at position 
205 (Q205L). This results in a markedly reduced GTPase function (Hermouet et al., 1991). 
CAM Gα12 has a single point mutation in the third switch region, in which a glutamine has 
been exchanged for a lysine at position 231 (Q231L), resulting in markedly reduced GTPase 
function.  
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CCR5 has been shown to directly induce changes in the actin cytoskeleton, by the activation 
of rho dependent cytoskeletal pathways (Di Marzio et al., 2005). The Gα12 subunit was 
included in these studies as it is a known player in the activation of rho dependent 
cytoskeletal pathways (Buhl et al., 1995). 
 
The specific mechanism by which DNM Gαi2 blocks G-protein signalling is not known. 
However, there are general mechanisms described in the literature and further possible 
theoretical mechanisms are also described. There are two mechanisms that have been 
experimentally described. The first of which involves DNM Gα subunits sequestering all βγ 
subunits, therefore preventing WT heterotrimers binding to the GPCR (Clapham et al., 
1997). The second described method involves DNM Gα sequestering activated GPCR either 
in combination with βγ or individually (Natochin et al., 2006; Yu et al., 1998).  
 
DNM and CAM Gα subunits will be used to help  disseminate the interactions of CCR5 with 
specific Gα subunits and thus provide information on the downstream signalling pathways 
that are activated by CCR5. In addition to data from studies with DNM and CAM, findings 
will be backed up by systematic siRNA knockdowns of Gα subunits. The use of siRNA 
provides a means to further investigation into the roles of Gα subunits through CCR5.  
 
The development of siRNA as a tool has provided the research community with a method 
to precisely target genes and knockdown of the expression of the protein. This specificity 
allows the removal of predicted players involved in CCR5 signal transduction. By monitoring 
the effects the systematic removal of Gα subunits has upon CCR5 signalling we hope to 
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provide evidence that CCR5 induced calcium mobilisation relies on other G-protein 
heterotrimers other than the already defined Gαi2 interaction.  
 
This study was focussed on measuring calcium release following stimulation of the 
receptor. Chemokine receptor activation patterns can differ between various read-out 
systems, so therefore, ideally, these experiments should be repeated using chemotaxis or 
GTPγS binding assays as well. However, this project will give a first indication as to whether 
CCR5 interacts with different G-proteins and will illuminate aspects of CCR5 G-protein 
interactions.  
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6.2 Results 
6.2.1 The Expression of DNM Gαi2, CAM Gαi2, and Gα12 Result in 
Increased Basal Calcium Levels. 
CHO.CCR5 were transiently transfected with DNM Gαi2, CAM Gαi2, or Gα12. Cells were 
harvested for calcium flux analysis 72 hours after transfection, and intracellular calcium 
levels were assessed. CHO.CCR5 was transfected with pcDNA3.1, and basal cytosolic 
calcium levels were compared with CHO.CCR5. There was no significant difference between 
untransfected and transfected controls, with the transfected control showing an average 
increase of 1.9% (±2.2 %, n=3, p=0.49399) CHO.CCR5 was used as control and ratiometric 
calcium measurements were normalised to control resting levels. All transfected cells 
displayed increased cytoplasmic calcium levels compared to control (Figure 6.1 A). Baseline 
levels of calcium were increased by approximately 30-40% of that of control, dependent 
upon the CAM or DNM transfected. Interestingly, Gαi2 G203T displayed the highest overall 
increase in resting calcium levels with an increase of 40.5% (±10.93%, n3, p=0.00099), with 
Gαi2 Q205L increasing basal calcium by 37.7% (±4.12%, n3, p=0.00001) over control and 
Gα12 Q231L increasing basal calcium 31.6% (±3.26%, n3, p=0.00003) over control (Figure 
6.1 B). 
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Figure 6.1 Transient transfection of DNM and CAM Gαi2 and CAM Gα12 result in increased basal cytosolic 
calcium. (A) Basal levels of calcium in transfected cells (mean ± SEM) show an increase in cytosolic calcium 
levels in unstimulated cells. These data represent the average basal levels of calcium normalised to control 
from three independent experiments. Double asterisks represent p<0.001 (B) Calcium traces showing basal 
levels of calcium in transfected cells. Cells were stimulated at 20 seconds with 200 nM CCL3. Points plotted 
represent the mean values weighed to their nine neighbours for three independent experiments.  
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6.2.1.1 The Expression of DNM Gαi2, CAM Gαi2, and Gα12 Affect Speed and Quantity 
of CCL3 Stimulated Calcium Mobilisation 
The expression of Gα12Q231L and Gαi2Q205L resulted in moderate increases in calcium 
mobilisation following 200nM CCL3 stimulation, with Gα12Q231L at 1.022 (±0.0058, n=3, 
p=0.625) and Gαi2Q205L at 1.044(±0.0109, n=3, p=0.570) that of control. Expression of 
Gαi2G203T resulted in a larger significant increase in calcium mobilisation following 
stimulation being 1.070 (±0.0112, n=3, p=0.0248) of control (Figure 6.2). Interestingly, the 
expression of Gαi2Q205L and Gαi2G203T, but not Gα12Q231L, resulted in an increase in the 
speed of calcium mobilisation following CCL3 stimulation with calcium flux peaking 
approximately 7.5 seconds faster than control in these cells (Figure 6.3). 
Figure 6.2 Transient transfection of DNM and CAM Gαi2 result in perturbation of typical CCR5 mediated 
calcium flux. (A). Calcium flux following 200 nm CCL3 stimulation shows a significant increase in the amount 
of calcium released in cells expressing Gαi2 G203T (p=0.0248), these data represent the mean and SEM for 
three independent experiments.   
Co
nt
ro
l
Q2
31
L
12G
Q2
05
L
i2G
G2
03
T
i2G
0.950
0.975
1.000
1.025
1.050
1.075
1.100
*
N
o
rm
al
is
e
d

F3
4
0
/
F3
8
0
146 
 
 
Figure 6.3 Expression of Gαi2G203T and Gαi2 Q205L increase the speed of calcium mobilisation. (A) Combined 
traces showing calcium flux and speed of mobilisation following stimulation at 20 second with 200 nM CCL3. 
(B) As figure A, but individual traces. Control and Gα12Q231L transfected cells require approximately 15 
seconds for calcium flux to peak. Gαi2Q205L and Gαi2G203T peak in approximately 7.5 seconds. Traces 
plotted are a single representative trace of three similar independent experiments.     
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6.2.2.1 Effects of systematic knockdown of Gα subunits. 
HeLa RC-49 cells were systematically transfected with validated siRNA capable of knocking 
down expression of Gαi (1-3) and Gαq, control cells were transfected with validated 
negative control siRNA (Qiagen). The negative control siRNA has no homology to any 
known mammalian gene. Cells were transfected and left to grow for 72 hours, in line with 
the manufacturers guidelines. Transfection procedures were optimised by varying the 
amounts of transfection reagent and rhodamine tagged negative control siRNA. 72 hours 
after transfection, cells were observed and compared using a fluorescence microscope. 
Transfection efficiency was compared by counting a random field in a transfection dish for 
transfected cells. The optimal transfection volumes were determined to be 1 µL Interferon 
(Polyplus) and 9.2 ng siRNA/ (7500 cells/100 µl). 
 
Individual knockdown of Gαi subunits (1-3) and Gαq, as well as combinations of 
knockdowns, did not result in increased basal levels of calcium, as seen in DNM and CAM 
transfected mutants. Furthermore, there was no change in the rapidity of calcium 
mobilisation following knockdown of any of the Gα subunits (data not shown). Following 
knockdown and stimulation with 200 nM CCL3 there was considerable variation in the 
amount of calcium released compared to control transfections. Generally, single Gα 
knockdowns released more calcium following stimulation compared to control, whereas 
dual knockdowns, where Gαq had been knocked down, resulted in a decrease in calcium 
mobilisation (Figure 6.4). Although trends were witnessed, no significant differences were 
measured at this concentration (Table 6.1). However, knockdown of G-proteins may affect 
receptor-CCL3 potency and efficacy rather than completely abolishing the signal, it is 
therefore paramount to perform concentration-response experiments. 
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Figure 6.4 Calcium mobilisation is affected by Gα knockdowns. Knockdown of single Gα subunits results in an 
increase in calcium mobilisation following 200 nM CCL3 stimulation. Combination Gαq/ Gαi knockdown 
resulted in lower calcium mobilisation for Gαq/Gαi1 and Gαq/Gαi2 knockdowns. Each bar represents the 
change in calcium levels normalised to the negative control, which was set to one for every assay. The points 
plotted are the mean and SEM of 2-5 independent experiments. 
Knockdown Mean SEM n 
Gαi1 1.311698 ±0.090492 3 
Gαi2 1.178028 ±0.20023 4 
Gαi3 1.198684 ±0.146654 3 
Gαq 1.276223 ±0.119457 5 
Gαi2 Gαi3 1.405027 ±0.511354 3 
Gαq Gαi1 0.866546 ±0.173759 4 
Gαq Gαi2 0.932072 ±0.087731 2 
Gαq Gαi3 1.173047 ±0.189597 2 
Table 6.1 Corresponding values for figure 4. Mean values represent data gathered from knockdown 
experiments and normalised to control samples set to one for each assay. Results for knockdown were 
analysed by Student’s T-Test to negative control results, no significant differences were calculated.   
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6.2.2.2 Gαi2 is not Involved in CCR5 Mediated Calcium Mobilisation 
Knockdown of Gαi2 with validated siRNA sequences was confirmed by western blot analysis 
(Figure 6.5). The effects of knockdown of Gαi2 in HeLa RC-49 were further explored by 
measuring calcium mobilisation in a CCL3 concentration dependent way. No significant 
difference in log EC50 was found between control and Gαi2 knockdown, with log EC50 values 
being -6.857 M (±0.04917 M, n=4) and -6.922 M (±0.03867 M, n=4), respectively. The 
intrinsic activity was likewise unaffected, with Gαi2 knockdown cells having a calculated 
efficacy of 92.9% (±4.08%, n=4) of that of control (Figure 6.6).     
 
6.2.2.3 Knockdown of Gαq Increases CCL3 Potency but not Efficacy 
Knockdown of Gαq with validated siRNA sequences was confirmed by western blot analysis 
(Figure 6.7). The knockdown of Gαq was found to cause a leftwards shift in concentration 
response curve compared to control (Figure 6.8). The log EC50 for Gαq knockdowns was                              
-7.045M (±0.1181 M), compared to -6.615M (±0.0473 M) for control, this represents a 
significant shift in potency (p=0.0105). 
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Figure 6.5 Western blots showing protein expression for CCR5 and Gαi2. Lane 1 HeLa RC-49. Lane 2 Negative 
control. Lane 3 Gαi2 knockdown.  
 
Figure 6.6 Concentration response curve for HeLa RC-49 Gαi2 knockdown. No significant differences were 
recorded between any points measured, log EC50, or calculated efficacy (cE). Control cE=100%, log EC50 -
6.857M, (±0.04917 M). Gαi2 knockdown cE=92.9% ± 4.08%, log EC50 -6.922 M (±0.03867 M). The points plotted 
on the graph represent the mean and the SEM of 4 independent experiments.  
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Figure 6.7 Western blots showing protein expression for CCR5 and Gαq. Lane 1 HeLa RC-49. Lane 2 Negative 
control. Lane 3 Gαq knockdown.   
Figure 6.8 Concentration response curve for HeLa RC-49 Gαq knockdown. No significant differences were 
recorded between any points measured, log EC50, or calculated efficacy (cE). Control cE=100%, log EC50 -6.615 
M, (± 0.04737M). Gαq knockdown cE=99.6% ± 12.34%, log EC50 -7.045 M (±0.1181M). The points plotted 
represent the mean and the SEM of 5 independent experiments.  
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6.2.2.4 Combination Knockdown Results in a Decrease in Efficacy 
Preliminary investigations into dual combination knockdowns of Gα subunits have yielded 
some interesting results with respect to calcium release following stimulation of CCR5 with 
CCL3. Knockdown of Gαq in combination with Gαi1 or Gαi2 seems to decrease the ability of 
CCR5 to mediate typical calcium mobilisation. Knockdown of two Gαi subunits did not 
result in a decrease in maximum calcium mobilisation levels (Table 6.2). The most 
pronounced decrease in calcium mobilisation was observed in Gαq and Gα1 knockdown in 
combination. Log EC50 values shifted significantly being -6.87M (±0.0847 M, n=3) for control 
and -7.456 M (±0.1093 M, n=2) for Gαq/Gαi1 knockdowns (p=0.02959). The calculated 
efficacy for CCL3 acting on Gαq/Gαi1 knockdowns was 52.2% (±2.95%, n=2) when 
normalised to control values. Knockdown cells had severely attenuated calcium 
mobilisation at high CCL3 concentrations, yet similar responses to control at lower 
concentrations. Therefore, the shift in the log EC50 recorded reports a relative change in the 
potency of CCL3 due to the effect knockdown has on CCR5-CCL3 intrinsic activity (Figure 
6.9). Unfortunately, dual knockdowns could not be adequately characterised by western 
blot analysis, therefore these data represent preliminary findings.  
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Figure 6.9 Concentration response curve for HeLa RC-49 Gαq/Gαi1 knockdown. Control cE=100%, log EC50 -
6.87M, (± 0.08477 M). Gαq/Gαi1 knockdown cE=52.2% ± 2.95%, log EC50 -7.456 M (±0.1093 M). cE values were 
normalised to the absolute calculated efficacy value for control in each independent experiment. The points 
plotted on the graph represent the mean and the SEM of 2 independent experiments. 
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Knockdown Gαi1 † Gαi2 Gαi3 † Gαq 
log EC50 -7.366 -6.922 -6.328 -7.045 
SEM 0.1046 0.03867 0.07349 0.1181 
p ns ns ns * 
Cal. Efficacy % 125.725 92.893 159.549 99.637 
Stdev 8.232 4.088 12.478 12.341 
P ** ns *** ns 
n 3 4 2 5 
Knockdown Gαi2 Gαi3 † Gαq Gαi1 † Gαq Gαi2 † Gαq Gαi3 † 
log EC50 -6.961 -7.456 -7.175 -7.095 
SEM 0.07902 0.1093 0.3479 0.2342 
p ns * ns ns 
Cal. Efficacy % 1.153 0.522 0.763 0.879 
Stdev 6.252 2.959 4.418 3.278 
P ns ** ns ns 
n 2 2 2 2 
Table 6.2 Table comparing knockdown induced changes to CCL3 efficacy and potency in HeLa RC-49 cells. 
Significance was determined by performing a two tailed unpaired t-test between control and knockdown 
samples. *=P<0.05, **=P<0.01, †=preliminary data.  
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6.3 Discussion 
The aim of this chapter was to explore the possibility that CCR5 display could signal via G-
protein heterotrimers, other than Gαi2. Dominant negative mutants of Gα subunits have 
been extensively utilised in other studies as a way to help delineate GPCR signalling 
pathways. The majority of this work has been carried out using Gαs, with a small but 
significant proportion being performed with Gαi2. Previous studies have indicated that Gαi2 
(G203T) has an important role to play in activation of cytosolic phospholipase A2 and 
consequently the synthesis of arachidonic acid (Murray-Whelan et al., 1995). The over 
expression of Gαi2 (G203T) in CHO.CCR5 did not result in the abrogation of calcium release 
following stimulation with CCL3, strongly implying that CCR5 is capable of interacting with 
and activating other G-protein heterotrimers that act to raise cytosolic calcium levels. 
These data suggest the involvement of other members of the Gαi family and/or the Gαq 
family, but not of Gα12. 
 
Counter intuitively, the over-expression of Gαi2 (G203T) resulted in higher basal levels of 
cytosolic calcium, which was not anticipated before experiments were undertaken. This 
result directly contradicts a previous study where Gαi2 (G203T) was over-expressed in CHO-
K1 cells, with no effect upon resting calcium levels (Murray-Whelan et al., 1995). One must 
draw the conclusion that the stable expression of CCR5 in conjunction with the expression 
of Gαi2 (G203T) in some way accounts for this increase in basal calcium levels, although it is 
currently unclear as to how these changes are brought about. One possible explanation is 
that CCR5 pre-couples predominantly with Gαi2 in its inactive state and the expression of 
Gαi2 (G203T) results in a “space” for other G-proteins to interact with CCR5. Furthermore, 
other heterotrimers could potentially be spuriously activated by the inactive form of CCR5, 
resulting in the release of Gβγ and consequently a rise in basal calcium levels. Of course, 
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this theory is dependent upon Gαi2 (G203T) being unable to interact with CCR5 specifically, 
as previous studies have indicated that the Gαi2 (G203T) heterotrimer interacts with 
greater affinity to the α2-adreneric receptor compared to wild type (Inoue et al., 1995).  
 
Previous studies have shown that Gαi2 (G203T) has a similar affinity for Gβγ compared to 
wild type. Furthermore, it is capable of interacting with the α2-adrenergic receptor, has a 
faster GDP dissociation and GTP turnover than wild type, and upon GTP binding does not 
form an active conformation (Inoue et al., 1995). Following stimulation of CHO.CCR5 with 
CCL3 there was a rapid increase in cytosolic calcium in cells transfected with Gαi2 (G203T). 
Presuming that the Gαi2 (G203T) heterotrimer does not undergo any sort of conformational 
shift and is incapable of releasing Gβγ subunits to activate downstream effectors which 
result in a release of cytosolic calcium, we must believe that CCR5 is activating different G 
protein heterotrimers. Work by Gales et al suggests that GPCR pre-couple to specific G-
proteins, granting them a level of cellular signal specificity (Gales et al., 2006). This work 
supports an earlier theory that CCR5 and members of the Gαi family are tightly associated 
in an inactive state (Mueller et al., 2004a). The non-abrogation of calcium release following 
CCL3 treatment of CHO.CCR5 transfected with Gαi2 (G203T) suggests that CCR5 induced 
calcium release is the effect of several G-protein heterotrimers being activated 
concomitantly and working in a coordinated fashion. 
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Data from this investigation demonstrate that there is a significant increase in calcium 
release following CCL3 stimulation in Gαi2 (G203T) transfected cells. It is unknown whether 
Gαi2 (G203T) interacts with CCR5 or leaves a “space” at the cytosolic tail free for other G-
protein heterotrimers to bind in its place. Some recent contentious reports suggest that the 
Gαi2 heterotrimer does not undergo full dissociation following activation (Bunemann et al., 
2003; Frank et al., 2005). If this is the case, presumably the heterotrimer would 
predominantly target activate one downstream effector, corresponding either to Gα of βγ 
subunit specificity. This could potentially provide an element of specificity to the signalling 
processes of GPCRs. There is a possibility that other G-protein heterotrimers that precouple 
to CCR5 in its inactive state are predominantly responsible for effects cumulating in the 
release of cytosolic calcium and that Gαi2 heterotrimers may well target other downstream 
effectors. Without Gαi2 heterotrimers binding to CCR5, the space once occupied by them 
could be occupied by other members of the Gαi family or even other G alpha family 
subunits. All members of the Gαi family share a strong homology (Suki et al., 1987) and 
there are examples where all three members of the family interact with the GPCR in 
question (Mukhopadhyay et al., 2005). An increase in the number of G-protein 
heterotrimers capable of activating PLCβ associated with CCR5 could explain the significant 
increase in calcium released in these experiments.  
 
The transfection of CHO.CCR5 with constitutively active Gαi2 Q205L resulted in an increase 
in basal levels of calcium. Although it is unclear as to whether Gαi2 undergoes dissociation 
following activation or not, the over expression of Gαi2 Q205L does result in calcium 
release, suggesting the activation of PLCβ by Gβγ. Presuming the dissociation of the 
heterotrimer, this implicates Gβγ subunits are free from active Gαi2. However, supposing 
the conformational change and non-dissociation of the heterotrimer, this result taken with 
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data from Gαi2 G203T data suggests that following saturation of other downstream 
effectors the active Gαi2 heterotrimer will also signal via its Gβγ pathway. The transfection 
of constitutively active Gα12 Q231L also resulted in an increase in basal levels of calcium. 
This is to be expected as Gα12 is a well characterised activator of PLCε (Wing et al., 2003). 
 
In summary of the DNM and CAM experiments; the introduction of dominant negative and 
constituently active forms of Gαi2 does not abrogate CCL3 stimulated CCR5 mediated 
calcium release. Furthermore, the introduction of Gαi2 G203T results in an enhanced 
release of calcium, strongly implying that other signalling mechanisms are primarily 
responsible in CCR5 mediated calcium mobilisation. The enhanced rapidity of calcium 
release also suggests a level of crosstalk between different signalling pathways, suggesting 
a role for Gαi2 as a moderator of calcium release rather than an enhancer, although it is not 
apparent by what mechanism this may act by. These data indicate that CCR5 signalling, 
even with one ligand, is a multifaceted signalling network which relies upon the 
orchestrated activation and interactions of many signalling molecules, of which Gαi2 is 
definitely a player.  
 
The knockdown of individual Gα subunits yielded some unexpected results. Knockdown of 
a single Gα subunit tended to result in an increase in CCL3 stimulated efficacy and potency 
of calcium release. This could indicate interesting compensatory measures undertaken by 
cells to ensure important cellular processes are not perturbed. One such method that this 
could be achieved is crosstalk between signalling pathways. One method cells may utilise to 
achieve this level of cross talk in signalling pathways is by the formation of heterodimeric 
GPCRs. Many GPCR heterodimers have been reported (Gurevich et al., 2008), and the act of 
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dimerisation can result in altered signalling properties (Milligan, 2006). Heterodimerization 
between the chemokine receptors CCR2 and CCR5 has been reported and was observed to 
synergistically increase in calcium mobilisation upon co-stimulation (Mellado et al., 2001). 
Evidence that mixed complexes of receptors enhance coupling to Gαq/11 has also been 
obtained in studies demonstrating that antagonism of either bradykinin B1 or B2 receptors 
reciprocally inhibits agonist mediated inositol phosphate production in prostate cancer PC3 
cells (Barki-Harrington et al., 2003). Despite a plethora of evidence of GPCR dimerization 
and an association of this with altered receptor function, including enhanced calcium 
signalling, the precise molecular mechanisms are still unclear. However, there are several 
consequences of dimerisation that could explain the unusual results seen in single 
knockdowns. One such method could be domain swapping (Gouldson et al., 1998).  
 
Domain swapping is a phenomenon by which a dimerised GPCR can undergo a 
conformational rearrangement in which receptors ‘borrow’ the transduction machinery of 
its dimeric partner (Maggio et al., 1993). Therefore, activation of one GPCR may result in 
the activation of another GPCR’s signalling machinery. Domain swapping and the activation 
of a dimerised GPCRs partner has been suggested as a way to prevent loss of function 
changes to a cells signalling mechanism (Gouldson et al., 1998). G-proteins are known to 
stabilise different GPCR conformations (Kobilka et al., 2007), therefore it is fair to presume 
that the removal of a Gα subunit that primarily interacts with a CCR5 may result in a 
destabilising effect and potentially a loss of normal function. Domain swapping could 
provide a method to functionally rescue compromised CCR5. In addition, it has been 
observed that calcium release can also be potentiated by a variant of this model in cells co-
expressing angiotensin II AT1 and bradykinin B2 receptors. The bradykinin B2 receptors are 
thought to ‘present’ G-proteins to the AT1 receptors within a dimeric complex to facilitate 
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Ca2+ signalling in response to AT1 receptor agonists (AbdAlla et al., 2000). Although we 
cannot be sure if CCR5 dimerises in HeLa RC-49, it is a possibility that should not be 
ignored.  
 
Although CHO K1 and HeLa cells are known not to express chemokine receptors, a simple 
literature review of proteomic characterisation of CHO K1 cells reveals many endogenous 
GPCR that could potentially interact with CCR5 (Holdsworth et al., 2005), as well as yet 
undefined orphan GPCRs (Kostenis, 2001). HeLa cells have also been shown to express 
several endogenous GPCR which may be able to interact with CCR5 as previously discussed 
(Steffen, 2008). For this reason caution must be exercised when trying to draw firm 
conclusions about CCR5 signalling mechanisms in model cell systems from the results 
grained from the individual knockdown of G-proteins.   
 
In addition to hypotheses regarding dimerisation, there is plenty of evidence to suggest 
that GPCR couple to more than one sub-type, or even, family of G-proteins and that these 
interactions are physiologically relevant (Laugwitz et al., 1996). It has been suggested that 
different conformational states in the same GPCR can alter the G-protein binding (Ahuja et 
al., 1996). This phenomenon has been described in CXCR2, where a low affinity ligand 
binding form has been shown to be responsible for calcium mobilisation and a high affinity 
form responsible for chemotaxis (Ahuja et al., 1996). Although the concept of precoupling 
is still a contentious issue, with equally strong supporting (Andressen et al., 2006) and 
conflicting evidence (Qin et al., 2008), it is possible that these GPCR binding states are 
stabilised by interactions with G-protein heterotrimers (Roka et al., 1999). Removal of a 
subunit by knockdown would leave the receptor open to binding another subfamily in great 
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numbers, hence amplifying those subfamilies effects, which potentially may be the release 
of calcium.   
 
Studies performed by Krumins et al. in HeLa cells investigated the effects targeted 
knockdown of Gα subunits had upon the expression of non targeted Gα and Gβ. They 
found that the knockdown of Gα subunits often results in a compensatory up-regulation of 
other G-proteins (Krumins et al., 2006). In particular, knockdown of Gαq/11 resulted in a 
twofold increase in Gαi1 subunits and knockdown of Gαi3 resulted in an increase of Gαq, 
Gαi1 and Gαi2. In fact, the only knockdown without effect was the knockdown of Gαi1. In 
relation to results seen in our experiments, this suggests that the increase of calcium 
following knockdown of a single Gα subunit may be due to compensatory methods within 
the cell.  
 
Knockdown of two Gα subunits in combination may be more telling of the heterotrimer 
associated with and activated by CCR5 in response to CCL3 stimulation. Although caution 
must be used when inferring from these results; the greatest effect upon calcium 
mobilisation occurred with simultaneous knockdown of Gαq and Gαi1 and Gαi2, indicating a 
role for these subunits in CCR5 mediated calcium release. Although calcium mobilisation 
was not completely abolished by combinational knockdown, these results strongly indicate 
that these subunits are somehow intertwined in the signalling response from CCR5. As with 
single knockdowns HeLa, cells could be undergoing compensatory mechanisms in order to 
prevent deleterious perturbations to the cells normal responses.  
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Taken together, this work provides additional data to support the hypothesis that GPCR 
associate with several discrete members of the Gα family. Although results gained are far 
from absolute, they do indicate that signalling through CCR5 is a complex network that 
relies upon more than a single subfamily of Gα proteins. Furthermore, these data also 
demonstrate that G-protein signalling is very resistant to change, and able to compensate 
for perturbations in the normal signalling machinery. The underlying methods for this are 
not clear and further work is needed in order to clarify the interactions and rescue 
mechanisms that underpin these findings.  
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Chapter Seven 
Small Molecule Interference of Gβγ 
Subunits 
7.1 Introduction 
Expression of DNM Gαi2 did not result in an inhibition of calcium release, suggesting that 
the Gαi2 heterotrimer is not essential for chemokine stimulated release of calcium. As such 
it was decided to further investigate the activation mechanisms of calcium mobilisation 
following chemokine stimulation. The Gβγ subunit was once thought to be a negative 
regulator of Gα signalling, acting to allow termination of Gα signalling and facilitating the 
reassociation of the heterotrimer with the GPCR. However, in 1987 purified Gβγ was shown 
to be involved in the activation of a cardiac potassium channel in vitro (Logothetis et al., 
1987). It was not until 1987 that the first example of Gβγ dependent signalling, in a 
physiological mammalian system was identified. Gβγ was shown to regulate inwardly 
rectifying KAch channels (Logothetis et al., 1987). We now know that the Gβγ subunit can 
modulate many downstream effectors(Clapham, 1996) and currently the functional 
properties of this subunit are under close scrutiny. 
 
Gallein, a synthetic derivate of the naturally occurring dye haematoxylin, was until recently 
used only as a histological stain to mark cell nuclei. However, new research indicates that it 
may have a role to play in HIV treatment (Cruceanu et al., 2006) and as a small molecule 
modulator of Gβγ function. Recent studies have shown gallein to inhibit Gβγ dependent 
chemotaxis and inflammation events in differentiated HL60 cells and in vivo in neutrophils 
(Lehmann et al., 2008).  
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Gallein has been shown to bring about its disruptive effects by binding to an area of the 
Gβγ subunit known as the “hot spot” (Lehmann et al., 2008). The hot spot is an area on the 
Gβγ subunit that has been shown to be a critical effector binding and signal transfer region 
(Davis et al., 2005). However, recent reports indicate that the hot spot is not the only signal 
transfer region, Gβγ may also activate downstream effectors through interactions with 
amino acids other than those in the hot spot area. The Gβγ subunit has been shown to 
activate PLCβ2, through a non hot spot region, independently of GPCR activation, upon 
binding activator of G protein signalling protein 8 (APS8) (Yuan et al., 2007).  
 
Gallein has only recently been characterised as a molecule capable of interacting with the 
Gβγ subunit, as such it is still poorly characterised and understood. These experiments aim 
to illuminate the mechanisms by which gallein brings about its physiological changes, and 
through its unique Gβγ modulating properties we hope to further elucidate CCR5 signalling 
pathways through G-protein heterotrimers.  
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7.2 Results 
7.2.1 Gallein Enhances CCR5 Mediated Calcium Release 
CHO.CCR5 were pre-treated for 30 minutes with varying concentrations of gallein prior to 
stimulation with CCL3 and the effects on cytosolic calcium mobilisation were monitored. 
Following stimulation with 100 nM CCL3, gallein treated cells exhibited enhanced levels of 
calcium mobilisation. The effect was concentration dependent; treatment with 20 mM 
gallein prior to experimentation resulted in the highest increases in calcium mobilisation 
(Figure 7.1). When analysed by Student’s t-test (paired, two-tailed), treatment with 10 mM 
gallein did not result in a significant increase in calcium release. However, calcium release 
following 20 mM and 30 mM treatments did result in a significant increase, with P values of 
0.0193 and 0.0129, respectively.  
Figure 7.1 Gallein has a concentration dependent effect on CCR5 mediated calcium release. CHO.CCR5 were 
treated for 30 minutes with different concentrations of gallein, following fura2 loading cells were stimulated 
with 100nM CCL3 and calcium release measured. Results (mean, SEM) gallein 10 mM 1.371 (±0.2309, n=4, 
p=0.2498), 20 mM 2.390 (±0.1962, n=4, p=0.0193) and, 30 mM 1.820 (±0.0939, n=4, p=0.0129). Graph is data 
from four independent experiments   
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7.2.1.2 Gallein Treatment Results in Enhanced CCL3 Efficacy but not Potency 
Concentration response assays were performed on CHO.CCR5 cells that had been treated 
with gallein at various concentrations. It was found that gallein treatment resulted in an 
increase in calcium mobilisation at all CCL3 concentrations. The intrinsic activity of CCL3-
CCR5 signalling was increased almost 2.5 fold at some concentrations. However, the 
potency of CCL3 acting through CCR5 did not differ from that of control cells, with Log Ec50 
values for control, 20 mM treatment and 30 mM treatment being, −7.586 (±0.08543 M, 
n=4), −7.516 (±0.1110 M, n=4) and −7.606 (±0.08398 M, n=4), respectively (Figure 7.2). 
Figure 7.2 Gallein increases CCL3 efficacy through the CCR5 receptor. Control: Calculated Efficacy (cE) 
cE=100%, LogEc50 -7.586 M, 20 mM cE=235.86%, LogEc50 -7.516 M, 30 mM cE=183.67%, LogEc50 -7.606 M. Data 
points plotted are the mean and SEM of four independent experiments. Curves were plotted with a 
theoretical hill co-efficient of one.  
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7.2.2 Gallein’s Effects are not Cell Type Specific. 
To ensure that the unexpected results gathered in experiments with CHO.CCR5 were not 
due to cell specific expression of isozymes involved with the generation of second 
messengers, such as adenylyl cyclase (AC) and phopoholipase Cβ (PLCβ), further 
experiments were performed on HeLa RC-49 cells. Cells treated with gallein for 30 minutes 
prior to CCL3 stimulation also exhibited substantial increases in calcium mobilisation. The 
effect was concentration dependent, with the largest increase in calcium mobilisation seen 
following 30 mM gallein treatment (Figure 7.3). When analysed by student’s t-test (paired, 
two tailed), treatment with 10 mM and 20 mM gallein did not result in a significant 
increase in calcium release, however 30 mM treatments did result in a significant increase 
with a P value of 0.0096.  
Figure 7.3 Gallein increases CCL3 stimulated calcium mobilisation in a concentrationdependent fashion in 
HeLa RC-49. HeLa RC-49 were treated for 30 minutes with different concentrations of gallein, following fura2-
AM loading cells were stimulated with 100nM CCL3 and calcium release measured. Results; 10 mM gallein 
1.287 (±0.0496, n=5, p=0.1020), 20 mM gallein 1.434 (±0.2481, n=5, p=0.1553), 30 mM gallein 2.623 (±0.3485, 
n=5, p=0.0096). The graph represents the mean and SEM from five independent experiments. 
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Concentration response assays were performed on HeLa RC-49 cells that had been treated 
with gallein at various concentrations. It was found that gallein treatment resulted in an 
increase in calcium mobilisation at all CCL3 concentrations. The intrinsic activity of CCL3-
CCR5 signalling was increased 2.26 fold at saturating concentrations of CCL3. The potency 
of CCL3 acting through CCR5 was not found to differ from that of control cells (see Table 
7.1), with Log Ec50 values for control, 20 mM, and 30 mM gallein treatment being, -7.192 
(±0.06993 M, n=5) , -7.304(±0.1899 M, n=5) and -7.225 (±0.1557 M, n=5), respectively 
(Figure 7.4).  
Figure 7.4 Gallein increases CCL3 efficacy through the CCR5 receptor. Control: cE=100%, Log Ec50 -7.192 M, 
gallein 20 mM cE=121.96%, Log Ec50 -7.304 M, gallein 30 mM cE=226.62%, Log Ec50 -7.225 M. Data points 
plotted represent the mean and SEM of five independent experiments. Curves were plotted with a 
theoretical hill co-efficient of one.  
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7.2.3 Gallein Treatment Increases resting cAMP Levels 
HeLa RC-49 cells were treated with 30 mM gallein and 10 µM forskolin for 30 minutes prior 
to 3 minute stimulation with CCL3. Relative cAMP levels were measured using the cAMP-
Glo™ assay kit (Promega). The relationship between cAMP concentration and 
bioluminescence is inversely proportional. Treated cells exhibited increased levels of cAMP 
and therefore reduced bioluminescence in the cAMP-Glo™ assay. Unstimulated cells had 
average luminescence values of 13724 (±1545.14, n=3) for control, and 7451 (±1088.36, 
n=3) for gallein treated. Cellular cAMP levels decreased in a concentration dependent way 
to CCL3 stimulation. Only at saturating concentrations of CCL3 did cAMP levels in gallein 
treated cells reach levels seen in unstimulated control cells (Figure 7.5).  
Figure 7.5 Gallein increases resting levels of cAMP in HeLa RC-49. Cells were treated with 30 mM gallein for 
30 minutes before stimulation with CCL3. cAMP levels were measured using the Promega cAMP-Glo kit. 
Gallein increased resting levels of cAMP two-fold, but did not significantly affect CCL3 stimulated inhibition of 
adenylyl cyclase. Results; Control Log Ec50 -6.918 M (±0.1864 M), gallein Log Ec50-6.448 M (±0.1475 M). Data 
points plotted represent the mean and SEM of three independent experiments. 
  
-8 -7 -6
5000
15000
25000
Control
Gallein 30 mM
CCL3 log [M]
R
.L
.U
.
170 
 
HeLa Rc-49 Control Gallein 10 mM Gallein 20 mM Gallein 30 mM 
Log EC50 [M] -7.192 -7.216 -7.304 -7.225 
SEM [M] ±0.06993 ±0.3849 ±0.1899 ±0.1557 
P value n/a P>0.05 P>0.05 P>0.05 
Cal. Efficacy 100% 138.44% 121.96% 226.62% 
SEM ±4.501% ±22.828% ±10.689% ±9.783% 
P value n/a * P > 0.05 ** 
n 5 5 5 5 
CHO.CCR5 Control Gallein 10 mM Gallein 20 mM Gallein 30 mM 
Log EC50 [M] -7.586 -7.662 -7.516 -7.606 
SEM [M] ±0.08543 ±0.2074 ±0.1110 ±0.08398 
P value n/a P>0.05 P>0.05 P>0.05 
Cal. Efficacy 100% 126.76% 235.86% 183.67% 
SEM ±4.110% ±26.164% ±5.926% ±12.943% 
P value n/a P > 0.05 ** ** 
n 4 4 4 4 
Table 7.1 Comparison of gallein induced changes to CCL3 concentration response.  
  
171 
 
7.3 Discussion  
Interference of the Gβγ subunit by the small molecule gallein resulted in some unexpected 
and novel results. Gallein concentration dependent increases in calcium mobilisation were 
observed following stimulation with CCL3. No increase in basal calcium levels between 
gallein treated and non-treated cells was observed. These data suggest that the unique 
properties of gallein potentiate CCR5 mediated calcium mobilisation, although it is not 
clear how, mechanistically, this is achieved. Increases in calcium mobilisation was not cell 
line dependent, with studies carried out in CHO.CCR5, HeLa RC-49 and preliminary studies 
in HEK.CCR5 (data not shown) all following the same trend, thus ruling out differences in 
relative expression levels of different second messenger isozymes, such as adenylyl cyclase 
or PLCβ accounting for these data. Interestingly, gallein treatment resulted in altered basal 
levels of cAMP production. Taken together, these data suggest that the binding of gallein to 
G-protein heterotrimer results in modulation of several second messenger pathways, 
without activation of the heterotrimer and disruption of the typical signalling mechanisms 
employed by CCR5 following CCL3 stimulation.   
 
Gallein has also been shown to bind to the Gβγ hot spot (Smrcka et al., 2008) and currently 
it is unknown what, if any, conformational change the Gαβγ heterotrimer undergoes upon 
gallein binding. Data gained from these studies indicates that incubation with gallein alone 
does not result in enhanced calcium mobilisation, but potentiates the effect of CCL3 
stimulation through CCR5. It is currently unclear how gallein brings about these effects. 
One plausible explanation is that gallein binding may modulate the traditional downstream 
effector targets of the active subunit. Several other compounds and proteins have also 
been shown to bind to the hot spot  and induce atypical Gβγ binding (Seneviratne et al., 
2009). In particular, the protein activator of G-protein signalling 8 (AGS8) has been shown 
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to bind to the Gβγ hot spot, resulting in a conformational change in the Gαβγ heterotrimer. 
This conformational change does not expose either the hot spot or the Gα subunit binding 
face but results in a atypical of Gβγ binding and activation of its downstream effectors. This 
is done without the dissociation of the Gαβγ heterotrimer and without the activation of 
any GPCR (Yuan et al., 2007). Mounting evidence suggests that not all subunits dissociate 
and assuming this is true for Gαi2, gallein could potentially block both traditional binding 
faces of the Gα and Gβγ subunits thus preventing typical binding and the 
activation/inactivation of downstream effectors. 
 
A potential downstream effector that may be affected by modulation of Gβγ binding 
patterns is PI3Kγ. Data from gene knockouts of Gβγ effectors in murine models have 
indicated that PI3Kγ is a common target for Gβγ subunits involved in inflammatory and 
chemotactic pathways (Li et al., 2000), (Hirsch et al., 2000). Activation of PI3Kγ results in 
the phosphorylation of phosphatidyinositol 4,5 biphosphate (PIP2)into phosphatidyinositol 
3,4,5 biphosphate (PIP3), which has been shown to increase calcium mobilisation by 
enhancing PLCγ and potentially PLCβ synthesis of inositol 1,4,5-trisphosphate (IP3) (Lian et 
al., 2005). The convergent point PI3K occupies in the signalling pathway has led to research 
into developing compounds capable of targeting PI3Kγ activity with the hope they may be 
able to modulate the catalytic activity of PI3Kγ, therefore preventing inflammatory events 
(Camps et al., 2005). The activity of PI3Kγ is directly regulated by Gβγ released from Gαi 
subunits activated by chemokine receptors (Stephens et al., 1997) and the PI3K family, 
specifically PI3Kα and γ, are also known to stimulate the mobilisation of calcium following 
activation (Hooshmand-Rad et al., 1997), (Quignard et al., 2001). A feasible mechanism for 
activation of PI3Kγ by gallein bound Gβγ is through interaction with N-terminus residues in 
Gβγ (Yuan et al., 2007). 
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Gallein treatment of HeLa RC-49 resulted in an increase in the relative rates of cAMP 
compared to control; however, it did not prevent CCL3 stimulated inactivation of AC. Gβγ 
has been shown to activate and inactivate specific AC isoforms (Tang et al., 1991). The 
dramatic rise in cAMP levels observed suggests that gallein interferes with a cellular 
process that regulates basal levels of cAMP. However, we were unable to identify which 
Gβγ subtypes were responsible and at what AC subtype they were acting. It is unclear by 
what mechanism gallein affects a cell’s ability to regulate cAMP levels.  
 
However, the most evident participants when investigating enhancement calcium 
mobilisation through GPCR signalling are PLCβ and PKA. Modulation of either of these 
proteins has been shown to affect calcium release (Harfi et al., 2006). The modulation of 
PLCβ is the most straight forward means of potentiating calcium signalling. Hydrolysis of 
PIP2 by PLC results in IP3 production, IP3 receptor activation, and the release of calcium 
from intracellular stores (Ferris et al., 1992). Clearly, enhancement of IP3 production could 
enhance calcium mobilisation. Although PLCβ isozyme expression can dictate the ability of 
Gβγ to mediate phosphoinositide and calcium signalling, results garnered from these 
experiments show gallein acts in a non cell type specific manner. This suggests that gallein 
interferes with general mechanisms that mediate second messenger synthesis.  
 
 
 
174 
 
PLCβ has been shown to have distinct binding sites for Gβγ and Gαq (Smrcka et al., 1993) 
and the dual occupation of these sites has been shown to be synergistic for its stimulation 
(Zhu et al., 1996). Currently there is a lack of evidence to suggest Gαi family subunits have a 
synergistic effect through the same mechanism. However, there is evidence that Gαi 
subunit activation may enhance calcium mobilisation in the presence of Gαq activation 
(Chan et al., 2000). CCR5 has been show to associate with Gαq in previous studies (Mueller 
et al., 2004a). A conformational change in Gαβγ by gallein that results in the Gβγ binding 
site on PLCβ becoming occupied may act to prime the enzyme ready for activation.  
 
The rise in the basal cAMP levels may also play a part in enhancing calcium mobilisation 
through PLCβ. Typically a rise in cAMP levels results in the activation of PKA, resulting in the 
phosphorylation and inactivation of PLCβ (Yue et al., 1998). However, active Gβγ subunits, 
specifically from Gαi, have been shown to inhibit phosphorylation of PLCβ by PKA and even 
enhance calcium mobilisation from intracellular stores following activation of Gαi/s subunits 
(Litosch, 1997; Yue et al., 2000). Generally PKA activation is viewed as inhibitory to PLCβ, 
but there are examples where the opposite is true (Pittner et al., 1989). 
 
In addition to enhancing calcium mobilisation via stimulation of PLC it is possible that the 
same effects could be achieved through an increase in the PIP2 cytosolic pool. It is 
conceivable that in some circumstances the supply of PIP2 could limit PLCβ activity. An 
enhanced pool of PIP2 could result in a quicker and larger production of IP3, resulting in a 
higher proportion of IP3 receptor activation and larger flux of calcium. Activation of src and 
Rho proteins have been shown to increase PIP2 production (Chong et al., 1994; Stephens et 
al., 1993). Src has also been shown to be stimulated by activation of the Gαi heterotrimer 
175 
 
(Arefieva et al., 2005) and Rho is well characterised as being activated by CCR5 (Mueller et 
al., 2004b). Although, from what is currently known about gallein binding to the Gαβγ 
heterotrimer, this explanation is less likely than others. It is more likely is that enhanced 
calcium mobilisation is the result of potentiation of the IP3 receptor (DeSouza et al., 2002); 
this is a possible mechanism by which calcium flux may be enhanced without an increase in 
the cytosolic PIP2 pool and subsequent production of IP3. cAMP stimulated PKA activation 
has been shown to sensitise the IP3 receptor through phosphorylation (Wojcikiewicz et al., 
1998). The potentiation of the IP3 receptor by this mechanism would increase calcium 
mobilisation without the requirement for additional PLCβ activation.  
 
Consideration must also be given to the long contested idea that a cell has a fixed amount 
of calcium stored in its intracellular stores (Blaustein et al., 2001). The size of the calcium 
stores may well vary under certain circumstances (Short et al., 2000). As gallein is currently 
poorly characterised, it is a possibility that enhancement of calcium release may be due to 
increases in specific intracellular calcium stores arbitrated by gallein. In conclusion, there 
are a myriad of potential ways gallein brings about these effects, so it is likely, due to the 
substantial increases in calcium mobilisation observed, that gallein interferes with more 
than one signalling mechanism (Figure 7.6). 
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Figure 7.6 Schematic of interactions leading to calcium mobilisation and potential sites that gallein may 
interfere with. (a) Gallein may cause Gβγ activation of adenylyl cyclase results in enhanced cAMP 
accumulation. (b) PKA activation by raised cAMP levels could result in IP3R phosphorylation and 
potentiation. (c) Gβγ may prevent phosphorylation of PLCβ, resulting in longer activation of it. (d) Gβγ 
activation of PI3K. (e) PIP3 synthesis enhances PLCβ and potentially enhances PLCγ catalysis. 
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Chapter Eight 
Summary 
8.1 Exploring G-protein Interactions with Resonance Energy 
Transfer 
Many research groups are interested in understanding the mechanisms of GPCR signalling, 
due to the multitude of physiological changes they are capable of bringing about. Recently 
there has been an influx of new, and sometimes controversial, knowledge regarding the 
signalling mechanisms that GPCR use to bring about the astonishing array of responses 
they are responsible for. As understanding of GPCR signalling pathways used to bring about 
cellular responses has increased, it has become clear, beyond doubt, that far from being 
the linear signal transduction routes they were once thought to be, GPCR signalling 
pathways are carefully orchestrated multi-protein events that rely on interactions with 
more than one family of G-proteins for correct transmission of signalling (Simmons, 2005). 
It has been known for some time that different cellular signalling pathways can interact, 
often providing specificity to GPCR responses and adding an additional layer of complexity 
to the process of signalling (Marinissen et al., 2001). Modulations to GPCR signalling 
pathways are not well understood and clarification of stand-alone GPCR signalling 
pathways and exploration of the effects of cross talk between signalling pathways could 
yield new targets for treatment of physiological conditions ranging from HIV infection to 
blindness.  
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Isolation of CCR5 in a living system was achieved by use of stably transfected CHO K1, 
HEK293 and HeLa cell lines. All these cell lines are easy to transfect, resilient to the stresses 
of cell culture, and do not express endogenous CCR5 or any other chemokine receptor, as 
judged by an absence of response to chemokine treatment, thus providing an ideal model 
for studying CCR5 G-protein interactions. A novel assay system was created in HEK.CCR5 
and CHO.CCR5 cell lines where G-protein subunits, tagged in such a way to permit 
fluorescence resonance energy transfer between the fluorescent protein tags were stably 
expressed. This system was used to recapitulate already identified G-protein heterotrimers 
that associate with and are activated by CCR5, namely the Gαi2β1γ heterotrimer (Zhao et 
al., 1998). Although this assay system was demonstrated to be reasonably successful, its 
further development was hampered by difficulties culturing triple transfected cell lines, 
ensuring adequate transgene expression and technical limitations with the equipment 
used. Problems were also encountered with the levels of cellular autofluorescence, 
probably due to increased levels of cellular stress resulting in the accumulation of 
fluorescent compound such as lipofuscin, NADPH, and FAD, which further hindered the 
exploitation of this innovative assay technology. For the time being, the measurement of 
protein-protein interactions will remain the preserve of live confocal microscopy imaging, 
but with current and future developments into plate reader technology equipment, 
limitations could soon be overcome. Promising recent studies have shown a confocal 
multiwell plate reader that allows high throughput screening of live cells (Talbot et al., 
2008). For the comprehensive development of this assay system, the creation of stable cell 
lines would also need to be refined. There has been an increase in demand for polycistronic 
expression vectors in recent years; as such, it is an exciting area of development with the 
potential to provide a method to overcome issues with the creation of stable cell lines. 
Recent advances have included the development of a multi-cDNA expression construct 
capable of robustly and stochiometrically expressing cDNAs from a single plasmid (Nishiumi 
179 
 
et al., 2009). This, coupled with a lentiviral transfection method and fluorescence activated 
cell sorting approach to creating stable cell lines, could streamline the production of cells 
suitable for a high throughput assay FRET assay to measure G-protein interactions in real 
time.  
 
A complementary approach to measuring protein-protein interactions by resonance energy 
transfer was attempted as a way to overcome issues encountered with the FRET assay. The 
use of a bioluminescent protein as the donor fluorophore in BRET allows for the removal of 
incidental autofluorescence caused by excitation of the donor fluorophore by an external 
light source. An increasing number of studies are using BRET as the choice method for 
studying protein-protein interactions in real time (Kocan et al., 2009; Navarro et al., 2009; 
Pfleger, 2009). BRET is still a rapidly evolving technology that over the last decade has been 
improved upon immensely from its first incarnation and is now a much more sensitive 
system capable of measuring previously undetectable signals (Kamal et al., 2009). The 
system employed during this study was an early adaptation of the original BRET assays first 
carried out in mammalian cells by Angers et al. (Angers et al., 2000). Unfortunately 
interactions between tagged Gαi2 and Gβ1 were unable to be characterised in this study 
using this BRET system. But with the creation of brighter isoforms of renillia luciferase and 
enhanced fluorescent proteins to act as acceptor molecules I believe a BRET based assay to 
measure the interactions of individual G-proteins within the heterotrimer will yield a trove 
of new interactome data. There are comparatively few publications where BRET has been 
used to explore the interaction of ‘free’ G-protein subunits with one another – often the Gα 
subunit is immobilised by linkage to a receptor of interest (Hollins et al., 2009). However, a 
recent publication demonstrates that these interactions can be measured in non 
immobilised G-protein subunits using YFP Venus tagged to the Gγ subunit (Ayoub et al., 
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2009). The present study demonstrates that a high throughput screen for G-protein 
subunits using resonance energy transfer as a direct method to measure protein-protein 
interactions is a reality and could plausibly be a routine lab technique in the near future. 
8.2 Interference of CCR5 G-protein signalling  
The transient transfection of dominant negative and constitutively active Gαi2 into cells 
expressing CCR5 showed that there is not a requirement for functional Gαi2 for CCR5 
mediated calcium release. Neither constitutively active nor dominant negative Gαi2 
resulted in the abrogation of calcium release following stimulation, strongly suggesting that 
CCR5 is functionally coupled to other members of the Gαi heterotrimer family or the Gαq 
heterotrimer family, both of which are capable of effecting the release of calcium upon 
activation (Berridge, 1987; Ghahremani et al., 1999). The expression of the two opposing 
forms of Gαi2 did result in a small increase in calcium mobilisation following stimulation. 
The mechanisms by which this increase occurred are currently unclear; however, it may 
suggest Gαi2βγ is not involved in calcium mobilisation following activation. Constitutively 
active Gα12 was also transiently transfected and was found to have no effect on the release 
of calcium following stimulation, this is in keeping with current literature which does not 
describe any direct association of Gα12 with CCR5, but is shown to be involved in 
cytoskeleton remodelling (Suzuki et al., 2003).  
 
Investigating CCR5 signalling using a dominant negative and constitutively active protein 
approach has certain limitations. The overexpression of a protein of interest may lead to 
effects on other cellular functions which may affect cellular behaviour (Lefrancois et al., 
2005). The effectiveness of these particular DNM and CAM proteins have not been 
extensively characterised and are regarded as having weak effects on normal function 
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(Barren et al., 2007). In order to overcome any deficiencies associated with a dominant 
negative approach and determine if Gαi2 heterotrimers play a role in calcium mobilisation, 
siRNA was used to reduce expression of Gαi2 and several other Gα subunits. Knockdown of 
Gαi2 did not result in any change in calcium mobilisation following stimulation, supporting 
results seen with DNM work.  
 
Published knockdown experiments on Gαi subunits show the bradykinin 2 receptor, 
another class A GPCR that is responsible for calcium mediated signalling(Hess et al., 1992), 
relies on activation of both the Gαi family and the Gαq subunits to ensure normal signalling 
(Yang et al., 1999). Similarly, knockdown of single Gα subunits in HeLa RC-49 resulted in 
little change to normal calcium mobilisation. This was possibly due to recently defined 
compensatory measures characterised in HeLa cells in response to knockdown of G-protein 
subunits (Krumins et al., 2006). However, upon knockdown of Gαq and a member of the Gαi 
family a significant decrease in calcium mobilisation at higher levels of stimulation was 
recorded. The preliminary data gathered in this investigation strongly support the notion 
that CCR5, like other GPCR, maintains its normal signalling pathways through concomitant 
activation of several combinations of G-protein heterotrimer. It is not clear from these 
experiments if the activation of Gαq is from direct association with CCR5 or if there is a 
crosstalk mechanism in place. An important step in confirming these results would be the 
characterisation of several second messenger pathways and the monitoring of any 
compensatory mechanisms cell lines may induce upon knockdown.  
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8.3 Small Molecule Disruption of G-Protein Interactions 
Calcium mobilisation resulting from the activation of Gαi heterotrimers is predominantly 
due to the actions of the Gβγ subunit. Due to the ubiquitous nature of the Gβ family, high 
sequence homology between subtypes, and a lack of compounds that suitably target Gβγ 
interactions, delineating Gβγ subunits interactions in a live cell system has not, until 
recently, been straightforward. A recent study identified gallein as a small molecule 
disruptor of Gβγ subunit signalling that inhibits chemotaxis in neutrophils (Lehmann et al., 
2008). Gallein is not completely characterised and this study, while not supporting 
currently published data regarding its effect on chemotaxis, does highlight the central role 
the Gβγ subunit plays in chemokine signal transduction (Dupre et al., 2009).  
 
Treatment of cells with gallein resulted in massively enhanced calcium mobilisation at high 
chemokine concentrations and a reduction in cAMP accumulation. These results alone 
suggest that gallein binding may actually be blocking heterotrimer interactions with 
adenylyl cyclase while enhancing or potentiating interactions with enzymes responsible for 
calcium mobilisation. It is currently unclear by which mechanism these effects are 
mediated. The Gβγ subunit, specifically Gβγ subunits in a Gαi heterotrimer, have been 
shown to target PI-3K (Hirsch et al., 2000); further studies monitoring the effect gallein has 
on PIP3 levels may provide a more complete picture of its modulatory effects.  
 
Biochemical studies have shown gallein binds to a region of the Gβγ subunit called the 
hotspot, this region is responsible for interactions with downstream effectors (Bonacci et 
al., 2006). Small molecule binding to this region may have an effect comparable to AGS 
proteins, which bind to the intact heterotrimer conferring a conformational change to it 
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and creating a new active face on the Gβγ subunit (Yuan et al., 2007). This work supports 
the notion that small molecule disruptors alter the signalling properties of chemokine 
receptors and could potentially be used to target interactions downstream of the active 
heterotrimer.  
 
8.4 Crosstalk in CCR5 Signalling Pathways 
From this study it is clear that the signalling mechanisms CCR5 uses are resilient to change 
and rely upon a plethora of known protein-protein interactions and potentially other, as 
yet, unidentified protein-protein interactions. The original scope of this research was to 
disseminate the heterotrimers that are activated following stimulation of CCR5, with a view 
to tracing those interactions to disease states. Investigations have expanded from this 
original scope to include the effects CCR5 stimulation has upon second messenger system, 
especially calcium release, which is an incredibly important effector of cellular function and 
response.  
 
In this study calcium release was measured and used as an indirect method to determine 
CCR5 activation of Gαi heterotrimers. However, it became clear that Gαq also plays a role in 
CCR5 mediated calcium release. The mechanisms by which this occur are not easily 
apparent, but are confirmed by combinational knockdown of subunits with siRNA. 
Currently there is little understanding regarding GPCR cross talk and no clear way to predict 
what modulations crosstalk brings about when it is in action. Nevertheless, there is a 
growing body of work that supports the notion of crosstalk as well as highlighting the 
potential physiological and pathological implications. It is well established that 
homodimerisation occurs between CCR5 and CCR2 and signals through the Gαq family 
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heterotrimers (Mellado et al., 2001). Results garnered in this study relied upon presumed 
monomeric CCR5 and also noted a role for Gαq signalling. Taken together, this information 
suggests that a cell’s individual GPCR expression profile may be one of the main causatives 
of signal pathway crosstalk. Thus, conferring specific functional selectivity, based on the 
location of expression. This notion is supported by previous research (Zlotnik et al., 2000). 
Data gathered from this investigation forms the bedrock for exploring cooperative effects 
between chemokine receptors upon additional receptor activation.  
 
It is clear that GPCR signalling is far more complex than the classical GPCR signalling model 
of “one ligand, one receptor, one G-protein per activation event”.  Understanding the 
interactions between canonical CCR5 signalling pathways and pathways that are 
intertwined through crosstalk mechanisms will contribute to the knowledge of therapeutic 
action, and potentially allow for better targeting of therapeutics by identifying common 
signalling bottle necks in signalling pathways.  
 
8.5 Conclusions 
The protein-protein interactions involved in the signalling pathways of GPCRs, although 
well studied, are only just beginning to be unravelled. The research contained in this thesis 
supports and confirms some established tenets about GPCR, such as activation of the 
Gαi2β1γ heterotrimer by CCR5. But also exposes several avenues of investigation that could 
result in a greater understanding of interactions between GPCR and other GPCR as well as 
exploring the interactions GPCR have with heterotrimeric G-proteins. 
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The FRET based assay system developed and used to determine the activation of the 
Gαi2β1γ heterotrimer is, to my knowledge, a novel technology which has been built upon 
the more cumbersome traditional FRET methods. Although the assay encountered 
problems that, unfortunately, didn’t allow it to reach its full potential, it has contributed to 
the understanding of this experimental technology. Recent advances in stable cell line 
development and fluorometer technology mean that the development of a high 
throughput FRET assay to measure protein-protein interactions in real time is considerably 
more feasible than it was even four years ago.  
 
Other research undertaken during the completion of this thesis has shown that the 
endogenous systems that control CCR5 signalling are very resilient to disruption of Gα 
subunits by DNM, CAM, and siRNA disruption. Further research is needed to characterise 
cellular interactions that occur following this disruption. The difficulties associated with this 
approach further support the development of a direct assay system to measure protein-
protein interactions. 
 
Currently there is a surge of interest in understanding the role that the Gβγ subunit plays in 
GPCR signalling. The data gathered in this research, suggest that the Gβγ subunit is far 
more complex than anticipated and considerable work must be undertaken to decipher its 
role in CCR5 and other GPCR signalling pathways. It is clear from results in this research 
that disruption of its normal interactions results in modulation of GPCR effects. Further 
work should focus on the potential therapeutic benefits associated with selective Gβ 
subunit targeting.   
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